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Macrophage Migration Inhibitory Factor (MIF) is a pleotropic cytokine first 
discovered over 50 years ago.  MIF and many MIF-like proteins contain an 
evolutionarily conserved proline residue that confers an enigmatic tautomerase 
activity.  Mammalian MIF proteins also contain an additional oxidoreductase 
domain whose activity is abrogated by substitution of two critical cysteine 
residues at position 57 and 60.  MIF is secreted constitutively by intestinal 
epithelial cells and is highly upregulated when barrier function is compromised 
such as in the case of inflammatory bowel diseases.  MIF homologues are also 
secreted by many parasitic organisms, one of which is the intestinal helminth, 
Trichinella spiralis.  T. spiralis secretes vast quantities of MIF upon entering the 
gastrointestinal tract  though to date the biological relevance of T. spiralis derived 
MIF in modulating host responses is undetermined. 
In this study the generation MIF proteins and mutants devoid of enzymatic sites 
enabled the analysis of MIF’s role within the intestinal immune environment 
including the transcriptomic assessment of ex vivo intestinal explants and primary 
macrophages.  Recombinant WT and tautomerase deficient proteins generated 
as part of this body of work modulated TLR-4 mediated NF-kB activation in the 
presence of LPS in a HEK and HT29 cell model indicating that MIF can modulate 
epithelial driven immune responses via a master regulator.  Consistent with this, 
ex vivo studies utilising murine intestinal explants revealed that murine and 
Trichinella derived MIF homologues modulate cytokines such as IL-6, TNF-a and 
IL-22 to drive distinct immune responses.  In addition, the modulation of IL-22 
and TNF-a was highly dependent on the presence of the tautomerase site for 




from MIF treated macrophages in the presence of TLR4 ligand, LPS, confirmed 
MIF’s role in modulating immune responses. 
Further characterization of BMDM macrophages using RNA seq technologies 
demonstrated that MIF homologues, and in particular, the tautomerase site, 
modulate the macrophage transcriptome priming cells for two discrete responses 
upon pattern recognition receptor (PRR) activation.  Mm-MIF-1 treated BMDM 
macrophages downregulated several genes associated with the TNF-a 
processing and secretion, ADAM28, Trp63 and Rab27b.  Conversely, the 
parasite-derived Ts-MIF-1 upregulated genes responsible for cell cycle 
regulation, differentiation and cellular architecture such as IGFBP2, BMP3, BMP7 
and several Krt genes. 
Overall, the data presented in this thesis provides clear evidence of  discrete roles 
for murine and parasite-derived MIF in modulating innate immune responses and 
demonstrates that, while the activity of the tautomerase site is context dependent, 











Table of Contents 
Abstract ............................................................................................................... I 
List of tables .................................................................................................... VII 
List of figures .................................................................................................. VII 
List of abbreviations ...................................................................................... XIII 
Acknowledgements ...................................................................................... XVI 
Chapter 1:  Introduction to the Immunology of the Gastrointestinal Tract 
and Macrophage Migration Inhibitory Factor (MIF) ....................................... 1 
1.1 Background and Purposes of this study. ............................................. 1 
1.2 The intestinal immune environment. ..................................................... 2 
1.2.1 Intestinal architecture. ...................................................................... 2 
1.2.2 Epithelial cells in the GT. ................................................................. 5 
1.2.3 Innate immune cells in the GT. ........................................................ 7 
1.2.4 Innate immune receptors in the GT. ................................................ 9 
1.3 The cytokine Macrophage Migration Inhibitory Factor (MIF). ........... 10 
1.3.1 The origins of MIF ........................................................................... 10 
1.3.2 MIF protein structure and enzymatic activities. ........................... 11 
1.3.3 MIF receptors. ................................................................................. 13 
1.3.4 MIF modulation of intestinal immunity and GT functions. .......... 17 
1.3.5 Parasite MIFs modulate mucosal immunity mimicking the 
tumour microenvironment. ..................................................................... 20 
1.4 Research aims and novel contributions. ............................................ 21 
Chapter 2:  Materials and Methods ................................................................ 23 
2.1. Bacterial strains and plasmids ............................................................ 23 
2.1.1. Growth of Bacterial strains ........................................................... 23 
2.1.2. Preparation of chemically competent TOP10 and BL21 E.coli 
cells. .......................................................................................................... 25 
2.1.3. Transformation of E.coli TOP10 and BL21 cells ......................... 25 
2.2. Molecular Techniques. ......................................................................... 26 
2.2.1.  RNA Isolation and purification. ................................................... 26 
2.2.1.1.  Cells ............................................................................................ 26 
2.2.1.2.  Tissue .......................................................................................... 26 
2.2.1.3.  DNase I treatment. ..................................................................... 27 
2.2.1.4.  RNA clean-up. ............................................................................ 27 
2.2.2.  Reverse Transcription. ................................................................. 28 
2.2.3.  End-point PCR. .............................................................................. 28 
2.2.4.  Detection of PCR products. ......................................................... 29 
2.2.5.  Cloning of MIF sequences. .......................................................... 29 
2.2.6.  Cloning of pIRES_CD74 and pIRES_CD74/CD44. ...................... 32 
2.2.7.  Real-Time PCR – relative quantification. .................................... 33 
2.2.8.  RNA seq. ........................................................................................ 33 
2.2.9.  RNA seq analysis. ......................................................................... 34 




2.3.1.  Expression of HsMIF-1, HsMIF1 P2G, MmMIF1 P2G, TsMIF1, 
TsMIF1 P2G. ............................................................................................. 34 
2.3.2.  Expression of Hs-MIF-1 C57S/C60S, Hs-DDT-1, Mm-DDT-1, Ts-
MIF-2. ......................................................................................................... 35 
2.3.3.  SDS-PAGE Gel electrophoresis. .................................................. 36 
2.3.4.  Coomassie Staining. ..................................................................... 36 
2.3.5.  Western Blot. ................................................................................. 37 
2.4.  Protein Purification. ............................................................................ 37 
2.4.1.  Preparation of samples for purification. ..................................... 37 
2.4.2.  Ni-NTA purification. ...................................................................... 38 
2.4.3.  Buffer exchange and sample concentration. ............................. 38 
2.4.5.  Anion exchange chromatography. .............................................. 39 
2.4.6.  BCA assay. .................................................................................... 39 
2.4.7.  Limulus amebocyte lysate assay. ............................................... 39 
2.5.  Enzyme Assays ................................................................................... 40 
2.5.1.  Tautomerase Assay. ..................................................................... 40 
2.5.2.  Oxidoreductase Assay. ................................................................ 41 
2.6. Cell Culture. .......................................................................................... 41 
2.6.1. Reagents. ........................................................................................ 41 
2.6.2.  Cells. .............................................................................................. 41 
2.6.3.  Generation of Bone Marrow Derived Macrophages. ................. 42 
2.6.4. Generation of stable hTLR4-NF-κB-mCherry, HT-29-NF-κB-
mCherry and HEK-SBE-eGFP reporter cell lines. ................................. 43 
2.6.5.  Transient Transfections of pIRES_CD74 and 
pIRES_CD74/CD44. .................................................................................. 43 
2.6.6.  HT29-NFκB-mCherry reporter assay. .......................................... 44 
2.6.7.  HEK-Blue™-hTLR4 reporter assay. ............................................. 45 
2.6.8.  HEK-hTLR4-NFκB-mCherry reporter assay. ............................... 45 
2.6.9.  TGF-β and BMP-4 timecourse assay. .......................................... 45 
2.6.10.  TGF-β and MIF assay. ................................................................. 46 
2.6.11.  LPS and MIF BMDM assay. ........................................................ 46 
2.6.12.  Ex vivo intestinal explant assay. ............................................... 46 
2.7.  Immunological assays. ....................................................................... 47 
2.7.1. ELISA .............................................................................................. 47 
2.7.2.  Flow cytometry. ............................................................................. 48 
2.7.2.1. Antibody staining. ....................................................................... 48 
2.7.2.2.  Detection of fluorescent proteins. ............................................ 48 
2.7.3.  Phagocytosis Assay. .................................................................... 49 
2.9. Statistical Data Analysis ...................................................................... 49 
Chapter 3: Cloning and Characterisation of Mammalian and Helminth-
derived Homologues of MIF. .......................................................................... 51 
3.1. Introduction. .......................................................................................... 51 
3.1.1.  MIF’s Protein Structure and Enzymatic Activity. ....................... 51 
3.1.2.  Production of recombinant MIFs using Escherichia coli. ......... 57 
3.1.2.1 Protein expression using BL21 derivative competent cells. ... 57 
3.1.2.3 Co-expression of chaperone plasmids to increase folding 
efficiency. ................................................................................................. 59 




3.2. Chapter aims and objectives. .............................................................. 61 
3.3.  Cloning of MIF homologue expression constructs. ......................... 61 
3.4.  Purification of wild-type and mutant MIF homologues. ................... 65 
3.5.  Recombinant MIFs retain critical enzyme activities. ........................ 72 
3.6. Discussion of cloning and characterisation of MIF and MIF 
homologues. ................................................................................................ 80 
Chapter 4:  The effects of MIF on intestinal epithelial immune signalling 84 
4.1.  Introduction. ......................................................................................... 84 
4.1.1.  The Intestinal Immune system. .................................................... 84 
4.1.2.  The role of Pathogen Recognition Receptors such as TLR4 in 
regulating immune responses in Intestinal Epithelial Cells. ............... 85 
4.1.3.  MIF and TLR4 ................................................................................ 86 
4.1.4.  MIF and TGF-β. .............................................................................. 87 
4.2.  Chapter aims and objectives. ............................................................. 87 
4.3.  MIF inhibits TLR4 mediated NF- B activation of HEK-Blue™-hTLR4 
cells. .............................................................................................................. 89 
4.4.  Isolation of a HT29 NF-κB mCherry reporter cell line. ................... 101 
4.5.  MIF inhibits NF- B activation in HT29-NF- B-mCherry reporter 
cells after LPS treatment. ......................................................................... 104 
4.6. MIF and TGF-β ................................................................................. 109 
4.7. Discussion of the effects of MIF on intestinal epithelial immune 
signalling. ................................................................................................... 115 
Chapter 5:  Evaluation of MIF’s role in murine bone-marrow-derived-
macrophages. ................................................................................................ 119 
5.1. Introduction. ........................................................................................ 119 
5.1.1. The history of Macrophages. .......................................................... 119 
5.2. MIF in macrophage studies. .............................................................. 122 
5.3.  Chapter aims and objectives. ........................................................... 124 
5.4.  MIF modulates the macrophage cytokine transcriptome in response 
to LPS. ........................................................................................................ 125 
5.5. Discussion of MIF’s role in modulation of cytokine and phagocytic 
responses to LPS in BMDM’s ................................................................... 133 
Chapter 6:  Transcriptomic analysis of MIF’s role using RNA Sequencing.
 ........................................................................................................................ 141 
6.1. Introduction. ........................................................................................ 141 
6.1.1.  Transcriptomic modulation by MIF homologues. .................... 141 
6.1.2.  Utilising RNA sequencing technologies to assess the 
transcriptome. ........................................................................................ 145 
6.2.  Research aims and objectives. ........................................................ 145 
6.3. Quality control of RNA sequencing. ................................................. 146 




6.4.1. Transcriptional divergence of TNF-α modulating genes in MIF 
and MIF P2G treated BMDMs. ............................................................... 157 
6.4.2.  Ts-MIF-1 primes BMDM’s for polarization inducing transcripts 
involved in cell cycle regulation. .......................................................... 164 
6.4.3.  Ts-MIF-1 drives architectural changes in murine BMDM cells.
 ................................................................................................................. 170 
6.5.  Discussion of the transcriptomic analysis of MIF’s role using RNA 
sequencing. ................................................................................................ 173 
Chapter 7:  Assessment of MIF’s role in the intestinal immune response in 
an ex vivo colonic explant model. ............................................................... 179 
7.1.  MIF and the intestinal immune response. ....................................... 179 
7.1.1.  IL-6 ................................................................................................ 180 
7.1.2.  IL-17 .............................................................................................. 181 
7.1.3.  IL-22 .............................................................................................. 182 
7.1.4.  TNF-α ............................................................................................ 183 
7.1.6. Ex vivo models ............................................................................. 185 
7.2. Chapter aims and objectives. ............................................................ 186 
7.3. MIF modulates the expression of IL-6, IL-17 and IL-22 transcripts in 
ex vivo intestinal explants. ....................................................................... 186 
7.4.  MIF treatment skews Th17 cytokines in response to LPS-mediated 
signalling. ................................................................................................... 192 
7.5. Discussion of MIF’s role in the intestinal immune response in an ex 
vivo colonic explant model. ...................................................................... 196 
Chapter 8:  General Discussion ................................................................... 207 
8.1 Discussion ........................................................................................... 207 
8.2. Future directions. ............................................................................... 218 
8.3. Concluding remarks. .......................................................................... 221 












List of tables 
Table 2. 1 Media recipes used in this study. ..................................................... 23 
Table 2. 2  Genetic characteristics of strains and plasmids used in this study. 24 
Table 2. 3  List of Takara Chaperonin plasmids used for protein expression. .. 36 
Table 2. 4  Cell culture media used in this study. .............................................. 42 
Table 2.5  DNA (ng) used to transfect WT HEK 293 cells. ............................... 44 
Table 2.6  Antibodies used in this study. ........................................................... 48 
Table 4. 1 Summary of the genetic background and origins of the cell lines used 
to complete these objectives. ............................................................................ 88 
Table 6. 1 RNA seq quality control metrics.   Quality control results for RNA 
sequencing showing the percentage of mRNA, percent of uniquely mapped 
sequences aligned to the reference genome, duplication rate in filtered reads, 
percentage of reads passing filter (PF), percentage of adapter trimmed reads.  
All values are depicted as percentages. ......................................................... 149 
Table A. 1 List of primers used for cloning. ..................................................... 282 
Table A. 2  Full sequences used for cloning. .................................................. 283 
Table A. 3  qPCR primers used in this study. ................................................. 295 
Table A. 4  Differentially expressed genes in MIF treated BMDMs ................. 296 
 
List of figures 




Figure 1. 2 MIF’s three dimensional structure. .................................................. 13 
Figure 1. 3 Summary of MIF signalling pathways. ............................................ 17 
Figure 2. 1 pGEM-T Easy Vector Map .............................................................. 30 
Figure 2. 2  pET29b Vector Map ....................................................................... 31 
Figure 2. 3 pIRES Vector Map. ......................................................................... 32 
Figure 3. 1  MIF-1 is highly expressed by T.spiralis and confers the prototypical 
tautomerase activities. ...................................................................................... 53 
Figure 3. 2 Multiple sequence alignment shows conservation of enzymatic 
domains across species. ................................................................................... 55 
Figure 3. 3 The three-dimensional x-ray structure of Hs-MIF-1 and Hs-DDT-
1/MIF-2 protein structure. .................................................................................. 56 
Figure 3. 4 Schematic representation of the cloning of the MIF homologues into 
pET29b. ............................................................................................................. 62 
Figure 3. 5 Schematic representation of PCR mutagenesis and crossover PCR 
mutagenesis utilised to generate MIF-1 and MIF-2 homologue P2G mutants and 
the Hs-MIF-1 C57S/C60S mutant. .................................................................... 64 
Figure 3. 6 Confirmation of successful cloning of MIF sequences into the 
pET29b expression vector. ............................................................................... 65 
Figure 3. 7 Hs-MIF proteins are successfully expressed in BL21 CODON PLUS 
cells. .................................................................................................................. 67 
Figure 3. 8 Mm-MIF proteins are successfully expressed in BL21 CODON 




Figure 3. 9 Ts-MIF-1 and Ts-MIF-1 P2G successfully induced and expressed as 
soluble protein. .................................................................................................. 70 
Figure 3.10 Ts-MIF-2 is successfully expressed in BL21 pGRO7 cells ............ 70 
Figure 3. 11 Example SDS PAGE gel of protein fractions after AKTA 
purification. ........................................................................................................ 71 
Figure 3. 12 Fully purified MIF proteins. ............................................................ 72 
Figure 3. 13 Commercially available rHMIF1 lacks enzyme activity. ................ 73 
Figure 3. 14 Expressed and purified mammalian and parasite MIFs possess 
tautomerase activity. ......................................................................................... 77 
Figure 3. 15 Optimisation of storage conditions for recombinant Ts-MIF-1. ..... 78 
Figure 3. 16 Purified Hs-MIF-1 and Mm-MIF-1 exhibit oxidoreductase activity. 80 
Figure 4. 1 MIFs modulate LPS responsiveness in HEK-Blue™-hTLR4 cells. . 92 
Figure 4. 2 Isolation and characterization of an NF- B responsive isogenic cell 
line HEK-hTLR4-NF- B-mCherry. .................................................................... 95 
Figure 4. 3 Confirmation of presence of the CD74 and CD44 cDNAs in pIRES 
vectors. .............................................................................................................. 96 
Figure 4. 4 Optimization of transient transfection of HEK293-hTLR4-NF- B 1C1 
cells with a biscistronic vector expressing CD74 and CD44. ............................ 98 
Figure 4. 5  MIF treatment inhibits NF- B activation by LPS in HEK-hTLR4-NF-
B-mCherry 1C2 cells transfected with pIRES-CD74-CD44. ......................... 101 
Figure 4. 6  Isolation of an isogenic HT29-NF- B-mCherry reporter cell line. 104 
Figure 4. 7  Priming of the HT29-NF- B-mCherry reporter cell line with IFN-γ is 




Figure 4. 8  Hs-MIF-1 suppresses TLR4-driven NF- B signalling in HT29-NF-
B-mCherry IC5 cells. .................................................................................... 109 
Figure 4. 9  Characterisation of HEK-SBE-eGFP Isogenic cell lines. ............. 112 
Figure 4. 10  Analysis of the temporal dynamics of TGFβ and BMP4 signalling 
and the expression of eGFP in the HEK-SBE-eGFP isogenic cell line, IC3. .. 113 
Figure 4. 11 MIF does not modulate TGF-b signalling in the HEK-SBE-eGFP 
isogenic cell line, IC3. ..................................................................................... 114 
Figure 5. 1  Successful generation of bone marrow derived macrophages from 
C57BL/6 female mice. ..................................................................................... 126 
Figure 5. 2  MIF homologues modulate the IL-6 transcriptional responses to 
LPS in BMDMs. ............................................................................................... 128 
Figure 5. 3 MIF homologues modulate the MCP-1 transcriptional responses to 
LPS in BMDMs. ............................................................................................... 129 
Figure 5. 4  MIF homologues do not modulate the IL-10 transcriptional 
responses to LPS in BMDMs. ......................................................................... 131 
Figure 5. 5  MIF homologues do not modulate the secretion of IL-6 and TNF-α 
from BMDMs after LPS stimulation. ................................................................ 132 
Figure 5. 6  Summary of MIF modulation of LPS-driven cytokine transcriptional 
responses in BMDMs. ..................................................................................... 138 
Figure 6. 1  Schematic representing RNA seq workflow. ................................ 148 
Figure 6. 2  Number of differentially expressed genes identified in MIF-treated 




Figure 6. 3  Number of differentially expressed genes identified in MIF-treated 
macrophages. ................................................................................................. 154 
Figure 6. 4  Comparison of DEG’s in Mm-MIF-1, Mm-MIF-1 P2G, Ts-MIF-1 and 
Ts-MIF-1 P2G treated BMDMs. ...................................................................... 156 
Figure 6. 5  Schematic of MIF’s TNF-α modulating capabilities. ..................... 164 
Figure 6. 6 Trichinella derived MIF’s halt macrophage polarisation. ............... 173 
Figure 7. 1 MIF homologues modulate the transcriptional responses of IL- 6 in 
an ex vivo explant model. ................................................................................ 188 
Figure 7. 2 MIF homologues supress LPS induced IL-17 transcription in an ex 
vivo explant model. ......................................................................................... 190 
Figure 7. 3  MIFs homologues supress LPS induced IL-22 transcription in an ex 
vivo colonic explant model. ............................................................................. 191 
Figure 7. 4 MIFs modulate secretion of the cytokines IL-6 and IL-22. ............ 194 
Figure 7. 5 MIFs modulate the secretion of TNF-α. ........................................ 195 
Figure 7. 6 Summary of transcriptional and secreted cytokine responses to LPS 
+ murine MIF homologues. ............................................................................. 199 
Figure 7. 7 Summary of transcriptional and secreted cytokine responses to LPS 
+ T. spiralis MIF homologues. ......................................................................... 202 
Figure 8. 1    Proposed model for Mm-MIF-1 mediated development of 
protective immune responses at the intestinal barrier surface after translocation 




Figure 8. 2  Proposed model for Ts-MIF-1 mediated development of Th1, Th22 
and ILC3 responses at the intestinal barrier surface after translocation of LPS.
 ........................................................................................................................ 217 




















List of abbreviations 
APC Antigen presenting cell 
 
BCA bicinchoninic acid 
 
BMDM Bone Marrow derived Macrophage  
BMP Bone Morphogenetic Protein 
CCL Chemokine ligand 
 
CD Cluster of differentiation  
cDNA complementary DNA 
 
CXCL C-X-C chemokine ligand  
CXCR C-X-C chemokine receptor 
CY-7 Cyanine -7  
 
DAMP damage associated molecular pattern  
DC Dendritic cell 
 
D-DT D-Dopachrome Tautomerase 
DEG Differentially expressed gene 
DMEM Dulbecco's Modified Eagle Medium 
DNA deoxyribonucleic acid 
 
dNTP Deoxyribonucleotide triphosphate  
eGFP Enhanced Green Fluorescent Protein 
ELISA Enzyme linked immunosorbent assay 
FACS Fluorescence-activated cell sorting 
FBS Foetal Bovine Serum 
 
FDR False Discovery Rate  
 
GO Gene Ontology 
 





HEK Human embryonic kidney 
His Histidine 
  
HRP Horseradish peroxidase 
IEC Intestinal epithelial cell 
 




ILC Innate lymphoid cell 
 
IPTG Isopropyl _- d-1-thiogalactopyranoside 
LB Luria-Bertani medium  
 
M cell Microfold cell 
 





MHC Major Histocompatibility complex  
MIF Macrophage Migration Inhibitory Factor 
mRNA messenger RNA 
 
NF-kB Nuclear Factor kappa-light-chain-enhancer of activated B cells 
ng nanogram 
  
Ni-NTA Nickel-nitrilotriacetic acid 
NLR Nod-like receptor 
 
No RT No reverse transcriptase  
NTC  No template control 
 
PAMP pathogen associated molecular pattern  
PBS Phosphate buffered saline 
PE Phycoerythrin  
 




PRR Pattern recognition receptor  
qPCR quantitative PCR 
 
RNA ribonucleic acid  
 
RNA seq RNA sequencing  
 
RPMI Roswell Park Memorial Institute 
RT Room temparature 
 
SBE SMAD binding element  
SDS Sodium dodecyl sulphate  
SDS-
PAGE Sodium dodecyl sulphate - polyacrylamide gel electrophoresis  
SEAP Secreted Alkaline Phosphatase 
SXT Somatic Extract  
TAE Tris-Acetic acid EDTA  
 
Taq Thermus aquaticus  
 
TBS-T Tris buffered saline-Tween 20  
TE Tris-EDTA   
 
TEMED  N,N,N',N'-tetramethylethane-1,2-diamine 
TGF-B Transforming Growth Factor Beta 
TGS Tris, glycine, SDS buffer  
Th T helper  
  
TLR Toll-like receptor 
 
TNF-a Tumour Necrosis Factor alpha  
UV Ultra violet 
  
X-gal 5-Bromo-4-Chloro-3-Indolyl _-D-Galactopyranoside 








There are many people that have contributed to this PhD and here I would like to 
thank those that have taken the time to offer support and guidance.  
First and foremost, I would like to thank my director of studies Dr David Guiliano.  
You believed in my abilities when I did not believe in myself.  The support and 
guidance you have shown me over the course of this PhD, despite me being an 
incredibly stroppy student, has been unending and for that I will forever be 
grateful.   
I would like to thank my additional supervisors: Dr Maria Teresa Esposito and Dr 
Lesley Smyth for offering me support when it was needed.   
I am also very grateful to Dr Jose Saldana who helped me with copious amounts 
of animal work, Dr Nati Garrido-Mesa for helping me with ex vivo models and the 
graduate school for funding this PhD work. 
I would like to extend my gratitude to Paola Niola and Tony Brooks at the 
Genomics facility, UCL, for the help and guidance with RNA sequencing methods 
and analysis.  
To my best friend, Alessia Taccogna, who is one of the main reasons I survived 
this PhD.  Not only an incredible scientist, but a powerful, kind and honest woman 
who is an absolute force to be reckoned with.  Thank you so much for your 
guidance, your no-nonsense talks, but most of all, for your friendship. 
It is difficult to put into words how grateful I am to my little family but here I will 
try.  Anthony, you have offered unending, unconditional support for me, picked 




organised our lives, ferried the children around continuously, worked full-time and 
dealt with a stroppy, grieving partner always making the time to listen to my PhD 
troubles on a daily basis without judgement.  All of this just so that I could achieve 
my goals and build a career that I loved.  I have no doubt that there are very few 
partners on this planet that would sacrifice the things you have for me.  Thank 
you.  
My beloved children, Niamh and Charlie, you have truly saved me, and I want to 
dedicate this PhD to you both as a small gesture to say thank you.  This PhD is 
proof that no matter what life throws at you, or where you came from, anything is 
possible if you’re willing to fight for it.  Never stop fighting for it.  
Lastly, to my treasured Nonna and Grandad, sadly lost before I could tell you I 
made it. You taught me many important lessons in life but mainly that, it is not 
your intelligence that defines you, but your ability to keep getting back up when 
you fall.  I know this would have made you so incredibly happy to see and I cherish 
all the valuable advice you offered; it has seen me through many difficult days of 





Chapter 1:  Introduction to the Immunology of the 
Gastrointestinal Tract and Macrophage Migration Inhibitory 
Factor (MIF)  
1.1 Background and Purposes of this study. 
The gastrointestinal tract (GT) is perpetually subjected to attack from potentially 
hostile microbes, many of which secrete immunomodulatory molecules that 
mimic host responses in order to subvert local responses.     
Macrophage Migration Inhibitory factor (MIF) or MIF-like proteins are produced 
by a vast number of organisms including mammals, bacteria and parasitic 
helminths, many of which have been widely investigated and their functions are 
understood (Bernhagen et al., 1994; Falcone et al., 2001a; Leng et al., 2003; M 
et al., 2012; Prieto-Lafuente et al., 2009a; Tan et al., 2001; Vermeire et al., 
2008a).  Various microorganisms and helminths that colonise the GT secrete 
homologues of MIF, although to date, the role(s) these proteins play in infection 
processes remain to be determined.  In mammals, MIFs are produced in large 
amounts within the GT in response to an infection.  Similarly, within the tumour 
microenvironment MIFs are also highly expressed proteins though 
controversially, in these contexts, they have been demonstrated to exert 
seemingly contradictory actions (Balogh et al., 2018; Dessein et al., 2010; 
Figueiredo et al., 2018).   
A common trait shared between many MIF homologues is an evolutionarily 
conserved N-terminal proline site which is required for its tautomerase activity.  
Substitution of the tautomerase-conferring proline site to an alternative residue 




Fingerle-Rowson et al., 2009; Robert Kleemann et al., 2000b; Senter et al., 
2002a).  Regardless of the fact that the proline site is conserved in most MIF-like 
proteins, studies investigating the biological relevance of MIF’s enigmatic 
tautomerase activity have provided very little clarity on how it specifically links to 
specific biological functions or provided an example of a biological substrate.   
The work encompassed in this PhD project focusses on understanding the 
potential roles mammalian and parasitic nematode derived MIFs have in 
modulating innate immune responses particularly in the intestine. It also tests the 
relationship between the biological activity of these MIFs and their tautomerase 
activity. 
1.2 The intestinal immune environment. 
1.2.1 Intestinal architecture.     
The gastrointestinal tract (GT) is a complex organ system covered by absorptive 
mucosal epithelia and an underlying layer of muscle, connective tissue, blood, 
lymphatic vessels and immune cells.  Continuously exposed to a wide variety of 
insults, including pathogen and self-derived antigens, the ability of the GT to 
maintain barrier and absorptive functions is a critical feature. Immune 
homeostasis is governed by several factors including the commensal microbiota, 
dietary components and endogenous regulatory mechanisms, all of which help 
to maintain barrier integrity.  A key feature of the immune system within the GT 
is its ability to differentiate between commensal and pathogenic microorganisms 
(Eberl and Lochner, 2009; Kaper and Sperandio, 2005). 
The intestinal immune architecture has a distinct structure and function which is 
largely dependent on a specific anatomical location within the GT (figure 1.1).  In 




responses occur within the small and large intestine.  The small and large 
intestine are covered in a single layer of columnar epithelial cells interspersed 
with junctional proteins which form the protective surface of this tissue, constantly 
responding to external stimuli in order to maintain mucosal barrier integrity 
(Peterson and Artis, 2014).  Within the small intestine, epithelial cells are covered 
by villi, sometimes referred to as a  brush border, which serve to increase the 
surface area for absorption of nutrients and secrete enzymes into the local area, 
whilst contrastingly, epithelial surfaces in the large intestine are smooth and 
lacking villi largely since the majority of nutrients are absorbed prior to this point 
(Agace and McCoy, 2017; Santaolalla et al., 2011).  The epithelium undergoes 
constant replenishment from immature stem cells which arise from structures 
known as crypts of Lieberkühn.  Here, multipotent stem cells mature into 
absorptive enterocytes or other intestinal cells such as goblet cells which secrete 
mucus forming the protective glycocalyx.  Immune responses in the intestinal 
tract occur primarily within the epithelial layer and the lamina propria and, despite 
being adjacent to one another, they confer distinct immune functions.  Studies 
have shown that the type of immune responses elicited at these sites vary 
significantly and may be compartmentalized due to the specific resident 
microflora they contain. This ensures that immune responses at these sites are 
contained, thereby preventing unnecessary escalation of systemic immunity 






Figure 1. 1 Haematoxylin and Eosin staining of the small intestine.  A) 
Duodenum architecture at 10X and 20X magnification.  Black box represents 
magnified area.  At 10X the Villi are clearly observed whilst at 20X the epithelial 
derived absorptive enterocytes and mucus-secreting goblet cells can be seen. B) 
Ileum structure at 10X.  The mucosa forms the protective barrier of the intestinal 
surface separating the luminal contents while absorbing essential nutrients. 
Peyer’s patches containing the highly specialised antigen sampling M-cells are 
found in the dome of Peyer’s patches. 
 
Within the GT, specialised gut-associated-lymphoid-tissue (GALT), consisting 
largely of innate lymphoid cells, mesenteric lymph nodes and Peyer’s patches 
which are confined to the small intestine, play a critical role in both the 
development of mucosal adaptive immune responses as well as the development 




Microfold cells (M cells), which reside on the luminal side of the Peyer’s patches 
(PPs) constitutively traffic antigen through the epithelial layer within the GT 
forming a critical part in eliciting immune responses.  Many of the immune 
responses within the GT are mediated by innate immune cells, of which, a large 
proportion are intestinal macrophages that can activate local CD4+ or CD8+ T-
cells, many of which display markers associated with memory effector cells.   
Intestinal macrophages, though being constantly replenished by extravasating 
blood monocytes, have unique characteristics such as the production of high 
levels of IL-10 whilst still retaining the capacity to become classically inflammatory 
when appropriately activated (Morhardt et al., 2019).   
The significance of immune homeostasis within the GT has been extensively 
studied and it is well-documented that intestinal immune dysregulation has the 
capacity to cause systemic pathologies including autoimmunity, diabetes and 
tumour development.  For instance, chronic state of inflammation and exposure 
to inflammatory mediators, such as reactive oxygen species within this tissue has 
been directly linked to the progression of GT cancers (Wang et al.,2016). 
Additionally, cytokines which may alter the kinetics of immune response 
resolution, such as Macrophage Migration Inhibitory Factor (MIF), prolonging or 
altering inflammatory states, have been shown to influence, generally promoting 
tumour development and growth (Simpson et al., 2012, Yaddanapudi et al., 
2013).     
1.2.2 Epithelial cells in the GT. 
Historically, intestinal epithelial cells were considered passive in terms of 
mediating immune responses in the GT, their principal role being to serve as a 
physical barrier between the luminal milieu and the internal environment.  In more 




been extensively researched and, it is now understood that they form a critical 
role as sentinels, mediating local immune responses due to their unique 
positioning along the GT.   IEC’s can secrete a wide array of cytokines and 
chemokines, including, but are not limited to: IL-1β, IL-6, IL-8, IL-18, TGF-β, MIF, 
TNF-α, CCL-2 and CXCL-8, at varying levels in response to innocuous and 
noxious antigens (Bauché and Marie, 2017a; Harrison et al., 2015; Jung et al., 
1995; Kucharzik et al., 2005; Maaser et al., 2002a; Takada et al., 2010a; Vujicic 
et al., 2018a) .  Besides this, IEC’s also secrete innate effector molecules such 
as antimicrobial peptides like REGIIIγ and several defensins that disrupt bacterial 
membrane or cell wall components including peptidoglycan.  
IEC’s respond to specific molecular patterns endogenous to harmful antigens or 
tissue damage by communicating with local innate immune cells.  Accordingly, 
stimulation of intestinal epithelial cell line, Caco2, with purified flagellin derived 
from enterohaemorrhagic Escherichia coli, 0157:H7 led to rapid secretion of IL-8 
and subsequent recruitment of leukocytes (Fraser-Pitt et al., 2011).  IL-8 and the 
murine homologue, MCP-1 recruit monocytes and macrophages to the site of 
inflammation (Bauermeister et al., 1998).  IEC’s also play a significant role in 
modulating immune response to intestinal parasites.  Nair et al (2008) 
demonstrated that IEC’s infected with the parasitic nematode, Trichuris muris, 
secreted resistin-like molecule beta (RELM-β), activating local macrophages to 
upregulate MHC class II and secrete pro-inflammatory cytokine IL-12 further 
driving local antigen-specific Th1 responses contributing to infection longevity. 
Another example of IEC modulation of local immune cells was discovered during 
infection of murine IEC’s with Vibrio cholerae which resulted in secretion of thymic 
stromal lymphopoietin and CCL20, attracting local dendritic cells to the site which 




CCL22 (Bhowmick et al., 2012).  Th2 responses to V.cholerae induce IgG4 and 
IgE production, in addition to, the recruitment of mast cells to resolve infection 
and provide future protective immunity (Bhuiyan et al., 2009). 
1.2.3 Innate immune cells in the GT. 
The GT contains vast and varied types of immune cells in order to respond rapidly 
to harmful antigens whilst maintaining tolerogenic properties at steady state.  
Classical antigen-presenting cells, such as macrophages and dendritic cells, 
make up a large percentage of cells along the GT.  Despite this, in the colon, 
macrophages constitute the major cell population and increase drastically in 
number from the beginning of the small intestine peaking in the caecum and colon 
(Denning et al., 2011; Nagashima et al., 1996).  Spatially, colonic macrophages 
are located in very close proximity to the epithelial layer demonstrating their 
importance in mediating epithelial driven immune responses (Carlsen et al., 
2006; Mahida et al., 1989).   Colonic macrophages typically express high levels 
of markers associated with activation including MHC class II, CD163 and CD40 
(Andrade et al., 2005; Mahida et al., 1989) in order to be able to respond rapidly 
once epithelial integrity is compromised.  Paradoxically, they also produce 
substantial quantities of IL-10 promoting anti-inflammatory processes, the 
survival of FOXP3+Treg cells, and maintenance intestinal tolerance (Murai et al., 
2009).  While intestinal macrophages are phenotypically and functionally 
specialised, being influenced to polarise to specific subtypes by the metabolic by-
products of resident commensal microbes, they are constantly replenished by 
bone marrow derived monocytes (Desalegn and Pabst, 2019). 
Though macrophages form the largest innate immune cell subset in the colon, 
several other innate immune cell types coexist with them including subset 1 




from those found in the small intestine.  Depletion of CD103+ CD11b- cDC1’s in 
Clec9A–diphtheria toxin receptor (DTR) mice resulted in severe dextran sodium 
sulphate – induced colitis at doses as low as 2% (DSS) (Muzaki et al., 2016) while 
depletion of subset 2 CD103+ Cd11b+ cDC2s had no effect on intestinal 
inflammation demonstrating the importance of cDC1 in maintaining colonic 
epithelial integrity. 
More recently, a third group of cells, innate lymphoid cells (ILCs) have been noted 
as critical mediators of mucosal immunity with their nomenclature divided into 
several subsets existing including ILC1, ILC2 and ILC3.  ILCs are considered to 
be the innate arm of their respective T helper cell subsets, for example, ILC1 
subsets promote the differentiation of Th1 cells including the secretion of IFN-g in 
response to archetypical Th1 associated cytokines, IL-12 and IL-18 whilst being 
regulated by the Th1 associated transcription factor, T-bet (Fuchs et al., 2013).  
ILC2  cells, much like their Th2 counterpart, are involved in the expulsion and 
clearance of helminth infections and allergy-associated inflammation, and 
respond to Th2 associated cytokines such as IL-2, IL-25 and IL-33 by producing 
IL-13 (Mjösberg et al., 2011). In addition to the aforementioned ILC subsets, ILC3 
cells form an interesting subset that play a significant part in maintaining barrier 
function within the intestine.  ILC3 cells are governed by the Th17 associated 
transcription factor, RORgt and secrete IL-17 and IL-22 in response to stimuli  
such as IL-1b and IL-23 from IECs and other innate immune cells (Melo-Gonzalez 
and Hepworth, 2017). To date, several studies have shown that  ILC1 cells are 
abundant throughout the human intestine but ILC2 and ILC3 decrease in  
absolute number as the small intestine transitions into the colon (Krämer et al., 




1.2.4 Innate immune receptors in the GT. 
One of the principal mechanisms by which immune responses are regulated in 
the GT is with the differential expression of innate pathogen recognition receptors 
(PRRs), such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs), in 
IECs and innate immune cells. The PRR repertoire is extensive and has evolved 
to distinguish the many existing pathogens based on their unique pathogen or 
damage-associated-molecular-patterns (PAMPs/DAMPs) such as 
lipopolysaccharide (LPS), Flagellin and the high motility group box 1 protein 
(HMGB1) (Johnston and Corr, 2016).  It has long been known that the ‘janitorial’ 
innate immune cells within the GT, such as macrophages and dendritic cells, 
express high levels of TLR-2 and TLR-4 at the cell surface.  Contrastingly, IECs 
express low levels of TLR-4 and the TLR-4 co-receptor MD-2, to prevent 
constitutive activation by intraluminal antigens such as the gram negative 
bacterial endotoxins (LPS), and further studies mapping the location of TLR4 in 
IECs have demonstrated that it is predominantly expressed at the basolateral 
surface in healthy colonic epithelium (Hornef et al., 2003; Santaolalla et al., 2013).   
That said, once the epithelial barrier is compromised antigens can rapidly diffuse 
into the basolateral compartment, be recognised and cleared due to countless 
surveying and resident innate immune cells in local proximity such as the 
aforementioned macrophages.   One of the most widely expressed TLR’s in IECs 
is TLR4 which recognises the bacterial endotoxin, LPS, and causes a classical 
inflammatory response.  Canonical activation of TLRs leads to a signal cascade 
mediated by TIRAP, TRIF and MYD88 and, typically results in the 
phosphorylation of master regulator NF-κB leading to upregulation of 
proinflammatory cytokine/chemokine expression and production. In murine 




shown to not only predispose individuals to dysbiosis of the commensals within 
the GT leading to more frequent opportunistic infections, but, also lead to loss of 
barrier functions which can lead to chronic inflammation, autoimmune disorders 
and potentially cancer (Fukata and Arditi, 2013; Noguchi et al., 2009).   
Interestingly, NOD2 has recently been shown to act as a sensor for TLR4 
signalling, driving responses based on the strength and duration of the TLR4 
mediated signal.  This unique mechanism of action provides some evidence for 
synergism between intracellular and extracellular PRR’s (Kim et al., 2015).  
1.3 The cytokine Macrophage Migration Inhibitory Factor (MIF).   
1.3.1 The origins of MIF  
Since its initial discovery as the first cytokine over forty years ago (Remold et al., 
1971), MIF an evolutionarily conserved pleotropic cytokine and hormone, has 
been implicated in numerous biological processes from counteracting the 
immunosuppressive effect of naturally occurring glucocorticoids, to the regulation 
of glucose and lipid metabolism (Finucane et al., 2014). However, MIF has 
recently been shown to be a significant player in the progression of many disease 
pathologies, as shown in table 1.1, which are a currently a serious cause for 
concern worldwide, such as autoimmune/autoinflammatory disease, 
cardiovascular disease and cancer (Murakami et al., 2002, Morand et al., 2006, 
Stosic-Grujicic et al., 2008, He et al., 2009, Sreih et al., 2011). MIF’s 
immunomodulatory activities have been extensively explored and it has been 
identified as a key regulator of both the innate and adaptive arms of the immune 
system. MIF has chemokine-like activities influencing both the recruitment of cells 
via migration (Fan et al., 2011; Hermanowski-Vosatka et al., 1999) and cytokine-
like activities regulating the effects of other inflammatory mediators. However, 




biological process such as cell cycle progress via p53, cell division and metabolic 
processes in both immune and non-immune cells (Brock et al., 2014).  MIFs 
precise role(s) in directing immune responses is controversial and to date and the 
molecular events underpinning MIFs mechanisms of actions remains to be fully 
elucidated.   
 
1.3.2 MIF protein structure and enzymatic activities. 
MIFs are small proteins ranging in size from 12-15 kDa. Human MIF-1 (accession 
number CAG30406.1) is composed of 115 amino acids and Human DDT/MIF-2 
(accession number CAG30317.1) is 118 aa.  MIF monomers are made up of two 
anti-parallel α-helices and a four-stranded β-sheet. MIFs assemble into a 
Table 1.1 A selection of disorders with pathophysiologies linked to MIF.   
Disease   Mechanism of action   Reference   
Rheumatoid 
Arthritis   
Upregulates RANKL expression 
leading to osteoclastogenesis.   
Kim et al., 2011   
Colorectal Cancer   Increase in MMP9 and VEGF 
promoting angiogenesis. 
He at al., 2009   
Diabetes Mellitus   Increases lymphocyte proliferation and 
adhesion driving inflammation.   
Stosic-Grujicic et al., 
2008   
Systemic Lupus 
Erythematosus   
Increase macrophage and B cell 
survival by inhibiting apoptosis.   
Sreih et al., 2011   
Crohn’s Disease   Activates dendritic cells and increases 
IL1β and IL8   
Murakami et al., 




homotrimer where two additional β-strands from each monomer interact with the 
β-sheet from adjacent monomers forming the monomeric interface. The overall 
quaternary structure results in the three co-joined β-sheets forming a barrel-
shaped solvent channel at the centre of the trimer as shown in figure 1.2 (H W 
Sun et al., 1996).  Unlike most cytokines, mammalian MIFs have two enzymatic 
activities conserved within an N-terminal proline residue and in MIF-1-like MIFs 
the CXXC motif.  The protein structure of MIF has a similar topology but no 
sequence similarity to two bacterial enzymes:  4-oxalocrontonate tautomerase (4-
OT) and 2-carboxymethyl-5-hydroxymucante isomerase (CHI) (Subramanya et 
al., 1996).  One unusual feature of MIFs, 4-OT and CHI, is that catalytic N-
terminal Proline residues Pro2 have a pKa of 7.0 when, comparably, a typical N-
terminal Proline would have a pKa of 3 pH units lower (Stivers et al., 1996).  
Studies have demonstrated that MIFs have the ability to keto-enol tautomerise 
two substrates in vitro, the naturally-occurring p-hydroxyphenylpyruvate and the 
artificial substrate L-dopachrome methyl ester (Rosengren et al., 1996, Bendrat 
et al., 1997, Rosengren et al., 1997, Lubetsky et al., 1999) and this activity is 
dependent on the formation of a trimeric complex.  However, as neither of these 
tautomerase substrates exist in humans, the significance of such enzymatic 
activity and its role in MIFs varied biological activities are poorly understood.   
Additionally, a second enzymatic site, containing a CXXC motif, found in MIF-1-
like family members, has been shown to be capable of functioning as protein 
oxidoreductase. In vitro, this has been demonstrated in the reduction of the 
mature insulin β-chain. The CXXC motif within human MIF has been implicated 
in a number of biological responses, from inducing intracellular signalling via Jab1 




(Luedike et al., 2012), and is believed to play critical roles in MIFs ability to act as 
a signalling molecule.    
 
 
Figure 1. 2 MIF’s three dimensional structure.  Human MIF-1 (PDB: 1MIF)  
and DDT-1 (PDB: 1DPT) form a barrel-like structure formed from three subunits 
joined by the inherent b-sheets.  The barrel-like structure contains the Pro2 
catalytic core.  Structures obtained from Protein Data Bank (PDB). 
1.3.3 MIF receptors. 
1.3.3.1 CD74.  
MIF’s signalling mechanisms have been widely studied and several cell surface 
and intracellular receptors have been proposed as transducer or receptors of MIF 
(figure 1.1).  The most well-established receptor to date is the MHC class II 
invariant chain, Ii or CD74, which exists as both a transmembrane and soluble 
forms.  CD74 was isolated as a MIF receptor in 2003 after a study by Leng et al 
(2003) demonstrated that antibody blockade of CD74 significantly decreased the 
amount of phosphorylated ERK 1/2 in response to 50ng/ml MIF treatment in 




affinity (Kd = 1.4nM) (Merk et al., 2012) triggering a signal cascade that leads to 
the recruitment of a further cell surface receptor, CD44, which lead to the 
activation of ERK 1/2.  Conflicting data from further studies indicate that, while 
CD44 is essential for canonical MIF signalling, the absence of CD44 does not 
completely abrogate MIF signal transduction.  Interestingly,  CD74 is expressed 
on the cell surface of non MHC class II cells such as epithelial cells suggesting a 
role, distinct from its function as chaperone for MHC-II and component of the 
antigen presenting machinery (Henne et al., 1995).  In B-cells, MIF signalling via 
CD74, induces the activation of NF-κB and downstream  transcription of survival 
factors such as Bcl-X (Starlets et al., 2006).  Similarly, CD74 activation by MIF in 
murine colonic epithelial cells led to rapid upregulation of the anti-apoptotic Bcl-2 
and cyclin E increasing cell survival (Maharshak et al., 2010a).  Importantly, a 
tautomerase deficient MIF generated by knock-in of a mutant MIF gene where 
Pro2 was changed to Glycine, exhibited reduced binding to CD74 with an 
equilibrium dissociation constant of 39nM and 9nM, respectively (Fingerle-
Rowson et al., 2009). These and other studies indicate MIF’s tautomerase activity 
or this site of the protein may be partially responsible for CD74 binding.  Beyond 
these initial studies how MIF’s tautomerase site modulates receptor binding still 
remains relatively unexplored.  
1.3.3.2 CXCR-2 and CXCR-4. 
Aside from MIF’s actions as a cytokine, it also confers chemokine-like properties 
binding to CXCR-2 and CXCR-4 which was demonstrated by MIF competing for 
binding to CXCR-2 and CXCR-4 against their cognate ligands such as CXCL-1.   
Additionally, MIF-binding to CXCR-2 promoted the formation of a receptor 
complex with CD74 leading to rapid chemotaxis of immune cells such as 




or CD74 in murine splenic B cells completely inhibits MIF-mediated chemotaxis 
suggesting that CD74 and CXCR-4 may work cooperatively to mediate MIF 
signalling (Klasen et al., 2014).   MIF shares several structural motifs with other 
chemokine-like ligands, namely a pseudo-ELR motif (Asp-44–X-Arg-11) which in 
one study, upon mutation of Arg-11 and Asp-44, led to a significant reduction in 
the MIF/CXCR-2 receptor complex (Weber et al., 2008) and subsequent 
leukocyte recruitment.  More recently, MIF been demonstrated to mediate, via 
CXCR-4, resistance to chemotherapeutic agents such as methotrexate and 5- 
fluorouracil in HT-29 cell and promotes an invasive phenotype.  Additionally, 
enzymatic inhibition of MIF’s tautomerase activity by ISO-1 significantly reduced 
the characteristics associated with metastasis indicating a potential functional 
role for MIF’s tautomerase activities in CXCR-4 binding  (Dessein et al., 2010).  
1.3.3.3 JAB/1.  
In addition to the surface receptor mediated signalling described above, MIF also 
exerts other effects intracellularly via c-Jun activation domain-binding protein-1 
(Jab1). Jab1 forms a critical part of the COP9 signalosome involved in promoting 
cell proliferation by disarming tumour suppressors such as p53 and p27Kip1 
(Shackleford and Claret, 2010).  MIF has been shown to bind and inhibit Jab1 
and AP1 leading to negative regulation of many genes such as cJun.  
Additionally, MIF stabilises levels of p27kip1 by inhibiting cullun-dependant 
proteolysis and degradation.  In this case, MIF did not affect the activation levels 
of NF-κB as was previously demonstrated indicating that in the context of a 
macrophage cell line, RAW 264 MIF inhibits AP-1 transcription independent of 
NF-kB (R. Kleemann et al., 2000a).  MIF’s cysteine residues within its CXXC motif 
have been suggested as possible binding sites for the formation of MIF/Jab1 




– 65 covering the CXXC motif that could bind Jab1 and increase ERK 1/2 
phosphorylation to the same extent as a full-length MIF protein.  However, 
cysteine mutants (C57S/C60S), which are devoid of any oxidoreductase activity, 
still bound Jab1 with identical capacity indicating that MIF binding to Jab1 may 
be driven or potentiated by other domains of the protein.  However, despite MIF 
cysteine mutants still binding to Jab1, the typical downstream activation of ERK 
1/2 was absent indicating that loss of Cys57 and Cys60 may drive modulation of 
ERK 1/2 via an alternative MIF receptor such as CD74. Interestingly, MIF’s 
interactions with Jab1 have also been implicated in its well-known role as a p53 












Figure 1. 3 Summary of MIF signalling pathways. MIF signals via several 
potential receptors.  CD74/CD44 – Binding of MIF to CD74 leads to recruitment 
of CD44, phosphorylation of SRC kinase and various downstream responses 
including inhibition of p53 and activation of MAPK/ERK pathway.  JAB1 – MIF 
can be endocytosed and signal intracellularly by binding to JAB-1, including 
inhibiting MAPK/ERK mediated gene expression.  CXCR-2 and CXCR-4 – 
Binding of MIF elicits a G-protein coupled response and activates or supresses 
NF-κB signalling modulating gene expression of cytokines and chemokines.  Both 
CXCR-2 and CXCR-4 can form a complex with CD74. 
1.3.4 MIF modulation of intestinal immunity and GT functions.   
The role of MIF in systemic inflammatory responses has been widely researched. 
However, little is known about its role in mucosal immunity and the GT.  Previous 
studies have focussed on MIFs ability to direct immune cell differentiation and 
migration within the GT.  Colonic epithelial cell derived MIF inhibits the migration 
of monocytic U937 cells towards the chemotactic agent SDF-1a (Maaser et al., 
2002a).  Additionally, recombinant human MIF converts colonic cancer cell line 




culture of MIF-producing cell line, Raji B cells, with Caco2 cells induces the M 
cells phenotype and this is ablated in the presence of a MIF-antibody (Man et al., 
2008a).  Despite efforts to understand MIF’s role within the GT, the effect on the 
epithelial cells that line the entire GT and serve as the initial point of contact for 
most invading pathogens, remains relatively unexplored.  Studies utilising murine 
MIF KO models have potentially identified a role for MIF in positively regulating 
intestinal permeability.  Absence of MIF in epithelial cells led to a significant 
increase in the mRNA of tight junction proteins, Zona Occludins 1 and Claudin 2 
and the aberrant expression of IL-18 which is known to cause disruption of 
epithelial junctions (Vujicic et al., 2018b). Evidence from a limited number of 
studies indicates MIF could play a key role in mediating protective immunity as 
demonstrated widely in the context of parasitic infections.  MIF deficient mice are 
susceptible to infection with Heligmosomoides polygyrus despite immunization 
and, whilst Th2 responses were typically unaffected, the innate arm of the 
immune response was severely comprised including reduced eosinophilia and 
delayed polarisation of macrophages to an M2 phenotype preventing expulsion 
(Filbey et al., 2019a).  Similarly, host MIF can stimulate responses to eliminate 
parasites such as Leishmania (Gupta et al., 2013) and Toxoplasma gondii 
(Cavalcanti et al., 2011a) by inducing the production of pro-inflammatory 
cytokines like IFN-y, IL-12 and nitric oxide (Bozza et al., 2012).  Furthermore, it 
has been demonstrated that endogenous MIF is produced by the gastric and 
intestinal epithelium (Maaser et al., 2002).  However in cancers MIF mRNA and 
tautomerase activity is significantly increased within epithelial cells from human 
sporadic colorectal adenocarcinomas (Wilson et al., 2005).  Additionally, MIF 
dysregulation within the GT also appears to be linked to the development several 




ulcer formation induced by the bacteria Helicobacter pylori. In this system 
production of too much MIF is linked to the inflammation of the mucosa, 
ulceration, and the development of gastric cancers (Beswick et al., 2006). 
However, the details of both the sources of MIF in the GT and its 
immunomodulatory functions remain largely undefined.    
Tumorigenesis is a multi-step process involving a complex array of steps where 
tumorigenic cells acquire the ability to overcome normal growth control process, 
colonize new tissue spaces and evade immune surveillance mechanisms that 
would typically destroy them (Dunn et al., 2002, Schreiber et al., 2011, O'Sullivan 
et al., 2012, Mittal et al., 2014). Genetic and molecular studies indicate MIF 
participates in each of these key steps (Choi et al., 2012). This includes promoting 
cell growth via inhibition of the master tumour suppressor gene p53 as well as 
facilitating the colonization of new tissue spaces by allowing tumour cell migration 
or induction of angiogenic responses (Coleman et al., 2008; Choudhary et al., 
2013). Critically, MIF is now believed to play a key role in the development of 
favourable immunological microenvironments for the growing tumour, 
suppressing local immune responses leading to the failure of immunosurveillance 
(termed cancer immunoediting) (Dunn et al., 2002, Dunn et al., 2004, O'Sullivan 
et al., 2012, Schreiber et al., 2011). Among the cancers that develop in the GT, 
colorectal cancers have been shown to secrete large amounts of MIF into the 
local environment (He et al., 2009). This is thought to assist tumour progression 
by inhibiting immune effector cell migration and promoting the transition of 
epithelial-to-mesenchymal cells with immunosuppressive activities (Boissiere-
Michot et al., 2014). Based on these observations MIF is now being explored as 




to each of these aspects of tumour development will be critical for the effective 
development of novel therapeutic strategies.   
1.3.5 Parasite MIFs modulate mucosal immunity mimicking the tumour 
microenvironment.   
Remarkably, many intestinal parasites have been shown to produce their own 
cytokine homologues of MIF including Entamoeba histolytica (Vermeire et al., 
2008), Strongyloides ratti (Younis et al., 2012), and Heligosomoides polygyrus 
(Filbey et al., 2019b). Additionally, Trichinella spiralis, a nematode which 
completes an entire life cycle within a single host, has been shown to produce 
two MIF cytokine homologues upon contact with the acidic gastric environment 
(Tan et al., 2001; Guiliano., unpublished). Infection with this nematode typically 
leads to a potent Th2-type immune response which in the case of T. spiralis but 
not S. ratti or H. polygyrus. Numerous studies have demonstrated T. spiralis’ 
propensity to modulate immune responses in a stage-specific manner in order to 
promote their own survival.  T. spiralis has been shown to increase the production 
of Th1 cytokines, such as IL12 and INF-γ, in early infective stages in order to 
regulate the number of new-born larvae whilst limiting worm expulsion via Th2 
mediated mechanisms (Helmby and Grencis., 2003).  Paradoxically, intravenous 
administration of T.spiralis new-born larvae leads to the rapid induction of IL-10-
producing innate immune cells which, in turn, promotes larval survival whilst 
limiting host collateral damage (Huang et al., 2014).  The molecular mechanisms 
utilised by this and other intestinal helminths to modulate host immunity in a way 
that promotes their survival bears a striking resemblance to that seen in some 
tumours (Elliott and Weinstock, 2012, Weinstock and Elliott, 2013).    
Analysis of parasite derived MIFs show that while they are quite divergent in 




a similar quaternary structure and maintain some of the critical enzymatic and 
other biological activities. However, these studies have also highlighted that they 
are capable of eliciting distinct responses from immune cells relative to 
endogenous human MIF. This indicates they may have additional or novel 
immunomodulatory properties. Comparative analysis of the human and parasite 
derived molecules may provide novel insights into the sites and mechanisms of 
action of these molecules. 
1.4 Research aims and novel contributions.   
The primary aim of this study is to develop an understanding of MIF’s role within 
the intestinal immune environment with particular emphasis on colonic epithelial 
cells and macrophages one of the innate immune cells that form the initial 
immune response to pathogens and facilitate adaptive immune responses within 
the GT.  Forming a significant part of this study is the production and comparative 
analysis of recombinant wild-type and tautomerase-deficient mammalian (human 
and murine) and Trichinella spiralis-derived MIF homologues to gain insight into 
the relatively unexplored biological relevance of the highly conserved enzymatic 
activities.  This would allow for the identification of specific MIF domains as a 
therapeutic target. 
In addition, part of this PhD work focused on developing a set of tools that would 
enable us to assess MIF’s function as a modulator of key immune protein 
complexes, such as NF-κB, a critical regulator of both epithelial and macrophage 
driven responses.  This includes the generation of several stable isogenic 
reporter cell lines derived from colonic cancer cell lines which upregulate 
expression of the fluorescent proteins GFP or mCherry in response to NF-kB 




expressing GFP after activation of a Smad-binding element, or signal HEK 293 
TLR-4 activation by secreted alkaline phosphatase were also used in conjunction 
with these MIF recombinants to explore its potential modulatory properties on 
these key innate signalling pathways. 
Similarly, a second focus point for this work included the examination of the 
effects of recombinant mammalian and parasite MIF treatment on cytokine 
production by murine bone marrow derived macrophages and whole tissue 
colonic explants under normal conditions or conditions mimicking loss of barrier 
function or infection such as PAMP stimulation.  To assess the relative 
contribution of the tautomerase activity to the biological activity of these enzymes, 
mutant recombinants were included as comparators. 
Finally, to uncover additional insight into how MIF alters the transcriptome and 
molecular signalling pathways in innate immune cells RNA-sequencing analysis 
was used to measure changes in gene expression in murine bone marrow 
derived macrophages after treatment with mammalian and parasite derived MIF 
homologues. The analysis of these datasets has allowed additional novel links 
between MIF, its immunomodulatory activities and several key signal 














Chapter 2:  Materials and Methods 
2.1. Bacterial strains and plasmids 
2.1.1. Growth of Bacterial strains 
Bacterial strains were maintained on either LB agar plates or, for long-term 
storage, in 20% glycerol at -70°.  Two bacterial strains were utilised within this 
study: TOP10 E.coli cells for propagation and stability of plasmids, and BL21 
expression derivatives for induction and protein expression.   All growth media is 
listed in table 2.1.  Bacterial strains and plasmids used in this study are listed in 
table 2.2. 
Media Component w/v 
LB broth Bacto-Tryptone 10g/L 
Yeast Extract 5g/L 
NaCl 5g/L 
Distilled H2O 1 litre 
LB agar As above + agar 15g/L 
2 x YT broth Bacto-Tryptone 16g/L 
Yeast extract 10g/L 
NaCl 5g/L 
Distilled H2O 1 litre 
2 x YT agar As above + agar 15g/L 
Tryptone Soy broth Oxoid (CM0129) 30g/L 








Table 2. 2  Genetic characteristics of strains and plasmids used in this study. 
Strain or plasmid Genotype  Source 
Strains    
TOP10 F– mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU galK 
λ– rpsL(StrR) endA1 nupG 
 Guiliano lab 
BL21(DE3) F– ompT hsdSB (rB–, mB–) gal dcm (DE3)  Guiliano lab 
BL21- 
CodonPlus 
F– ompT hsdS(r – m –) dcm+Tetr gal endA Hte [argU proL Camr]   Guiliano lab 
Plasmids   Inducer  
pGEM-T EASY Derivative of pGEM®-5Zf(+) vector, Ampr  Promega (Cat no. A1360) 
pET29b Bacterial expression vector, contains C-terminal 6Histidine-tag, 
Kanr 
IPTG Merckmillipore (Cat no. 
69872) 
pIRES Mammalian expression vector, Ampr, Neor - Takarabio (Cat no. 631605) 
pGro7 Contains chaperones groES-groEL, Camr L-Arabinose Takarabio (Cat no. 3340) 
pKJE7 Contains chaperones dnaK-dnaJ-grpE, Camr L-Arabinose Takarabio (Cat no. 3340) 
pG-Tf2 Contains chaperones groES-groEL-tig, Camr Tetracycline Takarabio (Cat no. 3340) 
pTf16 Contains chaperones Tig, Camr L-Arabinose Takarabio (Cat no. 3340) 
pG-KJE8  Contains chaperones dnaK-dnaJ-rpE groES-groEL, Camr L-
Arabinose, 
Tetracycline 
Takarabio (Cat no. 3340) 
 






2.1.2. Preparation of chemically competent TOP10 and BL21 E.coli cells. 
 
TOP10 and BL21 E.coli cells were made chemically competent following an 
adaptation of the well-established Inoue protocol (Inoue et al., 1990).  A single 
bacterial colony was picked from an agar plate containing the bacterial competent 
cells, inoculated into 5mL of 2 x YT broth containing the appropriate antibiotics 
and incubated overnight at 37°C.  Overnight cultures of E.coli were resuspended 
in 2xYT broth and grown to OD600 0.5-0.7. Cells were collected by centrifugation 
at 4700 rpm at 4°C for 10 minutes. Ensuring that cells always remained on ice, 
pellets were resuspended in 80mL of RF1 buffer (100mM RbCl, 50mM MnCl2, 
30mM KOAc, and 10mM CaCl2, 15% w/v glycerol, pH 5.8) and incubated on ice 
for 1 hour. Bacteria were centrifuged as described previously, resuspended in 
40mL RF2 buffer (10mM MOPS, 10mM RbCl, 75mM CaCl2, and 15% w/v 
glycerol) and incubated on ice for an additional 15 minutes. 500 µL and 100µL 
cells were then aliquoted into cryotubes (pre-chilled at - 70°C) and immersed into 
a Dewar flask containing liquid nitrogen before being stored at - 70°C until 
required.  
2.1.3. Transformation of E.coli TOP10 and BL21 cells  
Aliquots of 500µL or 100µL of frozen E.coli TOP10 and BL21 competent cells 
were allowed to thaw on ice and 0.1-1µg plasmid DNA, or 10µL ligation reaction 
mixture, were added and gently mixed. After incubation for 15 minutes on ice, 
cells were heat-shocked in a water bath at 42°C for 45 seconds and then promptly 
transferred to ice for 5 minutes. 500µL of 2xYT broth were added to the cells and 
incubated at 37°C for 1 hour with constant agitation before being aliquoted on LB 
agar plates containing the appropriate antibiotic for selection of positive 




2.2. Molecular Techniques. 
2.2.1.  RNA Isolation and purification. 
2.2.1.1.  Cells  
RNA from U937, HT-29, HEK 293 WT, C57BL/6 splenocytes and C57BL/6 
BMDM was isolated using a commercial RNA isolation kit (ISOLATE II RNA mini 
kit – Bioline).  Briefly, C57BL/6 spleens were homogenised by being pressed 
between two frosted glass slides, pipetted up and down until a single cell 
suspension was achieved, and then centrifuged at 1500rpm.   
Cell lines were washed in PBS to remove residual media and then centrifuged at 
1500rpm.  All pellets were resuspended in lysis buffer and β-ME and loaded into 
an isolate filter column and spun at 11,000 x g.  Flow through was precipitated 
with 70% EtOH, put through an isolate mini column, centrifuged at 11, 000 x g.  
Flow-through was discarded and the remaining column membrane desalted in 
preparation for DNase I treatment.  After DNA digestion, the column membrane 
was washed three times and then RNA eluted using 40µl RNase-free water.  RNA 
was quantified using a NanoDropTM 1000 spectrophotometer and quality 
checked by determination of absorbance ratio at 260 nm:280 nm (2.0-2.3) and 
260 nm:230 nm (>2.0). 
2.2.1.2.  Tissue  
RNA from intestinal biopsies was isolated using a TRIzol Chloroform protocol with 
an additional column purification step (Zymo Research Direct-zol RNA MiniPrep 
kit).  Briefly, three biopsies were placed into 500µl TRIzol (Thermo Fisher), 
homogenised using 1mm glass beads in a FastPrep-24 homogeniser (MP 
Biomedicals) for six cycles of 10 seconds at 6.5 m/sec each.  100µl Chloroform 




room temperature before centrifuging a 11,000 x g for 15 minutes.  The upper 
aqueous phase (approximately 200µl) containing total RNA was carefully 
removed to avoid protein contamination, an equal volume of 100% EtOH added 
and carefully mixed before loading into a Direct-zol column.  Samples were 
centrifuged at 11,000 x g, flow through discarded and the membrane washed 
through with RNA wash buffer in preparation for DNase I digestion.   After DNAse 
digestion, RNA isolation columns were washed through three times and RNA 
eluted using 50µl RNase free water.   
2.2.1.3.  DNase I treatment. 
5µl (6 U/µl) of previously resuspended DNase I was mixed with 75µl DNA 
digestion buffer, gently mixed and 80µl added directly to the centre of the RNA 
isolation column.  Samples were incubated at room temperature for 15 minutes 
before inactivating the digestion reaction by the addition of RNA wash buffer.  
2.2.1.4.  RNA clean-up. 
Samples exhibiting a low 260 nm:230 nm (<2.0) and therefore deemed to have a 
high residual salt contamination were subjected to a clean-up procedure to 
prevent any inhibitory actions on the RT reaction.  Briefly, RNA was precipitated 
by adding 1/10th total 3M Sodium Acetate plus three volumes of 100% EtOH and 
incubating at room temperature for 15 minutes.  Following this, samples were 
centrifuged at 13,000 rpm for 10 minutes and the pellet washed with 1mL of 75% 
EtOH.  If the pellet was dislodged samples were re-centrifuged at 13,000 rpm for 
5 minutes, supernatant removed and then the pellet left to air-dry for 10 minutes 




2.2.2.  Reverse Transcription. 
Reverse transcription was performed using a Sensifast cDNA synthesis kit 
(Bioline).  Briefly, 1µg RNA was added to a master-mix containing 4µL 5x 
TransAmp buffer (50:50 oligo dT/random hexamers), 1µL Reverse Transcriptase 
and DNase/RNase free water added to a total volume of 20µL.  The synthesis 
reaction was performed in a PCR thermocycler (Bio-Rad) at 25 °C for 10 min, 42 
°C for 15 min and 85 °C for 5 min to inactivate the reaction.  cDNAs were placed 
in -70 °C for long-term storage. 
2.2.3.  End-point PCR. 
PCR reactions were performed in a PCR thermocycler (Bio-Rad).   MIF 
sequences were amplified with overhangs for NdeI (CATATG) and XhoI 
(CTCGAG) restriction sites. Generally, PCR cycles included the following 
standard cycling conditions: Cloning - initial denaturing at 98 °C for 30 seconds; 
30 cycles of denaturing at 98 °C for 5 seconds, primer annealing at 52 °C – 60 
°C for 20 seconds, extension at 72 °C for 30 seconds; followed by a final 
extension period of  72 °C for 10 minutes. Reactions contained 10 µl 5X Phusion 
High Fidelity buffer (NEB), 5µl 2mM dNTPs (Thermo Fisher), 2.5µl 10µM forward 
primer (Eurofins), 2.5µl 10µM reverse primer, 0.5µl Phusion polymerase, 50ng 
DNA and up to 50 µl nuclease-free water.  PCR for qualitative assessment of 
target DNA/cDNA- initial denaturing at 95 °C for 30 seconds; 30 cycles of 
denaturing at 95 °C for 20 seconds, primer annealing at 52 °C – 60 °C for 30 
seconds, extension at 68 °C for 1 minute; followed by a final extension period of  
68 °C for 5 minutes. Reactions included 2.5µl 10X Standard Taq reaction buffer 
(NEB), 2.5µl 2mM dNTPs (Thermo Fisher), 0.5µl 10µM forward primer, 0.5µl 




25µl nuclease-free water.  Primers used in this study (Eurofins, UK) are listed in 
the appendix table A.1. 
2.2.4.  Detection of PCR products. 
PCR products were electrophoresed on a 1.5% - 2.5% agarose gel composed of 
1X TAE buffer with 0.01% SYBRSafe (ThermoScientific) at 100V for 30 – 40 
minutes.  To identify the size of generated PCR products samples were mixed 
with 4X loading dye (NEB) and run alongside a 2-log marker (NEB) before being 
visualised using a ChemiDoc MP T100 system (Bio-Rad). 
2.2.5.  Cloning of MIF sequences. 
After confirmation that the correct size amplicon (350 bp) was generated, PCR 
products were subject to on-column purification using a Qiagen QIAquick PCR 
purification kit according to the manufacturer’s protocol.  Purified fragments were 
quantified using a NanoDropTM 1000 spectrophotometer and quality checked by 
determination of absorbance ratio at 260 nm:280 nm (2.0-2.3) and 260 nm:230 
nm (>2.0).   Amplicons were initially ligated, using TA cloning, into pGEM-T EASY 
(Promega) (figure 2.1) insert:vector ratio of 6:1 as calculated using the online 
NEB ligation calculator tool.  Vector and insert were added to a ligation mix 
containing 5µl 2X Rapid Ligation Buffer, 1µl pGEM-T EASY vector, 1µl T4 DNA 
ligase, PCR product (variable) and nuclease-free water to 10µl and incubated at 



















Figure 2. 1 pGEM-T Easy Vector Map 
(https://www.snapgene.com/resources/plasmid-files) 
 
Ligation reactions were subsequently propagated by transformation into 
chemically competent E.coli TOP10 cells.  50µl, 100µl or 150µl transformants 
were plated on LB agar containing Ampicillin, IPTG and x-gal to allow for selection 
using white/blue screening.  Positive colonies were selected, re-plated and 
presence confirmed by colony screening using conventional PCR.  Plasmids 
were purified using a Monarch Plasmid Miniprep Kit (NEB) prior to sequencing 




To express proteins, MIF sequences were sub-cloned into pET29b expression 
vector which contains an endogenous 6His-tag sequence (figure 2.2).  Briefly, 
MIF sequences were digested from the pGEM-T EASY vector using restriction 
enzymes NdeI and XhoI and ligated to a previously digested pET29b using T4 
ligase (NEB).  Ligations to pET29b were performed at 16°C overnight and then 
heat inactivated at 65°C for 5 minutes. pET29b including MIF sequences were 
transformed into BL21-CodonPlus cells in preparation for protein expression.  Full 

















2.2.6.  Cloning of pIRES_CD74 and pIRES_CD74/CD44. 
Cloning of CD74 and CD44 containing restriction sites for NheI/XhoI and 
SalI/NotI, respectively, into pIRES was performed by Eurofins, UK.  Briefly, 
sequences for CD74 (accession number: NM_004355.3) and CD44 (accession 
number: AY101193.1) were selected based on publications which confirmed the 
presence of these receptors on the cell surface (further discussed in chapter 4).  
pIRES is biscitronic vector containing two multiple cloning sites allowing for the 
simultaneous expression of two genes of interest (figure 2.3).  The presence of 
CD74 and CD44 inserts were confirmed using qualitative endpoint PCR and 
















2.2.7.  Real-Time PCR – relative quantification. 
cDNA from HEK 293 WT, HEK SBE-isogenic cells, C57BL/6 intestinal explants 
and BMDMs was utilised in assays to assess transcriptional changes using an 
Agilent Aria Mx Realtime PCR system.  In initial assays, a titration for all primers, 
listed in the appendix table A.3. was utilised in order to firstly confirm the presence 
of a specific transcript and, secondly, to determine the correct primer 
concentration to use in the subsequent qPCR reaction.  All products were run 
and detected on a 2.5% agarose gel.  Following reaction condition optimization, 
qPCR analysis was performed using a SYBRgreen mastermix (Bioline) whereby 
a final amount of 10ng cDNA was used as template assuming that the RNA to 
cDNA conversion was 100%.  
The efficiency of all reactions was obtained by generating a standard curve and 
deemed suitable when between 90-110%.  Briefly, a series of cDNA dilutions at 
0ng, 0.1ng, 1ng, 10ng and 100ng were added to the reaction containing primers 
and the mastermix.  The efficiency of reactions was generated automatically by 
the Aria Mx software.  Relative quantification was deduced using the following 
well-documented Pfafll equation:   !"#$% = ("#$%&'#	∆*#)	(,-.#%-/0#%'$#'1)	("%'2'%'.,'	∆*#)	(,-.#%-/0#%'$#'1) 
2.2.8.  RNA seq. 
The quality of RNA samples to be sequenced was assessed using a bioanalyzer 
2100 (Agilent) and deemed of sufficient quality as all samples had a RNA Integrity 
Number (RIN) of >9.  Following this, mRNA capture, RNA fragmentation and 
cDNA synthesis was performed using a KAPA Stranded mRNA-Seq Kit (KAPA 
Biosystems).  Samples were subsequently assigned a unique molecular identifier 
to prevent PCR amplification bias prior to sequencing.  Libraries were subject to 




and quantification (Qubit, Thermo Fisher).  RNA sequencing analysis was 
achieved using an Illumina NextSeq 500 single end run at 15M reads per sample.  
2.2.9.  RNA seq analysis. 
Basic RNA seq analysis was performed by Dr Tony Brooks at the UCL genomics 
facility.  Briefly, reads were aligned to the genome using the well-established RNA 
seq aligner, STAR (Dobin et al., 2012).  Subsequently, quality control and 
filtering/adapter trimming of all reads was performed using the Fastp 
preprocessor (Chen et al., 2018).  To test for differential expression between the 
groups Mm-MIF-1, Mm-MIF-1 P2G, Ts-MIF-1 and Ts-MIF-1 P2G, the reference 
group was set to control (untreated) and analysed using the R vignette, DESeq2 
(Love et al., 2014).  Results were filtered to include those genes with a log2 fold 
change <1.5 or >1.5 and with an adjusted p value of < 0.05.  Heatmaps were 
generated using the complex heatmaps vignette in R (Gu et al., 2016) and all 
gene ontology analysis was performed using the widely established DAVID online 
software (Dennis et al., 2003).  
2.3.  Protein expression 
2.3.1.  Expression of HsMIF-1, HsMIF1 P2G, MmMIF1 P2G, TsMIF1, TsMIF1 
P2G. 
In order to express functional MIF proteins, inserts were digested from pGEMt 
using restriction enzymes Nde1 and Xho1 and ligated overnight, at 16°, to a 
previously digested pET29b (Novagene) expression vector containing a 
sequence for a Histidine tag.  pET29b containing MIF inserts were transformed 
into E.coli protein expression strain BL21-CodonPlus.  Seed cultures were grown 
overnight in Tryptic Soy broth containing 50µg/mL Kanamycin and 34µg/mL 




cultured at a 1:100 dilution and allowed to grow to an OD600 0.6 before being 
induced with 1mM IPTG for six hours at 37°C.  Post-induction, cultures were spun 
down at 4000 rpm for 10 minutes and pellets were resuspended in PBS before 
being re-centrifuged at 4000 rpm for 10 mins.  Following this, pellets were either 
resuspended in His-tag purification binding buffer (20mM Sodium Phosphate, 
500mM Sodium Chloride, 20mM Imidazole, pH 7.4.) in preparation for sonication 
on ice, or incubated in lysis buffer (20mM Sodium Phosphate, 500mM Sodium 
Chloride, 20mM Imidazole and 0.5% NP-40) for 30 minutes on a rocker at 4°C.  
Subsequently, lysates were spun at 4000 rpm for 20 minutes.  
2.3.2.  Expression of Hs-MIF-1 C57S/C60S, Hs-DDT-1, Mm-DDT-1, Ts-MIF-2. 
To obtain soluble extracts for Hs-MIF-1 C57S/C60S, Hs-DDT-1, Mm-DDT-1 and 
Ts-MIF-2, several adapted and optimised conditions were used.  Briefly, for Hs-
MIF-1 C57S/C60S, Hs-DDT-1, Mm-DDT-1 expression was induced once the 
OD600 reached 0.8 with 100µM IPTG.  Additionally, cultures were incubated at 
15°C at 150 rpm for 12 hours.   
Ts-MIF-2, could not be found in the soluble protein fraction of BL21 CODON plus 
cells so several chaperonin cell lines (table 2.2), purchased from Takarabio, were 
tested (Chen et al., 2018) and Ts-MIF-2 was found to express and be present 
soluble fraction of BL21 pGRO7.  pGRO7 co-expresses the E.coli chaperonin 
GroEL/ES in the presence of L-Arabinose.  Overnight cultures were diluted 1:50, 
2mg/mL L-arabinose was added to ensure high level expression of GroEL/ES, 
cells were grown to OD600 prior to induction with 200µM IPTG.  Following this, 






2.3.3.  SDS-PAGE Gel electrophoresis.  
A 15% denaturing polyacrylamide gel was used to resolve all MIF proteins in TGS 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS).  Resolving gel was composed 
of 375mM Tris-HCl, pH 8.8, 0.1% SDS, 0.05% ammonium persulfate and 0.1% 
TEMED whilst the stacking gel was 4% acrylamide, 125mM Tris-HCl, pH 6.8, 
0.1% SDS, 0.05% ammonium persulfate and 0.1% TEMED.   Protein lysates 
were OD corrected in a previous step to ensure an equal amount of protein across 
samples. Protein lysates were mixed with Laemmli buffer (Bio-Rad), including 
20mM β-ME, in the following ratios:  Total and insoluble fractions – pellet 
resuspended in 1X Laemmli; soluble – 1-part lysate to 3 parts 4X Laemmli buffer.  
Following this, samples were heated at 95°C for 5 minutes before loading into the 
gel.  All protein gels were run at 100V for 45 minutes allowing complete 
separation of proteins and the Precision Plus pre-stained standard (Bio-Rad).  
2.3.4.  Coomassie Staining. 
Proteins were initially detected using a Coomassie staining procedure prior to 
antibody-probing.  Briefly, gels were incubated in a 0.25% Coomassie solution 
(0.25g Coomassie Brilliant Blue R250, 50% MeOH, 10% glacial acetic acid) 
rocking overnight at room temperature.  Excess Coomassie was removed by 
Table 2. 3  List of Takara Chaperonin plasmids used for protein expression. 
Plasmid Chaperone Resistance Chaperone Inducer 
BL21-CodonPlus - Cm - 














washing the stained gel using a de-staining solution (50% MeOH, 10% glacial 
acetic acid) and visualised using a ChemiDoc MP T100 imaging system (Bio-
Rad).   
2.3.5.  Western Blot. 
Resolved proteins were transferred to a nitrocellulose membrane (0.2 µm pore 
size, GE Lifesciences) using a Transblot Turbo Transfer System (Bio-Rad).  
Briefly, gels were sandwiched between two blotting pads and a nitrocellulose 
membrane and the stack pre-soaked in transfer buffer (25 mM Tris, 192 mM 
glycine, 20% v/v methanol) for 3 mins before being placed into the Transblot 
cassette and run at 25V for 8 minutes.  Membranes were immediately placed 
into a blocking solution of 5% w/v non-fat powdered milk in TBS-T (20 mM 
Tris, 150 mM NaCl, 0.1% Tween 20), rocking for one hour at room 
temperature.  Membranes were washed five times with TBS-T after blocking 
and then incubated overnight with an HRP conjugated monoclonal anti-His-
tag antibody, used at 1:3000 dilution in 5% powdered non-fat milk in TBS-T.  
Membranes were washed as described previously and proteins detected and 
visualised using Clarity Western ECL substrate (Bio-Rad) in a ChemiDoc MP 
T100 imaging system (Bio-Rad).   
2.4.  Protein Purification. 
2.4.1.  Preparation of samples for purification. 
Frozen pellets of bacterial cultures were resuspended in lysis buffer at 5mL per 
1g wet weight and briefly vortexed to mix.  Lysis buffer was selected over 
sonication methods due to how time consuming the sonication process was when 
numerous samples were involved.  A direct comparison of MIF’s enzyme 




Samples were incubated for 30 minutes on a rocker at 4°C, before being 
centrifuged at 4000 rpm for 20 minutes at 4°C to separate the soluble and 
insoluble fractions.  Ts-MIF-2 could not be detected using this method so an 
alternative method was employed.  Ts-MIF-2 was resuspended in 10mL His-tag 
binding buffer and sonicated on ice using 20 second pulses/20 second rest at 
38% for a total period of 5 minutes.  Following this, lysates were centrifuged at 
4000 rpm for 20 minutes at 4°C ready for purification.    
2.4.2.  Ni-NTA purification. 
Protein lysates were purified using a Protino Ni-NTA 1mL column (Macheray-
Nagel).  Prior to injection of the sample onto the column, using the ӒKTAprime 
plus (GE Life Sciences), His-tag binding buffer and His-tag elution buffer were 
washed through loops A and B at a 1mL/min flow rate, respectively, to ensure 
efficient binding of sample to the matrix.  Sample injection was set at 0.5mL/min 
in order to increase the efficacy of sample binding then increased back to 
1mL/min for washing and elution (precise breakpoints can be seen in table 2.4).  
Protein fractions were collected in 1mL fractions and analysed on a 15% SDS 
PAGE gel.    
2.4.3.  Buffer exchange and sample concentration. 
His-tag purified fractions were collected and concentrated using a Vivaspin 20 
Ultrafiltration Unit (Sartorius) with a molecular weight cut off of 3,000 Da.  In 
addition to this, Vivaspin units were utilised to buffer exchange the samples 
allowing them to be subject to the final purification anion-exchange step.  Briefly, 
20mL lysates were loaded into the Vivaspin tubes and centrifuged at 4000 rpm 
for a total period of 90 minutes at 4°C with intermittent pipetting every 10 minutes 
to prevent blockage of the PES membrane.  Following concentration of the 




Tris 50mM, pH 8.0 to allow for buffer exchange.  This step was repeated three 
times ensuring all samples were compatible with anion exchange 
chromatography.  
2.4.5.  Anion exchange chromatography. 
Anion exchange chromatography was performed using Pierce strong anion 
exchange columns in order to remove residual endotoxin from samples.  Briefly, 
the anion exchange spin column was equilibrated using 50mM Tris buffer, pH 8, 
before concentrated MIF samples were applied to the column, spun at 7,000 rpm 
for 10 minutes and purified flow-through collected.  
2.4.6.  BCA assay. 
Quantification of purified proteins was performed utilising a BCA assay (Thermo 
Scientific Pierce) which measures protein driven reduction of Cu+2 to Cu+1.  
Briefly, a series of BCA protein standards from 0µg/mL – 2000 µg/mL were 
prepared in order to generate a standard curve.  Purified protein samples were 
diluted 1:5, 1:10 and 1:20 and 10µL of each sample and standard added to a 
microtitre plate.  Subsequently, 50-parts BCA reagent A were added to 1-part 
BCA reagent B and mixed to form the working BCA reagent; 190µL was added 
to all wells and incubated at 37°C for 30 minutes before being quantified 
spectrophotometrically at 562nm using a microplate reader (Synergy HTX, 
BioTek). 
2.4.7.  Limulus amebocyte lysate assay. 
The quantification of residual bacterial endotoxin contamination in the purified 
recombinant proteins was performed using a LAL Chromogenic Endotoxin 
Quantitation Kit (Pierce).  Briefly, a series of endotoxin standards between 0.1 – 




concentrations.  Samples were diluted 1:10 and 1:100 prior to being added to a 
microtitre plate at a volume of 50µL along with the standards and negative 
controls consisting of endotoxin-free water and 50mM Tris buffer (pH 8.0), 10% 
glycerol.  50µL of LAL reagent was added to all wells and plates incubated at 
37°C for 10 minutes.  Subsequently, 100µL of prewarmed chromogenic substrate 
was added and plates returned to incubate at 37°C for 6 minutes.  Finally, 100µL 
stop solution (25% acetic acid) was added to halt the reaction before being 
analysed spectrophotometrically at 410nm using a microplate reader (Synergy 
HTX, BioTek). 
2.5.  Enzyme Assays 
2.5.1.  Tautomerase Assay. 
The tautomerase activity of all MIF proteins was determined as previously 
described (Melissa Swope et al., 1998). Equal volumes of L-dopachrome methyl 
ester (10mM) and sodium periodate (20 mM) were mixed and incubated for 5 min 
to form the L-dopachrome methyl ester required for the assay. Tautomerase 
enzymatic activity was measured in 96-well microtitre plates containing a reaction 
mix of 25 mM potassium phosphate, 0.2% Tween 20, pH 6.0.  160ul of buffer was 
mixed with 20µl of L-dopachrome methyl ester.  T. spiralis, murine or human MIF 
was added at a final concentration of 20µg/mL as this was found to have the most 
efficient rate of reaction.  In some reactions MIF inhibitor (4-Iodo-6-
phenylpyrimidine) was added at the start of the reaction at a final concentration 
of 25µg/mL. MIF-catalysed reduction of absorbance was monitored over time 




2.5.2.  Oxidoreductase Assay. 
Oxidoreductase activity of Hs-MIF-1, Hs-MIF-1 C57S/C60S, Mm-MIF-1 and Ts-
MIF-1 was determined using the well-established insulin reduction assay which 
leads to an increase in turbidity measured at 650nm. PDI-catalysed reduction of 
Thioredoxin was used as a positive control.   
Oxidoreductase activity was measured in 96-well microtitre plates containing a 
reaction mix of 25 mm potassium phosphate, 0.2% Tween 20, pH 6.0.  160ul of 
buffer was mixed with 20ul of L-dopachrome methyl ester.  Ts-MIF-1, Mm-DDT-
1, Hs-DDT-1, Hs-MIF1-C57S/C60S was added at a final concentration of 
20µg/mL as this was deemed to have the most efficient rate of reaction. MIF-
catalysed reduction of absorbance was monitored spectrophotometrically over a 
time period of 60 minutes.    
2.6. Cell Culture. 
2.6.1. Reagents.  
LPS (Salmonella enterica serotype typhimurium, L6143) was purchased from 
Sigma-Aldrich (now Merck).  TNF-α, IFN-γ, TGF-β and rHMIF1 were all 
purchased from Biolegend UK. 
2.6.2.  Cells.    
Cell culture media components used in this study are listed in table 2.3.  
Colorectal adenocarcinoma cells - Caco2, HT-29 and HT-29 NFκB-mCherry 
cells, embryonic kidneys cells - HEK 293 WT, HEK-Blue™-hTLR4, HEK 293 NF-
κB-mCherry, NFκB-mCherry and HEK SBE-GFP cells were maintained in 
complete DMEM.  Bone-marrow-derived macrophages were cultured in BMDM 
differentiation media.  Isolated cells were seeded at 6 x 106 cells/petri dish in 




After 7 days cells were analysed for F4/80 expression using flow cytometry (BD 
Celesta).  All cells were maintained in a 37° incubator under 5% CO2. Cell lines 
were repeatedly checked for low-lying bacterial contamination by culturing in 
antibiotic-free media.  
Media  Components 
Complete DMEM DMEM, high glucose, GlutaMAX(TM), pyruvate. 
10% Heat inactivated FCS. 
1% Penicillin/Streptomycin 
 
Complete RPMI RPMI 1640 





DMEM, high glucose, GlutaMAX(TM), pyruvate. 




HEK-Blue™-hTLR4 media DMEM, high glucose, GlutaMAX(TM), pyruvate. 





BMDM differentiation media  RPMI 1640 
30% L-cell conditioned media 
20% Heat inactivated FCS 
1% Penicillin/Streptomycin 
 
2.6.3.  Generation of Bone Marrow Derived Macrophages.  
Bone marrow cells from femurs of C57BL/6 mice were used to generate BMDMs 
using batch tested L929-cell conditioned medium as a source of macrophage 
colony stimulating factor. The cells were resuspended in 10 mL BMDM 
differentiation media at a density of 5 X 106 cells per non-tissue culture treated 




petri dish.  Cells were incubated at 37°C in a 5% CO2 atmosphere. One day after 
seeding the cells, an additional 10 mL of fresh bone marrow differentiation media 
was added per plate and cells were incubated for an additional 3 days.  At day 3 
and 5, 10mL was removed and replaced with fresh bone marrow differentiation 
media.  To obtain the BMDMs, the supernatants were carefully aspirated, and the 
attached cells were washed with 10 mL of sterile PBS and placed on ice for 2 
minutes whilst scraping with a disposable plastic scraper. The cells were 
centrifuged at 1800 rpm for 5 minutes and resuspended in 2 mL of RPMI media, 
counted and assessed for F4/80 expression.  
2.6.4. Generation of stable hTLR4-NF-κB-mCherry, HT-29-NF-κB-mCherry 
and HEK-SBE-eGFP reporter cell lines.  
Polyclonal HEK 293 or HT-29 cells stably transduced with pHRSIN-SBE-eGFP 
or pHRSIN-NF-κB-mCherry (Breckpot et al., 2010a) reporter constructs were 
provided by D.B. Guiliano.  In order to isolate isogenic single cell clones, cells 
were plated at 0.5 cells per well in a 96-well plate, using either complete DMEM 
or HT-29 NFκB-mCherry media, in order to ensure the growth of a single cell.  
Cells were periodically assessed for expression of GFP/mCherry using a BD 
FACS Celesta flow cytometer (BD Biosciences) and six positive single cell clones 
were subsequently expanded and stored in the liquid nitrogen storage facility for 
later use.  The isogenic cell line with the greatest fold change and lowest 
background expression, after treatment with 2.5ng/mL TGF-β (SBE-eGFP) or 
50ng/mL TNF-α (NFκB-mCherry) stimulation, were used in future reporter 
assays.     
2.6.5.  Transient Transfections of pIRES_CD74 and pIRES_CD74/CD44. 
HEK 293 cells were seeded at 3 x 104/0.5mL in a 24 well plate using complete 




titration of vector DNA (pIRES):carrier DNA (pBluescript_empty), to a total 
amount of 750ng DNA, was prepared to assess the optimum conditions for CD74 
and CD44 expression.  Briefly, varying amounts of pIRES plasmid DNAs were 
added to jetPRIME buffer (see table 2.4) and vortexed to mix.  The jetPRIME 
reagent was subsequently vortexed and centrifuged at 11,000g for 1 min before 
adding 1.5µL to the DNA mix.   Reactions were incubated for 10 minutes at room 
temperature before 50µL was added drop-wise to each well and gently rocked to 
ensure complete coverage.  Plates were incubated for 5 hours before removing 
the transfection media and adding fresh complete DMEM and allowing cells to 
rest for an additional 24 hours prior to analysis for cell surface expression of CD74 
and CD44 using flow cytometry (BD FACSCelesta).  Antibodies used were PE-
CD74 and PE-Cy7 CD44 (Biolegend).   
   
2.6.6.  HT29-NFκB-mCherry reporter assay. 
HT29-NFκB-mCherry isogenic cells, IC5, were seeded at 5 x 105/mL and 0.5mL 
added to all wells of a 24-well plate. Following an 8-hour period of settlement cells 
were primed with 10ng/mL IFN-γ for 12 hours before removing the supernatant 
and replacing with fresh complete DMEM containing 100ng/mL LPS or 100ng/mL 
LPS and 100ng/mL Hs-MIF-1 and incubated for 20 hours before assessing 
mCherry expression using a BD FACSCelesta.  50ng/mL TNF-α was used as a 
positive control. 
Table 2.5  DNA (ng) used to transfect WT HEK 293 cells.  
pBluescript 
(ng) 






0 750 75 1.5 
250 500 75 1.5 
500 250 75 1.5 




2.6.7.  HEK-Blue™-hTLR4 reporter assay. 
HEK-Blue™-hTLR4 (Invivogen) cells, between passage number 9 and 20, were 
seeded at 5 x 103 cells/100µL in a 96 well plate and allowed to adhere for 2 hours 
before the addition of 10ng/mL LPS and coadministration of 10ng/mL LPS and 
100ng/mL Hs-MIF-1, 100ng/mL Hs-MIF-1 P2G, 100ng/mL Mm-MIF-1, 100ng/mL 
Mm-MIF-1 P2G and 100ng/mL Ts-MIF-1.  Optimal LPS concentrations were 
previously determined using a dose response curve (S. Paraliker, 2017, 
unpublished) whilst MIF concentrations and experimental times were determined 
using previously published data by Kudrin et al (2006). Plates were incubated for 
18 hours before being assessed for secreted alkaline phosphatase utilising a 
well-documented p-Nitrophenol phosphatase assay.  100 µL of freshly prepared 
pNPP (as before) reaction mix was added to 50 µL of each sample and the plates 
were incubated at 37°C for 20 minutes and 5% CO2.  Reactions were assessed 
spectrophotometrically at OD405 using a microplate reader (BioTek, 
Synergy™HTX).  
2.6.8.  HEK-hTLR4-NFκB-mCherry reporter assay. 
Isogenic HEK-hTLR4-NFκB-mCherry cells were cultured as described previously 
(2.7.2) and cultured with 10ng/mL LPS or 10ng/mL LPS and 100ng/mL Hs-MIF-
1, 100ng/mL Hs-MIF-1 P2G, 100ng/mL Ts-MIF-1, 100ng/mL Ts-MIF-1 P2G and 
100ng/mL Ts-MIF-2 before being assessed for mCherry expression using a BD 
FACSCelesta.  Optimal LPS and MIF concentrations and experimental times 
were determined as previously mentioned (2.6.7). 
2.6.9.  TGF-β and BMP-4 timecourse assay. 
Isogenic clone IC3 HEK-SBE-eGFP cells were seeded in triplicates at 3 x 103 
cells per well in a 96 well plate and allowed to adhere overnight in a 37°C, 5% 




was administered and cultured for 4, 8, 12 or 24 hours before assessing the 
expression levels of eGFP using a BD FACSCelesta.  
2.6.10.  TGF-β and MIF assay. 
Isogenic clone IC3 HEK-SBE-eGFP cells were seeded and incubated as 
mentioned in section 2.7.5.1.  Following this, 2.5ng/mL TGF-β or 2.5ng/mL TGF-
β and MIF homologues were added to wells and incubated for 18 hours before 
assessing the levels of eGFP expression using a BD FACSCelesta.   
2.6.11.  LPS and MIF BMDM assay. 
BMDMs were plated at 1 x 106 cells/mL in a 24 well plate before being allowed to 
rest overnight without L292-conditioned media prior to further experimental 
procedure.  After overnight incubation in a 37°, 5% CO2 incubator, 10ng/mL LPS 
or 10ng/mL LPS and 100ng/mL Mm-MIF-1, 100ng/mL Mm-DDT-1 100ng/mL Mm-
MIF-1 P2G, 100ng/mL Ts-MIF-1, 100ng/mL Ts-MIF-1P2G or 100ng/mL Ts-MIF-
2 were co-administered and incubated at 37° for 20 hours.   After this time, 
supernatants were stored at -20 for future cytokine analysis whilst cells were 
trypsinised and resuspended in RNA later at -20° for mRNA analysis.  Optimal 
LPS and MIF concentrations and experimental times were determined as 
previously mentioned (2.6.7). 
2.6.12.  Ex vivo intestinal explant assay.  
Intestinal biopsies were taken from the ascending, transverse and descending 
colon of C58BL/6 female mice in order to obtain results representative of the 
entire colon.  Punch biopsies were 3mm2 (Miltex) and three biopsies were 
seeded, in complete RPMI, per well in a 24 well plate.  Explants were stimulated 
with 100ng/mL LPS in the presence or absence of 100ng/mL Mm-MIF-1, 




100ng/mL Ts-MIF-2 and incubated at 37° for 24 hours.   After treatment, 
supernatants were stored at -70 for future cytokine analysis whilst tissue was 
carefully removed using tweezers and placed in RNA later at -20°C for 
transcriptomic analysis.  LPS and MIF concentrations were determined using 
previously published data (Suzuki et al., 2003; Kudrin et al., 2006).   
2.7.  Immunological assays.  
2.7.1. ELISA 
Supernatants from experimental intestinal explant cultures or BMDM’s were 
assessed for secretion of cytokines utilising ELISA assays for TNF-α, IL-6 and IL-
22 (Thermo Fisher).  Briefly, plates were coated with 100µL capture antibody and 
allowed to incubate overnight at 4°C before washing anyway any unbound 
antibody using ELISA wash buffer (1 x PBS and 0.05% Tween 20).  A series of 
standards were prepared according to manufacturer’s instructions, and 
experimental samples diluted 1:10 or 1:20 before adding 100µL of each to the 
microtitre plate.  Plates were incubated as previously described to allow for the 
optimum sensitivity.   After 24 hours, plates were washed five times with washing 
buffer to remove excess standard and sample material before adding 100µL 
detection antibody to each well and incubating at room temperature for 1 hour.  
Plates were washed five times before 100µL of Avidin-HRP was added to each 
well and incubated for 30 minutes at room temperature before being washed as 
before.  100µL of substrate solution was added to each well and left to incubate 
for 15 minutes at room temperature before 50µL stop solution (1M phosphoric 
acid) was added to inhibit further reactions.  Cytokine levels were quantified 





2.7.2.  Flow cytometry. 
All samples were analysed using a BD FACS Celesta and analysed in FlowJo. 
2.7.2.1. Antibody staining. 
HEK 293 cells and BMDMs were washed with 1 x PBS before the addition of 
50uLTrypsin to each well or scraping with a 1mL pipette tip (BMDM).  Plates were 
incubated at 37°C for 5 minutes and then complete 150uL complete was DMEM 
added to stop further trypsinization.  Plates were spun at 1800 rpm for 5 minutes 
at 4°C, supernatants removed, and cell pellets washed twice with 1 x PBS.  
Following this, cells were resuspended in 100uL FACs staining buffer containing 
Fc receptor block CD16/CD32 (eBioscience) and incubated on ice for 10 minutes.  
After this, cells were resuspended in 100uL freshly made FACS buffer (2% FCS, 
1 x PBS, 1mM EDTA) to which antibodies were added at the specified 
concentration (table 2.5).  Plates were incubated on ice for 60 minutes in the dark 
before being washed twice with FACS staining buffer.  The cell pellets were 
resuspended in 200uL FACS staining buffer before being analysed for CD74-PE 
or CD44-PECy7 (HEK 293) or F4/80 – Brilliant Violet 421 (BMDM).  
Antibody Supplier Volume used (per 1µL FACS 
buffer) 
CD74-PE Biolegend 5µL 




CD16/32 eBioscience 1µL 
 
2.7.2.2.  Detection of fluorescent proteins. 
Following treatment with trypsin or scraping, HT-29 NF-κB-mCherry, hTLR4-NF-
κB mCherry and HEK-SBE-eGFP cells were washed twice with 1 x PBS before 




being resuspended in 500uL FACS buffer and strained through a 70µM cell 
strainer prior to running through the BD FACSCelesta.   
2.7.3.  Phagocytosis Assay. 
BMDMs were seeded at 1 x 106/mL using 0.5mL per well in a 24-well plate and 
left to adhere for 2 hours in a 37°C, 5% CO2  before the addition of 10ng/mL LPS 
or 10ng/mL LPS and 100ng/mL Mm-MIF-1, 100ng/mL Mm-MIF-1 P2G, 100ng/mL 
Ts-MIF-1, 100ng/mL Ts-MIF-1 P2G and 100ng/mL Ts-MIF-2. Stimulated BMDMs 
were incubated for 20 hours prior to incubation with Zymosan A Alexa Fluor 488 
particles (Thermo Fisher).  Briefly, Zymosan particles were resuspended in 1 x 
PBS and sonicated for 3 x 20 seconds to create a homogenous suspension.  
Particles were centrifuged at 11000 rpm for 5 minutes before being resuspended 
in mouse serum and incubated at 37°C for 1 hour to augment opsonisation before 
being washed 3 times with sterile 1 x PBS.  Zymosan particles were resuspended 
in complete RPMI before being added to cells at a particle:macrophage ratio of 
20:1 and plates spun at 1000 rpm to ensure particles were at the bottom of each 
well.  Following an incubation period of 45 minutes at 37°C plates were briefly 
incubated at 4°C for 3 minutes to stop further phagocytosis.  Cells were washed 
3 times with 1 x PBS followed by the addition of 200µL Trypsin incubated at 37°C 
for 5 minutes to remove non-internalised Zymosan A particles.  Finally, cells were 
removed by scraping with a 1mL pipette tip and resuspended in 500µL FACS 
buffer being strained through a 70µM strainer and analysed for Alexa Fluor 488 
expression using a BD FACSCelesta. 
2.9. Statistical Data Analysis   
Prior to inferential statistical tests, all data were tested for normality using the D-
Agostino Pearson Omnibus Normality and Kolmogornov-Smirnov tests.  Student 




were statistically significant.  ANOVA tests were further analysed using the Tukey 
or Dunn post-hoc test in order to make judgements regarding differences within 
groups.  Data was considered statistically significant at the following values:  


















Chapter 3: Cloning and Characterisation of Mammalian and Helminth-
derived Homologues of MIF.  
3.1. Introduction. 
3.1.1.  MIF’s Protein Structure and Enzymatic Activity. 
MIF is a 12.5-kDa, 114 amino acid polypeptide, widely expressed in vertebrates 
and is a fundamental regulator of innate immune responses.  Aside from the 
canonical mammalian MIF-1 a number of other MIF paralogues have been 
isolated. In mammals a MIF homologue, D-dopachrome tautomerase, D-DT/MIF-
2, was identified after the discovery that B cells from CD74 -/- mice display a 
pronounced susceptibility to apoptosis when compared to MIF deficient B cells 
(Gore et al., 2008).  MIF and D-DT are ligands for the MIF receptor, CD74 (Meza-
Romero et al., 2016); both upregulate MAPK/ERK (1/2) activity (Merk et al., 
2011a); and lead to the expression and secretion of pro-angiogenic factors IL8 
and VEGF (Coleman et al., 2008).  Aside from mammals and other vertebrates, 
MIF homologues have been discovered in many eukaryotic pathogens including: 
P. falciparum, the protozoan parasite responsible for Malaria (Cordery et al., 
2007); B. malayi, the causative agent of lymphatic filariasis (Pennock et al., 1998); 
and E. histolytica, which has been shown to promote secretion of IL-6 and TNF-
α macrophage cell line, RAW 264.7 and is responsible for over 100, 000 deaths 
per annum (Moonah et al., 2014).   
To assess the role of MIF and D-DT within the GT, including whether the 
evolutionarily conserved tautomerase plays a role in any observed responses, it 
was essential to clone and express MIF proteins using a suitable expression 
system which could be exploited in large scale protein production.  Initial studies 
performed within this project indicated that the commercially available 




with MIF proteins.  In addition to this, the manufacturer’s instructions relating to 
the use of these recombinants in macrophages migration assays utilised 
concentrations of MIF that were significantly higher ( g vs ng) than those 
reported in the literature or would be biologically relevant.  As part of this work 
sought to assess the role of MIF’s tautomerase activity in influencing intestinal 
innate immune responses, it was critical to utilise enzymatically/biologically active 
MIF proteins.   
For the purposes of this PhD project, it was necessary to produce recombinant 
human and murine MIF proteins as our studies aimed to assess MIF’s role in 
intestinal epithelial cells and murine APCs.  In addition, for comparative purposes, 
two additional MIF homologues were selected for use in the immunological 
bioassays. These MIFs were isolated from the gastrointestinal parasite Trichinella 
spiralis, a parasitic nematode capable of infecting a wide variety of species 
including humans. T. spiralis has a well characterised lifecycle during which the 
adult nematodes transiently colonize the GT. The  roles of various immune cells 
and effector mechanisms in establishing protective responses are known in T. 
spiralis and the parasite is known to secrete a number of potentially 
immunomodulatory factors including two MIF homologues Ts-MIF-1 (Pennock et 
al., 1998; Tan et al., 2001) and Ts-MIF-2 (D. Guiliano, unpublished).  T.spiralis 
larvae produce large amounts of MIF-1 upon contact with the acidic environment 
of the stomach as previously determined by D. Guiliano (unpublished) (figure 3.1) 
and despite the fact that MIF-1 expression is common amongst trichocephalids 
this study will focus on T. spiralis.  Both Ts-MIF1 and Ts-MIF-2 share the 
conserved Proline residue (figure 3.2.) required for tautomerase activity with all 
vertebrates MIF sequences. However, neither have the CXXC domain which is 




Ts-MIF-1 have shown that it has a six-fold greater tautomerase activity than that 
of Hs-MIF-1 (Tan et al., 2001) rendering it a valuable comparator in MIF cellular 
studies. 
 
Figure 3. 1  MIF-1 is highly expressed by T.spiralis and confers the 
prototypical tautomerase activities.  A) Excretory secretory products (ESP) 
from various stages of the T.spiralis and T.muris life cycle tautomerize the 
conversion of methyl ester of 2-carboxy-2,3-dihydroxyindole-5,6-quinone (L-
dopachrome) to the methyl ester of 5,6-dihydroxyindole-2-carboxylate.  mL1, 
infective muscle stage larvae; BAmL1, bile activated mL1; Ad, adult worms.  B) 
Western blot depicting MIF-1 protein in T.spiralis life cycle stages (as before).  
Samples probed with an a-MIF-1 antibody. ESP, excretory secretory products; 





The fact that MIF’s enzymatic activity may be instrumental in coordinating or 
subverting immune responses validates the importance of expressing and 
purifying an active correctly folded MIF protein, though so far, attempts to identify 
a physiological substrate for the tautomerase have been unsuccessful.  
Numerous studies have investigated the role of species-wide MIFs on immune 
responses, however, to date there are few that focus on the importance of the 
tautomerase activity due to conflicting opinions on whether it has biological 
relevance or is, in fact, a degenerate function.  The limited research that has taken 
place has led to contradictory results where one study using MIF mutants which 
have Proline-2 (Pro2) substituted for an alternative amino acid, continue to retain 
the classical glucocorticoid-inhibition override activity while a subsequent study 
shows a loss of this activity (Hermanowski-Vosatka et al., 1999; Klaus Bendrat et 
al., 1997; Lubetsky et al., 2002).  In addition, studies using other bioassays have 
shown that tautomerase-activity (or Pro2) is required for MIF mediated of increase 
MMP1 and MMP3 activity in synovial fibroblasts (Onodera et al., 2000) and  
superoxide generation in activated neutrophils (M Swope et al., 1998).     
As previously mentioned, many vertebrate MIF proteins also contain a CALC 
(Cys57-Ala-Leu-Cys60) motif (figure 3.2) which forms an intramolecular 
disulphide bridge and functions as the catalytic centre of an oxidoreductase 
activity.  Unlike Pro2, the CALC sequence has long been recognised as having a 
critical role in MIFs inflammatory actions.  Utilising the well-established 
macrophage activation assay or Leishmania intracellular killing assay  
(Bernhagen et al., 1994; Thierry Calandra et al., 1995a)  Kleemann et al (1998) 
revealed that Cys57 and Cys60 but not Cys81 MIF-1 mutants lacked the capacity 




and Cys60 MIF mutants could not override glucocorticoid inhibition in a 
macrophage cell line, RAW 264.7 (Robert Kleemann et al., 2000b).  Interestingly, 
vertebrate D-DT/MIF-2 and Ts-MIF-1/Ts-MIF-2 do not contain a complete CALC 








Figure 3. 2 Multiple sequence alignment shows conservation of enzymatic 
domains across species.  Genbank protein sequences for Mm-MIF-1 
(Accession number CAA80583.1), Ts-MIF-1 (Accession number CAB46354.1 ), 
Hs-DDT-1 (Accession number CAG30317.1), Mm-DDT-1 (Accession number 
NP_034157.1) and Ts-MIF-2 (D. Guiliano) were aligned (JalView) with the protein 
sequence for Hs-MIF-1 (Accession number CAA80598.1).  Conserved residues 
are shown in the grey shaded areas.  The tautomerase active site Proline is 
highlighted in red whilst the Cysteine resides associated with MIF’s 
oxidoreductase activity is in green. The tautomerase-conferring proline residue 
at the N-terminal is retained across all species whilst the oxidoreductase catalytic 
centre, Cys-57 and Cys-60, can be found only in Hs-MIF-1 and Mm-MIF-1.  The 
secondary structure of Hs-MIF-1 is depicted as a cartoon and was adapted from 





MIF’s three-dimensional structure is assembled by the joining of six α-helices and 
three β-sheets to form a solvent-exposed barrel-like structure (Figure 3.2); three 
active sites exist within the barrel with each monomer containing an N-terminal 
Proline residue acting as a catalytic nucleophile.  The enzymatic activity of 
recombinant MIF is wholly reliant on the correct three-dimensional confirmation 
being formed in vitro.  One important point to consider is that, although MIF has 
been detected as monomers, dimers and trimers, only the trimeric form is thought 
to confer enzyme activity.  This reiterates the importance of obtaining MIF 
proteins with the correct tertiary structure and, analysis of MIF proteins within the 
tautomerase assay, allows for rapid determination of folding efficiency. 
 
Figure 3. 3 The three-dimensional structure of Hs-MIF-1 and Hs-DDT-1/MIF-
2 protein as determined x-ray crystallography.  Left, human MIF -1 x-ray 
structure from PDB entry 1MIF. Right, human DDT-1/MIF-2 x-ray structure from 
PDB entry 1DPT.  The tautomerase conferring site (Pro2) is highlighted in pink 
(magnified area) whilst the oxidoreductase conferring sites (Cys57 and Cys60) 





3.1.2.  Production of recombinant MIFs using Escherichia coli. 
Production of recombinant proteins within bacterial systems is often achieved 
using Escherichia coli as the expression host.  Theoretically, over-expression of 
proteins in E.coli is straightforward due to its ease of culture and genetic 
manipulation.  Typically, cloning the gene of interest into an expression vector, 
transforming the vector into an appropriate host and induction of protein 
expression results in a high level of the desired protein.  However, many issues 
arise with the expression of eukaryotic proteins in prokaryotic organisms, such as 
E.coli, due to a lack of proper machinery required for translation and protein 
folding.  Additionally, differences in codon bias between species the protein is 
isolated from and the production host can also present additional problems which 
negatively influence protein production.  While it is not possible to fully 
recapitulate the eukaryotic translational environment in E. coli there are several 
widely used approaches including the use of plasmids under the control of a 
tightly regulated promoter, and transformation into competent cells that contain 
additional factors to increase translation efficiency and limit protein folding issues. 
The most commonly used bacterial cells for heterologous protein expression are 
a series of E.coli derivatives known as BL21.  
3.1.2.1 Protein expression using BL21 derivative competent cells.  
The origins of the BL21 competent cell line can be traced back to an E.coli B 
strain as early as 1942 (Daegelen et al., 2009) and has several genetic 
characteristics consistent with other parental B strains, such as, the absence of 
the Lon protease responsible for degrading many unrelated proteins.  
Additionally, OmpT, an outer membrane protease which degrades extracellular 




protein production thereby preventing the degradation of desired proteins 
(Grodberg and Dunn, 1988).  In DE3 strains of BL21, the λDE3 prophage has 
been introduced to the genome and contains a T7 RNA polymerase which is 
controlled by the lacUV5 promoter.  Neither BL21 nor BL21 (DE3) confer any 
antibiotic resistance which was importance for the purposes of this study to 
prevent antibiotic resistance incompatibility when using additional chaperonin 
plasmids which will be discussed further on in this chapter.  
BL21-CodonPlus Competent cells are a codon bias-adjusted cell line originating 
from another BL21 derivative known as BL21-Gold.  BL21-CodonPlus (DE3) have 
been utilised in this study to overcome to issues with codon bias in prokaryotic 
cells and contain the preferential tRNAs required by vertebrates to facilitate the 
production of heterologous recombinant proteins.  Without this, low abundance 
tRNA’s are rapidly depleted leading to terminated or truncated polypeptides 
significantly reducing the levels of protein expression.  In this study, BL21-
CodonPlus cells were used as an initial test of protein expression and only 
continued after significant amounts of soluble protein could be ensured.  
An important point to consider when expressing proteins is the expression vector 
as incompatibility of vector and cell line can lead to, at best, aggregation of 
recombinant proteins. Problems can also arise when basal expression of the 
protein of interest is leaky, that is, not under the control of a tightly regulated 
promoter leading to constitutive expression.  This is a common problem in 
traditional expression systems utilising the lac system; such consistent 
expression of a protein leads to issues such as inadequate growth of the host cell 
due to plasmid instability and toxicity of the target protein.  Numerous expression 
vectors have been developed to counteract the problem with leaky protein 




overcome the issue with constitutive expression by exploiting a T7 lac promoter.  
Downstream of this lies a sequence for a lac operator and the lac repressor (lacl) 
which converge to suppress transcription of the host cell T7 RNA polymerase and 
the T7 lac promoter in pET29b to inhibit transcription by any T7 polymerase that 
may be produced ensuring a two-step checkpoint to prevent basal expression 
and potential toxicity issues due to expression of the recombinant protein prior to 
induction.   
3.1.2.3 Co-expression of chaperone plasmids to increase folding efficiency. 
Despite the development of numerous specialised competent cell lines for the 
production of heterologous recombinant proteins, problems can still arise in the 
absence of sufficient molecular chaperones to assist in the proper folding of the 
desired protein leading to the formation of inclusion bodies and insoluble protein.  
The co-expression of a chaperone such GroEL-GroES, DnaK-DnaJ-GrpE and the 
chaperone-like trigger factor, alongside a plasmid containing the protein of 
interest, can significantly increase soluble protein yield and is a beneficial tool in 
the case of error-prone proteins. As the chaperone plasmids confer 
chloramphenicol resistance, they can be used alongside the kanamycin resistant 
expression vector, pET29b, for co-expression purposes. Several studies have 
shown considerable success employing this method utilising a commercially 
available set of chaperone plasmids (refer to Materials and Methods).  Nishihara 
et al (1998, 2000) employed the use of the aforementioned chaperones when 
attempting to co-express the relatively unstable protein, Japanese Cedar pollen, 
showing considerable success with increased protein production and stability 
within the soluble fraction.  An important consideration when co-expressing two 
plasmids for the generation of recombinant proteins is the compatibility of plasmid 




(DE3) cells described above as they carry no antibiotic resistant genes ensuring 
that both expression plasmids can be successfully selected. 
3.1.3.  Production of MIF proteins using E. coli expression systems. 
Historically, studies that have investigated MIF’s structure and function have used 
bacterial expression systems such as the E. coli BL21-CodonPlus (DE3) as their 
host expression cells of choice.  Typically, studies have suggested there are 
difficulties in obtaining protein within the soluble fractions of protein lysate; 
whether these studies attempted to optimise the growth and induction conditions 
to increase solubility is unspecified and numerous MIF studies relied on the 
unpredictable protocol of lysing inclusion bodies, denaturing the protein for 
purification and then performing a refolding procedure to renature the protein.  
However, the refolding methodology has several drawbacks: the process of 
dialysis to remove any denaturant is time-consuming; final protein yield is often 
minimal even in large scale cultures; and the entire process is largely 
experimental.   In addition to this, studies that utilised earlier versions of pET 
vectors such as pET11b (Bernhagen et al., 1994; Fan et al., 2013; Kleemann et 
al., 1998a; Kudrin et al., 2006; H. W. Sun et al., 1996) and pKP1500 (Mozetic-
Francky et al., 1997), which lack the endogenous 6His-tag sequence found in 
pET29b, were reliant on purification techniques such as gel filtration and anion 
exchange chromatography which because of technical limitations do not allow for 
quick one-step purification of recombinant protein.  In this study, we selected the 
pET29b vector containing a poly-histidine tag to clone sequences into as various 
studies expressing and purifying MIF homologues from Brugia malayi illustrate 
considerable success purifying using this system (Falcone et al., 2001b; Pennock 




3.2. Chapter aims and objectives. 
To produce a set of functional, enzymatically active MIF proteins and 
tautomerase/oxidoreductase mutants for use in future cellular assays the 
following aims were proposed: 
1. Clone human, murine and helminth MIF homologues into expression 
vector pET29b for large scale protein expression and purification. 
2. Clone, express and purify MIF mutants lacking tautomerase activity (P2G) 
for Hs-MIF-1, Mm-MIF-1, Ts-MIF-1 and oxidoreductase deficient mutants 
(C57S/C60S) for Hs-MIF-1 using site-directed mutagenesis. 
3. Assess all recombinant MIF proteins for native tautomerase and 
oxidoreductase enzyme activity to confirm they have been expressed and 
purified with a native structure and thus are suitable for downstream bioassays. 
 
3.3.  Cloning of MIF homologue expression constructs. 
Hs-MIF-1, Hs-DDT-1, Mm-MIF-1 and Mm-DDT-1 sequences were selected 
based on published data and synthesized using first strand synthesis from RNA 
derived from human U937 monocyte cells and murine C57Bl/6 female mice and 
products were cloned into shuttle vector pGEM-T.  Sequences were subsequently 
PCR amplified and subcloned into expression vector pET29b containing a C-
terminal His-tag site, using restriction sites NdeI and Xho1 (Figure 3.3.A.).  Ts-
MIF-1 and Ts-MIF-2 in pET29b were kindly provided by Dr David Guiliano (UEL).   
















Figure 3. 4 Schematic representation of the cloning of the MIF homologues into pET29b.  A)  Cloning schema for MIF homologues. 
The pET29b vector and MIF cDNA sequences were digested with the restriction enzymes NdeI and XhoI.  The MIF cDNAs were ligated to 
complimentary ends of pET29b.  B)  Shows a sample chromatograph confirming successful in-frame cloning of MIF cDNAs into pET29b 




Hs-MIF-1 P2G, Mm-MIF-1 P2G and Ts-MIF-1 P2G inserts were generated by 
synthesizing the forward PCR primers substituting the N-terminal Proline 
residues to Glycine and is schematically represented in figure 3.4.A.  Glycine was 
selected based on several publications that demonstrated that substitution of 
Proline with other amino acids such as Serine, did not significantly limit the 
enzymatic activities and monocytic migration when compared to substitution with 
Glycine (Bendrat et al., 1997; Hermanowski-Vosatka et al., 1999; Lubetsky et al., 
1999; M Swope et al., 1998).   In addition to this, Glycine is the smallest amino 
acid and has no net charge, therefore, reducing the likelihood of the substitution 
affecting MIF’s three-dimensional structure. Hs-MIF-1 C57S/C60S, lacking two 
critical cysteine residues that have been substituted for serine, was constructed 
using a crossover PCR reaction as depicted in figure 3.4.B.   Cloning of all MIF 

















Figure 3. 5 Schematic representation of PCR mutagenesis and crossover 
PCR mutagenesis utilised to generate MIF-1 and MIF-2 homologue P2G 
mutants and the Hs-MIF-1 C57S/C60S mutant. A) tautomerase and 
oxidoreductase conferring amino acid ands and corresponding DNA sequence. 
MIF mutants tautomerase mutants substitute proline for glycine whist the 
oxidoreductase mutants substitute cysteine for serine residues. B) Overlapping 
fragments substituting cysteine residues for Serine residues were initially 
amplified from Hs-MIF-1 in pET29b.  PCR purified fragments were then mixed, 
annealed to each other and a second round of PCR amplification performed 
utilising standard Hs-MIF-1 primers annealing to the 5’ end of fragment 1 and 3’ 
end of fragment 2 which amplifies the full sequence containing the SALS site.  


















Figure 3. 6 Confirmation of successful cloning of MIF sequences into the 
pET29b expression vector. After isolation of pET29b transformants the 
presence of the MIF homologue cDNAs were confirmed using PCR and MIF 
homologue specific Fw and Rv primers. PCR products were run on a 1.2% 
agarose gel in TAE buffer.  All of the resulting amplicons were the anticipated 
size for the cDNA fragments. A) Left to right - Ts-MIF-1, Ts-MIF-1_P2G, Ts-MIF-
2. B) Left to right - Mm-MIF-1, Mm-MIF-1_P2G. C) Left to right - Hs-MIF-1, Hs-
MIF-1_P2G, Hs-MIF-1_C57S/C60S fragment Fw, Hs-MIF-1_C57S/C60S 
fragment Rv, Full length Hs-MIF-1_C57S/C60S. M – NEB 2-log marker.  
 
 
3.4.  Purification of wild-type and mutant MIF homologues. 
To obtain fully functional MIF proteins, pET29b vectors containing the MIF 
sequences were initially transformed into BL21-CodonPlus (DE3) expression 
cells and expressed as His-tag fusion proteins.  Hs-MIF-1 and Hs-MIF-1 P2G 
were successfully induced and expressed within the soluble extract under 
standard conditions (1mM IPTG for 6 hours at 37°).  However, we encountered 
numerous problems when attempting to obtain Hs-MIF-1 C57S/C60S and Hs-
DDT-1 from the soluble extract as these were initially found solely within the 
insoluble fraction.  This was consistent with previous studies revealing that 
substitution of Cys 60 for an alternative amino acid, impedes the formation of a 
disulphide bridge leading to misfolding of MIF and hence detection solely within 
the insoluble (Herrero et al., 2011; Kleemann et al., 1998b, 1998a, 1999a).  
Though the aforementioned studies successfully purified Cys60 mutants from the 
insoluble fraction using a denaturing and refolding protocol, this could not be 




such as Ts-MIF-1 and Ts-MIF-2 lack these cysteine residues however these 
homologues are still able to fold correctly.  Therefore, assessed a number of 
different expression conditions for these proteins that have been reported to 
increase protein solubility.  Normally proteins are induced when cultures are in 
the exponential phase of growth, typically at OD600 0.6, however in proteins that 
are susceptible to misfolding or toxic to the cell it is often beneficial to induce at a 
later stage thereby slowing the rate at which proteins are expressed and folded.  
For this reason, several conditions were tested which revealed that induction of 
Hs-MIF-1 C57S/C60S and Hs-DDT-1 at a higher OD, OD600 0.8 prevents 
misfolding.  In addition to this, the induction conditions were adapted to growth at 
15°, 150rpm, 100µM IPTG, for 12 hours.  Figure 3.8.6 and 3.8.8 show the 
successful expression of Hs-MIF-1 C57S/C60S and Hs-DDT-1 within the soluble 
















Figure 3. 7 Hs-MIF proteins are successfully expressed in BL21 CODON 
PLUS cells.  Proteins were resolved on a 15% SDS PAGE gel and stained with 
Coomassie Brilliant Blue.  A.1-8) Total protein: 1- non-induced Hs-MIF-1; 2- 
induced Hs-MIF-1; 3- non-induced Hs-MIF-1 P2G; 4- induced Hs-MIF-1 P2G; 5- 
non-induced Hs-MIF-1 C57S/C60S; 6- induced Hs-MIF-1 C57S/C60S; 7- non-
induced Hs-DDT-1; 8- induced Hs-DDT-1. B.1-8) 1- insoluble Hs-MIF-1; 2- 
soluble Hs-MIF-1; 3- insoluble Hs-MIF-1 P2G; 4- soluble Hs-MIF-1 P2G; 5- 
insoluble Hs-MIF-1 C57S/C60S; 6- soluble Hs-MIF-1 C57S/C60S; 7- insoluble 
Hs-DDT-1; 8- soluble Hs-DDT-1. 
 
Mm-MIF-1 was previously cloned into pET29b, expressed and purified under 
standard conditions (Paraliker, 2017).  Figure 3.9.A shows the successful 
induction of Mm-MIF-1 P2G and Mm-DDT-1 in total protein lysates; Mm-MIF1- 
P2G was expressed predominantly within the soluble fraction, as shown in figure 
3.8.B-2, whilst Mm-DDT-1 was initially found all in the insoluble fraction.  Mm-
DDT-1, like Hs-DDT-1, was grown in the adapted conditions discussed previously 
after which protein was easily detected within the soluble fraction (figure 3.9.C-
























Figure 3. 8 Mm-MIF proteins are successfully expressed in BL21 CODON 
PLUS cells.  Proteins were resolved on a 15% SDS PAGE gel and stained with 
Coomassie Brilliant Blue.  A.1-6) Total protein: 1- non-induced Mm-MIF-1; 2- 
induced Mm-MIF-1; 3- non-induced Mm-MIF-1 P2G; 4- induced Mm-MIF-1 P2G; 
5- non-induced Mm-DDT-1; 6- induced Mm-DDT-1.  B.1-2) 1- insoluble Mm-MIF-
1, 2- soluble Mm-MIF-1.  C.1-2) 1- insoluble Mm-MIF-1 P2G, soluble Mm-MIF-1 
P2G.  
 
Initially, Ts-MIF-1, Ts-MIF-1 P2G and Ts-MIF-2 were induced using 1mM IPTG 
for a total period of six hours.  Ts-MIF-1 and Ts-MIF-1 P2G were successfully 
induced when compared to their non-induced counterparts (figure 3.9.A), and 
both constructs were found to be largely within the soluble extracts of protein 
lysates, as depicted in figure 3.9.B indicating that Ts-MIF-1 and Ts-MIF-1 P2G 




BL21-CodonPlus (DE3) cells when assessing total protein content (figure 3.10.A), 
we did however, encounter several issues in generating any soluble protein 
(figure 3.10.B).  In order to optimise the solubility of Ts-MIF-2 we screened a set 
of commercially available BL21 expression hosts which also co-express 
additional chaperonins to assist in protein folding.  Ts-MIF-2 was successfully 
expressed within the soluble extract of pGRO7 cells after induction with 200µM 
IPTG and 2mg/ml L-arabinose at 25° for 10 hours and could not be found in the 
soluble lysates of any other chaperonin cell line (figure 3.10.C).  pGRO7 cells co-
express the heat shock proteins or chaperonin GroEL and co-chaperonin GroES 
in the presence of L-arabinose.  GroEL forms a barrel-like structure which retains 
the protein whilst GroES acts as the ‘lid’ cooperatively protecting the folding 






Figure 3. 9 Ts-MIF-1 and Ts-MIF-1 P2G successfully induced and expressed 
as soluble protein.  Proteins were resolved on a 15% SDS PAGE gel and 
stained with Coomassie Brilliant Blue.  A. 1-6) All total extract: 1-non-induced 
empty pET29b; 2- induced empty pET29b; 3-non-induced Ts-MIF-1; 4-induced 
Ts-MIF-1; 5-non-induced Ts-MIF-1 P2G; 6-induced Ts-MIF-1 P2G.  B. 1-4) All 
induced: 1-soluble Ts-MIF-1; 2-insoluble Ts-MIF-1; 3-soluble Ts-MIF-1 P2G; 4-













Figure 3.10 Ts-MIF-2 is successfully expressed in BL21 pGRO7 cells. 
Proteins were resolved on a 15% SDS PAGE gel and stained with Coomassie 
Brilliant Blue.  A.1-2) Total protein extract: 1-Non induced Ts-MIF-2; 2-Induced 
Ts-MIF-2.  B.1-6) Soluble: 1-CODON PLUS; 2-Tf2; 3-Tf16; 4-KjE7; 5-KjE8; 6-
pGro7.  C.1-6) Insoluble: 1-CODON PLUS; 2-Tf2; 3-Tf16; 4-KjE7; 5-KjE8; 6-





Expressed proteins were purified utilising the C-terminal His-tag and Ni-affinity 
purification on an AKTA prime. All fractions collected and assessed for presence 
of MIF protein.  Figure 3.11 shows a typical gel containing all fractions after 
purification; His-tagged MIF can be seen exclusively within the elution fractions.   
Elution fractions were subsequently concentrated, and buffer exchanged before 
the final anion-ion exchange purification in order to remove any residual LPS. 
Purified proteins were detected using a probe targeted to MIF’s C-terminal 6His-
tag (figure 3.12).  Endotoxin contamination was assessed utilising a limulus 
amebocyte assay and all samples contained <1ng/ml endotoxin per 1mg/ml MIF 
protein.  Within our experiments all MIF proteins were diluted to a final 
concentration of 100ng/ml, so endotoxin levels throughout cellular assays were 








Figure 3. 11 Example SDS PAGE gel of protein fractions after AKTA 
purification.  Proteins were resolved on a 15% SDS PAGE gel and stained with 
Coomassie Brilliant Blue. W = wash, E = elution.  1 – W1, 2 – W2, 3 – W3, 4 – 

















Figure 3. 12 Fully purified MIF proteins. Proteins were resolved on a 15% SDS 
PAGE gel, transferred to nitrocellulose membrane and recombinant proteins 
detected by Western blot using a HRP-conjugated anti-His-tag probe.  A) Mm-
MIF-1, Mm-MIF-1 P2G, Mm-DDT-1; B) Hs-MIF-1, Hs-MIF-1 P2G, Hs-MIF-1 
C57S/C60S, Hs-DDT-1; C) Ts-MIF-1, Ts-MIF-1 P2G, Ts-MIF-2. 
 
3.5.  Recombinant MIFs retain critical enzyme activities. 
To confirm whether the purified recombinant MIF homologues were enzymatically 
active and to assess what differences there were in the enzymatic activities of the 
MIFs produced by mammals and T. spiralis a series of assays were employed to 
measure the previously characterized MIF tautomerase activity using pseudo-
biological substrate L-dopachrome methyl ester.  L-dopachrome methyl ester is 
chromogenic, forming an orange colour when added to the enzyme buffer.  MIF-
tautomerisation of L-dopachrome methyl ester generates indole derivatives that 
are colourless; the loss of colour is detected spectrophotometrically and used to 




Initial studies revealed that a commercially available recombinant human MIF 
protein lacked both the tautomerase and oxidoreductase activity (figure 3.13) 
associated with many of MIF’s immunomodulatory roles which resulted in 
generation of recombinant MIF proteins for this study.  Commercially purchased 
rHMIF may lack enzymatic activities due to lyophilisation disrupting the structure 












Figure 3. 13 Commercially available rHMIF1 lacks enzyme activity.  A) MIF 
proteins were added to an enzyme solution containing L-dopachrome methyl 
ester and sodium periodate and absorbance values were recorded every 30 
seconds for approximately five minutes.  Graph depicts enzyme activity as OD475 
versus Time (secs).  Spontaneous reaction is the natural tautomerization of L-
dopachrome methyl ester and contains all reagents excluding MIF. B) Graph 
depicts increase in absorbance at 650nm due to an accumulation of the Insulin-
β chain in the presence of MIF. The data represents the mean ±SEM (n=2).     
Figure 3.14 shows that all generated, purified WT MIF recombinants have 
tautomerase activity demonstrating that these proteins are folding efficaciously in 




Pennock et al (1998) and Tan et al (2001), purified Ts-MIF-1 has a specific 
enzyme activity (359.69 µmol.min-1.mg-1) much greater than that of Hs-MIF-1 and 
Mm-MIF-1 proteins at 178.01 µmol.min-1.mg-1 and 194.33 µmol.min-1.mg-1, 
respectively.  However, the previous studies examining Ts-MIF’s tautomerase 
activities proposed that the critical enzyme activity was six-fold higher than that 
of Hs-MIF-1, whereas in this study it was found that Ts-MIF-1 tautomerase activity 
is two-fold greater.  Additionally, we corroborate, along with previous findings, 
that the MIF paralogues Hs-DDT-1 and Mm-DDT-1 also have tautomerase 
activity, 74.83 µmol.min-1.mg-1 and 52.17  µmol.min-1.mg-1, albeit with lower 
activities than MIF-1 proteins.   An interesting point to note is that there is a 
39.73% decrease in specific tautomerase activity when comparing Hs-MIF-1 
C57S/C60S (107.28 µmol.min-1.mg-1) to Hs-MIF-1 (178.01 µmol.min-1.mg-1) 
despite the N-terminal Proline being intact.  Though some studies hypothesise 
that this is a result of a conformational change in the three-dimensional structure 
due to an inability to form disulphide bridges, this seems unlikely as Ts-MIF-1, 
which also lacks any cysteine residues, retains significant tautomerase activity. 
Ts-MIF-2 is a novel T. spiralis MIF paralogue identified by Dr David Guiliano 
(UEL), it has not been previously characterised, and like all other MIF proteins, 
has the conserved proline residue.  Enzymatic analysis revealed that Ts-MIF-2 
has a specific enzyme activity of 131.83 µmol.min-1.mg-1 approximately three-fold 
lower than that of Ts-MIF-1.  The differences in catalytic efficiencies between 
MIF’s suggest that additional amino acid sequences assist in conferring activity 
despite the catalytic centre being the N-terminal Proline. 
In addition to the WT MIF proteins, we confirm that MIF P2G mutants lack the 
ability to tautomerise L-dopachrome methyl ester decreasing enzyme activity by 




commercial inhibitor 4-IPP, which covalently binds to MIF’s N-terminal Proline 

























Figure 3. 14 Expressed and purified mammalian and parasite MIFs possess 
tautomerase activity.  MIF proteins were added to an enzyme solution 
containing L-dopachrome methyl ester and sodium periodate and absorbance 
values were recorded every 30 seconds for approximately five minutes.  A) Graph 
depicts enzyme activity as OD475 versus Time (secs). B) Bar graph shows specific 
enzyme activity of recombinant MIF proteins.  C)  Table showing absolute values 
for specific enzyme activity.  The data represents the mean ±SEM (n=3).   (*) p-
value ≤ 0.05, (**) p-value ≤ 0.01, (***) as verified by ANOVA with Dunnett’s 
correction for multiple tests. 
 
With the intention of reducing batch to batch variability in enzyme activity, 
including the detrimental effects of freezing and thawing on protein structure, 
optimisation of storage solutions was critical to prevent precipitation of 
recombinant proteins and loss of enzyme activity.  Employing Ts-MIF-1 as a 
model recombinant protein, solutions were resuspended in varying 
concentrations of cryo-preservative, glycerol, at a final concentration of 1mg/ml 
and stored at the specified conditions.   After a 12-week period, recombinant 
proteins were assessed for tautomerase activity as an indicator of protein stability 
and compared to freshly purified Ts-MIF-1.  As expected, Ts-MIF-1 stored in 
glycerol (10%) at -80⁰ retained the highest level of specific enzyme activity at 
297.33 µmol.min-1.mg-1 when compared to the newly purified Ts-MIF-1 which 
displayed a specific enzyme activity of 359.67 µmol.min-1.mg-1 (figure 3.15).  
Although this is a decrease of 17.33%, loss of activity is expected to some degree 
due to the freeze-thaw method.  Unexpectedly, Ts-MIF-1, which was stored 






substantial amount of specific enzyme activity (147.93 µmol.min-1.mg-1) when 
compared to the specific enzyme activity of Ts-MIF-1 solutions which contain 
levels of glycerol at 20% and 30%, 75.33 µmol.min-1.mg-1 and 93.24 µmol.min-
1.mg-1, respectively.  This suggests that levels of glycerol above 10% inhibit 
enzyme activity, nonetheless, an investigation into the effects of glycerol of 














Figure 3. 15 Optimisation of storage conditions for recombinant Ts-MIF-1.  
Ts-MIF-1 was stored under varying conditions for 12 weeks and assessed for 
tautomerase activity thereafter. A)  Enzyme activity depicted as OD475 versus 
Time (secs). Graph depicts tautomerase activity of Ts-MIF-1 under varying 
storage conditions. B) Bar chart shows specific enzyme activity in µmol.min-1.mg-







Finally, to confirm the presence of oxidoreductase activity in MIF proteins an 
assay utilising reduction of the insulin β-chain was employed. Oxidation of the 
cystine residues in insulin result in precipitation of the β-chain as aggregates that 
can be detected spectrophotometrically.  As expected, figure 3.16 shows that Hs-
MIF-1 and Mm-MIF-1, have high oxidoreductase activity with a rate of 
precipitation at 1.08 and 0.87 (∆A650 x min), respectively.  In contrast, Ts-MIF-1 
conferred no oxidoreductase activity, as expected, due to the absence of cysteine 
residues and catalytic CALC domain.  Similarly, Hs-MIF-1 C57S/C60S which has 
cysteine substituted for serine residues at location 57 and 60 lacks any notable 
oxidoreductase activity.  Comparative analysis revealed that the rates of reaction 
for Ts-MIF-1 and Hs-MIF-1 C57S/C60S were significantly lower (p ≤0.001) than 
Hs-MIF-1. 
   The presence of these critical enzyme activities within WT MIF proteins and the 


















Figure 3. 16 Purified Hs-MIF-1 and Mm-MIF-1 exhibit oxidoreductase 
activity.  A) Graph depicts increase in absorbance at 650nm due to an 
accumulation of the Insulin-β chain in response to MIF.  B)  Bar graph showing 
rate of precipitation.  C)  Table illustrates values representing time taken to 
precipitation and rate of precipitation. The data represents the mean ±SEM (n=3).  
(***) p-value ≤ 0.001 as verified by ANOVA with Dunnett’s correction for multiple 
tests.  
 
3.6. Discussion of cloning and characterisation of MIF and MIF homologues. 
Previous research examining MIF’s immunomodulatory mechanisms utilised 
commercial recombinant MIF proteins, however, in this study we show that some 
commercially purchased MIF’s lack the critical enzymatic activities associated 
with many of its classical inflammatory features.  Additionally, companies that sell 
recombinant lyophilised MIF proteins neglect to assess the enzyme activity of MIF 
as part of the validation and quality control process (Bank et al., 2012; Beswick 
and Reyes, 2008; Figueiredo et al., 2018; Ko et al., 2019; Letta et al., 2018; 
Lourenco et al., 2015; Rossello et al., 2016; Stephenson et al., 2019; Voss et al., 
2019; Zhang et al., 2015).  Consequently, it was vital for the purposes of this 
research program to clone, express and purify recombinant MIF proteins in order 
to retain the enzymatic characteristics. 
MIF homologues were successfully cloned and expressed as 6His-tag fusion 
proteins in pET29b and subsequently isolated utilising an Ni-NTA system.  
Although we initially encountered issues expressing soluble protein from Ts-MIF-
2, Hs-DDT-1, Hs-MIF-1 C57S/C60S and Mm-DDT-1, this was overcome by 






post-induction greatly increased the amount of protein within the soluble extract.  
Nonetheless, the final MIF protein yield was considerably lower in these 
recombinants than Hs-MIF-1, Ts-MIF-1, Mm-MIF-1 and their associated P2G 
mutants. 
 A common feature of the sequences that are liable to misfold is that they lack 
Cys-60; a cysteine residue which has previously been identified as the controller 
of redox activities in MIF (Fan et al., 2013; Kleemann et al., 1998b, 1998a; Robert 
Kleemann et al., 2000b).  However, a caveat to this theory is that the Ts-MIF-1 
protein sequence lacks any cysteine residues and is uncomplicated in terms of 
expression and purification on the basis that the protein undergoes precise 
folding.  One explanation for this includes the possibility that single cysteine 
residues within the amino acid sequences of Ts-MIF-2, Hs-DDT-1 and Mm-DDT-
1 have greater reactivity and, for example, may interact with exogenous factors 
within the bacterial cell during expression, although this is likely to be contingent 
on the locality of residues and the proximity to charged amino acids such as 
asparagine and lysine; single cysteine residues closer to the N-terminus are more 
likely to undergo protonation whilst residues at the C-terminus tend to be 
concealed within the protein structure (Haase-Pettingell et al., 2001; Miseta and 
Csutora, 2000; Netto et al., 2007).  To determine whether this is conclusively the 
case, additional studies will need to be performed. 
In this study, having enzymatically active MIF’s were essential for attempting to 
interpret their role in MIF’s well-documented immunomodulatory mechanisms.  
Here, we illustrate that MIF proteins expressed and purified in the pET29b/BL21-
CodonPlus system maintain the correct three-dimensional structure by use of 
assays which assess tautomerase and oxidoreductase activity.  There were 






that of published work by Tan et al (2001), namely that the specific enzyme 
activity during this study was three-fold lower.  This variation may occur because 
of a number or reasons. Throughout this project the detergent TWEEN was 
utilised in the tautomerase assay to act as a molecular crowding agent and 
prevent binding of the MIF protein to plasticware (Kudrin et al., 2006). However, 
there is a possibility that TWEEN may interact with the active site thus reducing 
activity levels (Acker and Auld, 2014). Substrate concentrations vary largely 
between published data, after an initial period of optimisation we used 
concentrations of L-dopachrome methyl ester ten-fold lower than Tan et al (2001). 
Finally, as the specific enzyme activity is a representation of enzyme purity there 
is the possibility that these values will fluctuate widely between purification 
methods and published work.    
In this study, along with others, we noted that the specific tautomerase activities 
of Hs-DDT-1, Mm-DDT-1 and Ts-MIF-2 were significantly lower than the related 
MIF-1 counterparts and is likely to be a consequence of different amino acids 
surrounding the proline residue. Merk et al (2011) identified that, while the active 
site of both human MIF-1 and DDT-1 is positively charged, the surrounding area 
has a positive charge in MIF-1 and a negative charge in DDT-1 likely modifying 
the binding capacity of the active site. On the other hand, as no physiological 
substrate has been identified for the tautomerase activity of MIF-1 and DDT-1, 
there is the possibility that they act on different biological substrates. Merk et al 
(2012) previously discovered that DDT-1 undergoes an additional de-
carboxylation step to form 5,6-dihydroxyindole whereas MIF-1 catalyses a bona 
fide tautomerisation to produce 5,6-dihydroxyindole-2-carboxylic acid.  Aside 
from this, we successfully produced MIF P2G mutants in which all tautomerase 






The enzymatic profile of Ts-MIF-2 is a novel finding and from the specific enzyme 
activity it would appear that it is, as expected, a homologue of mammalian DDT-
1.  Although Ts-MIF-2 confers tautomerase activity two-fold higher than Hs-DDT-
1, this is also two-fold lower than Ts-MIF-1 which follows a similar pattern to 
HsMIF1 and Hs-DDT-1.  Further work will be required to address more 
complicated questions regarding Ts-MIF-2 enzyme activity including kinetic 
studies to determine the exact behaviour and compare to Hs-DDT-1.   
To ensure that MIF proteins were attaining the correct structural confirmation, 
oxidoreductase activity was also evaluated.  Hs-MIF-1 and Mm-MIF-1 displayed 
clear redox capacities while Hs-MIF-1 C57S/C60S lacked any notable activity 
alongside Ts-MIF-1; as Ts-MIF-1 and Hs-MIF-1 C57S/C60S were Cys-57 and 
Cys-60 deficient this was anticipated.             
 The biological relevance of MIF enzyme activity has been subject to considerable 
scrutiny with frequent contradictory results in different studies in terms of whether 
tautomerase or oxidoreductase deficient MIF retain the pro-inflammatory qualities 
of WT MIFs.  Further work in this thesis examines the effects of catalytic domain 
mutants on intestinal immune responses.   
In summary, this chapter has demonstrated that MIF and DDT homologues can 
be purified using a Ni NTA method while avoiding the time-consuming and 
inaccurate refolding procedure.  Additionally, we have characterised the enzyme 
characteristics of MIF and DDT, and identified a novel T. spiralis tautomerase, 










Chapter 4:  The effects of MIF on intestinal epithelial immune 
signalling 
4.1.  Introduction. 
4.1.1.  The Intestinal Immune system. 
 
The intestinal immune system has been extensively explored and is known to 
play a key regulatory role in both local and systemic immune responses.  Many 
of the immune cells within the GT are well characterised and their functions 
understood.  Antigen presenting cells such as dendritic cells and macrophages 
sample antigens from the intestinal lumen and go on to release chemotactic 
signals and present the processed antigens to adaptive immune cells (Bain and 
Schridde, 2018; Stagg, 2018).  Epithelial cells, which form the mucosal barrier 
surface, were once considered to be passive in their immune functions, however, 
studies have revealed that these are an integral point for the initiation and 
regulation of immune responses.  Epithelial cells maintain barrier function by 
secreting IL-6 and TGF-beta into the local environment which are involved in 
regulating the T-reg/Th17 axis (Walia et al., 2003).  Dysfunction of these 
cytokines has been shown to lead to local inflammation and many chronic 
inflammatory diseases such as inflammatory bowel disease (IBD) are attributed 
to issues with these key cytokines (Andrews et al., 2018; Neurath, 2014).  
Moreover, chemical inhibition or mutation of the IL-6 and TGF-beta genes can 
induce IBD-like symptoms in mice (Jeffery et al., 2017).  Expression of IL-6 and 
TGF-β, like other cytokines involved in mucosal immunity, are modulated by the 







4.1.2.  The role of Pathogen Recognition Receptors such as TLR4 in 
regulating immune responses in Intestinal Epithelial Cells. 
 
The role of innate immune receptors (Pathogen Recognition Receptors, PRRs) 
in the GT must not be underestimated.  TLR’s expressed on the surface of 
epithelial cells are responsible for distinguishing between commensal and 
pathogenic microorganisms and eliciting appropriate responses.  It has 
demonstrated that TLR4 plays a significant role in regulating local immune 
responses and IECs have been shown to express TLR4 on the basolateral 
surface of IECs and within the cytoplasmic compartment, restricting reactions to 
its canonical ligand LPS to circumstances where barrier function is compromised. 
This represents a critical control mechanism as LPS is constantly present in the 
GT due to a large number of Gram-negative organisms found in the intestinal 
lumen.  LPS activation of TLR4 requires two co-receptors for efficient signalling, 
CD-14 and MD-2.  The co-factors form a heterotrimer when TLR4 is activated 
forming part of this critical immune signalling complex.   
LPS is a large glycolipid with that forms a structural component of the outer 
membrane of selective Gram-negative bacteria.  Three structural domains make 
up the glycolipid:  lipid A, the core oligosaccharide, and the O antigen (Raetz and 
Whitfield, 2002).  Whilst the lipid A portion and the core oligosaccharide tend to 
be conserved between species, the O antigen is highly variable.   LPS from 
different organisms vary in their ability to elicit immune responses by differences 
within the O antigen and steric arrangements of the protein (Bertani and Ruiz, 
2018).  Regardless, it is the lipid A domain that binds to the LPS canonical 






shown to co-signal concurrently through TLR2 and TLR4.  LPS from Salmonella 
enterica is specific for TLR4 and studies have shown that this particular LPS lacks 
the capacity to bind TLR2.   TLR 4 is regulated by a complex array of growth 
factors and soluble mediators within the GT.  Two of the most common regulators 
of TLR4 expression within IEC’s are IFN-γ and TGF-β and numerous studies 
have revealed a critical role for these in epithelial driven innate immune 
regulation.  Priming of IEC’s with 10ng/mL – 40 ng/mL recombinant INF-γ for over 
12 hours significantly increases TLR4 expression and induces LPS 
responsiveness in HT29 cells (Abreu et al., 2002; Suzuki et al., 2003a).  
Conversely, expression of TLR4 and TGF-β appear to be part of a reciprocal 
feedback loop:  while TLR4 supresses TGF-β signalling in RAW264.7 
macrophages (Liu et al., 2008), mutation of the TGF-β type II receptor in mice 
with DSS-induced colitis led to a significant increase in TLR4 expression and LPS 
hyperresponsiveness in IEC’s when compared to WT mice (Hahm et al., 2001).  
4.1.3.  MIF and TLR4 
 
MIF is constitutively expressed and secreted by epithelial cells within the GT at 
low levels. However, the precise role of MIF in this context is currently unknown.  
Several studies have confirmed that there is a dramatic increase production of 
MIF in many pathological conditions. Examples include IBD and the colonic 
tumour microenvironment where MIF is believed to promote inflammation and in 
the context of cancer increase cell survival promoting tumorigenesis and 
angiogenic responses.  Currently, studies exploring the interplay between MIF 
and TLR4 in the GT in both normal and pathological conditions are lacking. The 






conditions where macrophages are MIF-deficient (Roger et al., 2003). These 
studies also have shown MIF enhances LPS signalling in a fibroblast cell line (Xi 
et al., 2016), and  that the overall expression pattern of TLR4 is reduced in cells 
lacking the MIF (Roger et al., 2001).  Taken together, this suggests that MIF may 
modulate TLR4-mediated signalling in GT cells and potentially be critical for IECs 
immune activation by LPS. 
4.1.4.  MIF and TGF-β. 
As described earlier in this chapter, TGF-β is a well-established regulator of 
epithelial-mediated immune responses in the GT and plays a number of key roles 
in the polarisation of immune cell subsets.  TGF-β is most commonly reported to 
confer regulatory properties and is associated with counter-regulation of 
inflammatory response and the induction of regulatory immune cell subsets such 
as M2 macrophage phenotypes and Foxp3+ T-reg cells.  However, more recently 
TGF-β has been implicated in the development of several potential pathogenic 
immune cell subsets such ILC3, Th17 and Th22 cells (Bauché and Marie, 2017b); 
all of which are known to exacerbate colonic inflammation during the onset of 
intestinal disorders such as Ulcerative Colitis and Crohn’s disease.   
4.2.  Chapter aims and objectives. 
 
In order to examine the effects of MIF on intestinal epithelial immune signalling a 
set of aims were employed, and these are described below: 
1. Assess if MIF can modulate responses to LPS in a commercially available 
TLR4 reporter cell line HEK-Blue™-hTLR4. 
2. Develop a derivative of HEK-Blue™-hTLR4 within which the NF-kB 






and also over express the MIF receptors CD74 and CD44. Assess the activity of 
MIF on the responses of these cells after LPS treatment. 
3. Generate a colonic epithelial transcriptional reporter cell line using HT29 
cells which expresses the fluorescent protein mCherry under the control of NF-
kB. 
4. Identify conditions within which HT29 reporter NF- κB cells are responsive 
to LPS and assess the activity of MIF on LPS activation of these cells. 
5. Generate a TGF-β HEK reporter cell line which expresses the fluorescent 
protein eGFP under the control of the SMAD binding elements.  Assess the 
activity of MIF on the responses of these cells after LPS treatment. 
 
Table 4. 1 Summary of the genetic background and origins of the cell lines 
used to complete these objectives.  
Cell name Cell 
type 













































4.3.  MIF inhibits TLR4 mediated NF-kB activation of HEK-Blue™-hTLR4 
cells. 
Despite MIF’s role in immune modulation being well studied, it’s precise 
mechanisms within the context of immune signalling is poorly understood.   
Recently, MIF has been shown to activate the master regulator NF-kB  in a CD74-
dependent fashion in murine splenocyte-derived B-cells (Gore et al., 2008), and 
upregulate genes associated with cancer progression such as ICAM-1, BCL-XL 
and MMP2 (Kim et al., 2017).  Conversely, MIF has been shown to inhibit AP-1 
activity by binding to its proposed intracellular receptor Jab-1 in HEK 293T cells 
(Robert Kleemann et al., 2000a). However, this particular interaction between 
MIF and AP-1 did not alter NF-kB activity. NF-kB is a key component of many 
critical cell processes including those which govern immune responses such as 
cytokine and chemokine release, cell cycle progression and the upregulation of 
adhesion molecules.  The vast majority of cell surface receptors will have 
signalling pathways which converge upon the NF-kB family of proteins. TLR4 is 
a PRR which recognises the endotoxin, LPS, leading to phosphorylation of the 
intracellular tyrosine kinase associated motifs (ITAMs) triggering downstream 
NF-kB activation.   
In order to explore the role of MIF in TLR4-mediated NF-kB activation we utilised 
a commercially available HEK 293 cell line HEK-Blue™-hTLR4 (Invivogen) 
containing an inducible secreted alkaline phosphatase (SEAP) NF-kB reporter 
gene on a pNifty2 SEAP vector.  The pNifty2 vector contains 5 NF-kB 
transcription factor binding sites under the control of a proximal ELAM promoter 






Importantly, the ELAM promoter gene is a truncated version which lacks the 
typical AP-1/CREB site found in the full-length sequence ensuring NF-kB 
specificity.     The commercially available HEK-Blue™-hTLR4 cell line has been 
previously co-transfected with TLR4, the LPS coreceptors CD14 and MD-2, and 
respond to bacterial endotoxin, LPS activating downstream mediator NF-kB 
which, in turn promote secretion of alkaline phosphatase into the culture media.  
As HEK 293 cells lack any endogenous TLR receptors they are a useful tool for 
examining this specific cell signalling pathway.  Previous research within our lab 
has confirmed that HEK 293 pNifty2 SEAP (https://www.invivogen.com/pnifty2-
seap) transfected cells, lacking the TLR4 receptor, do not show NF-kB activation 
when stimulated with LPS (Paralikar., 2017) whilst HEK-Blue™-hTLR4 cells are 
LPS-responsive from 0.1ng/ml.   
Though many studies looking at the interplay between MIF, LPS and NF-kB 
activation have taken place, the concentrations of endotoxin used to mimic 
biological interactions often exceed those that would normally be considered 
relevant in vivo.  Within a healthy intestinal environment, LPS levels typically 
range from 0.1pg/ml – 50pg/ml, within the lumen, whilst a diseased intestine, such 
as that found in many inflammatory bowel diseases, can increase to levels of up 
to 100ng/mL (Leaphart et al., 2007; Sodhi et al., 2010). (A. S. Andreasen et al., 
2008; Hurley, 1995; Marshall et al., 2002; Sharma et al., 2007; Wellmann et al., 
1986).  Taken together, all experiments within the remits of these investigations 
utilised LPS concentrations ranging from 10ng/ml – 100ng/ml.    
Countless gram-negative bacterial species produce LPS which differ in structure 
and ability to act as PAMPs. In some circumstances LPS’s manipulate the host 






which is characterised by a unique structure usually within the O antigen, a 
repeating unit of oligosaccharides.  In a healthy intestine, epithelial integrity is 
maintained by the cooperative actions of the microbiota and the intestinal immune 
system whilst intestines in a diseased state fail to preserve barrier function, due 
to dysbiosis and epithelial dysfunction, allowing LPS to enter the sub-epithelial 
space.  Salmonella enterica serotype typhimurium is a significant opportunistic 
enteropathogenic bacterium expressing a unique LPS pattern containing an extra 
O-antigen which specifically binds to TLR4.  S. enterica serotype typhimurium is 
normally prevented from causing gastroenteropathy by the competing intestinal 
flora, however, in IBD patients dysbiosis leads to a severely inflamed epithelium 
with loss of tight junctions enabling S. enterica to invade the epithelial cells 
thereby activating the intracellular TLR4 compartment.  Therefore, in this study 
observing the effects of MIF on TLR-4 signalling, we utilised LPS derived from S. 
enterica serotype typhimurium. Figure 4.1.A. confirms that HEK-Blue™-hTLR4 
cells respond to both LPS (p≤0.01) and the positive control, TNF-α (p≤0.001), as 
expected.  While there was no significant difference between cells stimulated with 
LPS alone and those co-incubated with LPS and MIFs (figure 4.1.B.), however, 
there is a notable difference between cells with LPS and Ts-MIF-1 co-
administered and the LPS control.  Despite this, further work examining MIF’s 
role in LPS mediated responses in the context of MIF receptors, CD74 and CD44 
required additional transfection of HEK cells.  To overcome issues with 
incompatibility in terms of antibiotic resistance and toxicity the decision was made 

















Figure 4. 1 MIFs modulate LPS responsiveness in HEK-Blue™-hTLR4 cells.  
The graphs show levels of secreted alkaline phosphatase (SEAP) in the media 
of HEK-Blue™-hTLR4 cells after treatment with different stimulants. The SEAP 
activity was detected using p-Nitrophenyl Phosphate (pNPP). Response rate is 
calculated as: OD405 experimental sample/OD405 control sample.  A) HEK-Blue™-
hTLR4 cells incubated with 10ng/ml LPS or 50ng/ml TNF-α for 18 hours.  B)  
HEK-Blue™-hTLR4 cells treated with 10ng/ml LPS +/- MIF for 18 hours.  The 
data represents the mean ± SEM (n=3) of the response ratio. (*) p-value ≤ 0.05 
(**) p-value ≤ 0.01, (***) p-value ≤ 0.001 as calculated by one-way ANOVA with 
Dunnett’s correction for multiple tests. 
 
To investigate whether the effects of MIF on TLR-4 signalling were influenced by 
the levels of the canonical MIF receptors, CD74 and CD44, we generated a 
derivative of the HEK-Blue™-hTLR4 cell line which expresses mCherry in 






the HEK-Blue™-hTLR4  cell line was already under selection with multiple 
antibiotics (blasticidin, hygromycin, and zeocin) a  viral transduction based 
selection process that did not require additional antibiotics utilized to introduce 
the NF-kB mCherry reporter. HEK-Blue™-hTLR4  cells which had previously 
been transduced with the lentiviral vector pHRSIGN-NF-κB-mCherry (Breckpot 
et al., 2010b) were kindly provided by Dr D.B Guiliano (UEL).  Stably transduced 
cells, termed HEK-hTLR4-NF-κB-mCherry, were initially characterized by FACs 
and then isogenic clones selected and assessed for presence of the reporter and 
responsiveness to activation stimuli 10ng/mL LPS and 50ng/mL TNF-α.   Figure 
4.2.A. shows the results of testing of the two stimulants on three of the isolated 
isogenic clones. After stimulation IC1 (p≤0.0001) and IC2 (p≤0.0001) respond to 
LPS and TNF-α to a greater extent than IC3 (p≤0.0001) when assessing the 
number of mCherry expressing cells compared to non-transduced cells  Similarly, 
the mCherry MFI (fold change) of clones IC1 (p≤0.0001) and IC2 (p≤0.0001) is 
greater than that of IC3 with IC2 being selected for use in further studies and later 























Figure 4. 2 Isolation and characterization of an NF-kB responsive isogenic 
cell line HEK-hTLR4-NF-kB-mCherry. HEK-Blue™-hTLR4 cells previously 
transduced with the pHRSIN- NF-kB mCherry lentiviral vector were plated at 0.5 
cells per well to allow for single cell expansion and the resulting clones assessed 
for mCherry expression after stimulation with 50ng/ml TNF-α.    A) Gating strategy 
for the assessment of mCherry expression:  doublets were excluded using FSC-
H versus FSC-A.  Within this population dead cells were excluded using SSC-A 
versus FSC-A; mCherry expression was analysed within this subset of HEK293-
hTLR4- NF-kB cells. B) Histograms depict mCherry expression, in response to 
50ng/ml TNF-α, within selected isogenic clones.  C) Graphical representation of 
mCherry expressing cells (expressed as a fold change) in selected isogenic 
clones.  D) Graphical representation of mCherry MFI (expressed as a fold 
change) in selected isogenic clones.   The data represents the mean ± SEM 
(n=3).  (***) p-value ≤ 0.001 or (****) p-value ≤ 0.0001 as calculated by one-way 
ANOVA with Dunnett’s correction for multiple tests.   
 
Cell surface CD74 and CD44 have been identified as primary (but not exclusive) 
receptors for MIF signalling and deletion of CD74 in mice has been shown to 
exhibit similar effects as that of some MIF knockout models (Mun et al., 2013, p. 
74) indicating that CD74 is critical for MIF signalling to occur in some systems.  
To this end, we transiently transfected the HEK293-hTLR4-NF-kB clone 1C1 cells 
with a bicistronic vector, pIRES (Eurofins), which contains the cDNAs for CD74 
and CD44 (pIRES-CD74-C44) or CD74 cDNA alone (pIRES-CD74).  The 
presence of the expected cDNA inserts was confirmed using endpoint PCR with 






cell line (and HEK cells generally) have a high basal expression of CD44 as seen 
by staining in the controls.  However, after transfection the MFI of CD44 PE-CY7 
(figure 4.4.E) increased in a linear fashion as the concentration of pIRES-CD74-
CD44 increased confirming that the transfection was successful and that 
transfected cells are incorporating numerous pIRES vectors per cell.  
Unexpectedly, the presence of CD74 detected at the cell surface was minimal 
regardless of carrier DNA:experimental vector ratio suggesting after translation 
the receptor is prevented from being trafficked to the cell surface.  This supports 
earlier evidence to suggest that CD74 is rapidly degraded within lysosomes after 






Figure 4. 3 Confirmation of presence of the CD74 and CD44 cDNAs in pIRES 
vectors.  PCR was performed on each pIRES vector using cDNA specific primers 
and gel electrophoresis of amplicons is shown.  1) CD74 amplified from pIRES-
CD74 using CD74 specific primers. 2) No amplicon detected for CD44 from 
pIRES-CD74, as expected, using CD44 specific primers.  3) CD74 amplified from 
pIRES-CD74-CD44 using CD74 specific primers.  4) CD44 amplified from pIRES-
CD74-CD44 using CD74 specific primers. M, 2-log DNA ladder.  PCR products 
























Figure 4. 4 Optimization of transient transfection of HEK293-hTLR4-NF-kB 
1C2 cells with a biscistronic vector expressing CD74 and CD44.  HEK293-
hTLR4-NF-κB 1C1 were transiently transfected with varying concentrations of the 
plasmids pIRES-CD74 and pIRES-CD74-CD44 and the surface levels of each 
protein assessed by FACs. A total of 1 ug of DNA was used in each transfection 
with carrier DNA being used to supplement the quantity of total DNA used.  A) 
Dot plots depicting transfected cells and analysed using CD74 PE versus CD44 
PE-Cy7.  B) Bar graphs depicting the MFI of CD74 or CD44 in hTLR cells 
transfected with pIRES-CD74 or pIRES-CD74-CD44. C) Bar graphs depicting the 
percentage of positive cells expressing CD74 or CD44 in hTLR4 cells transfected 
with pIRES-CD74 or pIRES-CD74-CD44.  The data represents the mean ± SEM 
(n=3). 
 
Despite the fact that cell surface expression of CD74 did not markedly increase 
after transfection with all of the plasmids, we sought to determine whether a small 
increase enhanced the effect of MIF in the presence of LPS.  After transfection 
of HEK-hTLR4-NF-kB-mCherry 1C2 with pIRES-CD74-CD44 cells were 
incubated with 10ng/ml LPS or LPS and 100ng/mL MIF for 18.  In this instance, 
Hs-MIF-1 and Hs-MIF-1 P2G were capable of decreasing LPS-driven NF-kB 
signalling which agrees with earlier results using the SEAP reporter which 
suggested that Hs-MIF-1 and Hs-MIF-1 P2G might modestly enhance NF-kB 
activation after LPS treatment (Figure 4.5).  Multiple studies have found that MIF 
does not behave consistently in one bioassay depending on the cell line used 
and specific output.  Examined data, although preliminary, suggests that the 






and that MIF may exert its effects via numerous receptors and pathways including 
























Figure 4. 5  MIF treatment inhibits NF-kB activation by LPS in HEK-hTLR4-
NF-kB-mCherry 1C2 cells transfected with pIRES-CD74-CD44. After 
transfection with pIRES-CD74-CD44 HEK293-hTLR4-NF-kB 1C2 were treated 
with LPS and or MIF homologues and the level of mCherry assessed by FACs 
after 18 hrs.  A) Histogram depicts mCherry expression of untransduced  and 
untreated hTLR4-NF-kB-polyclonal cells. B) Histograms depict mCherry 
expression after administration of transfected HEK293-hTLR4-NF-kB 1C2 cells 
with 10ng/ml LPS and or 100ng/ml MIF. C)  Bar graphs represent fold change of 
mCherry MFI expression after administration of transfected hTLR4-NF-kB cells 
with 10ng/ml LPS +/- 100ng/ml MIF.  (N=1). 
 
4.4.  Isolation of a HT29 NF-κB mCherry reporter cell line. 
As our previous work indicated that MIF may play a role in TLR-4 mediated LPS 
signalling within model cell line HEK 293, we wanted to investigate whether this 
could be replicated within an intestinal epithelial cell line, such as HT29.  HT29 
cells are mucus-producing adenocarcinoma cells which have been shown 
previously to respond to LPS (Angrisano et al., 2010; Guo et al., 2013, p. 29; 
Mastropietro et al., 2015, p. 29). Studies, optimising the growth of another 
commonly used IEC line, Caco2, showed that these cells were not responsive to 
LPS in any of the conditions tested (Appendix) so all experiments focused us of 
the HT29 cell lines. Prior to commencing any experiments examining MIF’s role 
in signalling by LPS, an isogenic HT29 NF-kB reporter cell line was isolated from 
a polyclonal HT29 cell line which had been transduced with pHRSIN-NF-kB-
mCherry (provided by D.B Guiliano, UEL).  Figure 4.6.A illustrates the gating 






initial findings, shown in figure 4.6.B, indicate that polyclonal HT29-NF-kB-
mCherry cells treated with 50ng/ml TNF-α show an increased bimodal mCherry 
expression when compared to unstimulated cells. To increase the sensitivity and 
reliability of the mCherry reporter assay six single cell isogenic clones of HT29-
NF-kB-mCherry were isolated (figure 4.6.B.). After subsequent characterisation 
the clone IC5 (p-value ≤ 0.0001) was selected for use in all further studies as this 
clone responded to TNF-α to a greater extent and lacked the bimodal histogram 
pattern observed in other clones (figure 4.6.B) indicating that there may be a 
subpopulation of cells that are either not responding to TNF-α or they are very 
























Figure 4. 6  Isolation of an isogenic HT29-NF-kB-mCherry reporter cell line.  
HT29 cells previously transduced with the pHRSIN-NF-kB mCherry lentiviral 
vector were plated at 0.5 cells per well to allow for single cell expansion and 
assessed for mCherry expression after stimulation with 50ng/ml TNF-α.  A) 
Gating strategy employed for mCherry analysis.  Firstly, doublets were excluded 
using FSC-H versus FSC-A, then live cells were gated using FSC-A versus SSC-
A and finally assessed for mCherry expression.  Wide-type (untransduced) HT29 
cells were used as a negative control.  B) Histograms depict mCherry levels in 
selected isogenic clones.  C) Number of mCherry expressing cells depicted as a 
fold change in response to TNF-α administration.  D)  mCherry MFI depicted as 
fold change in response to TNF-α stimulation. Cells were analysed for mCherry 
expression using a BD FACS Celesta.  The data represents the mean ± SEM 
(n=3). (*) p-value ≤ 0.05 (**) p-value ≤ 0.01, (***) p-value ≤ 0.001, (****) p-value ≤ 
0.0001 as calculated by one-way ANOVA with Dunnett’s correction for multiple 
tests. 
 
4.5.  MIF inhibits NF-kB activation in HT29-NF-kB-mCherry reporter cells 
after LPS treatment. 
 
Following selection of the IC5 HT29-NF-kB-mCherry-clone, cells were examined 
for LPS responsiveness in order to determine whether activation of NF-kB within 
the reporter could be observed after TLR4 signalling.  Initial studies showed that 
LPS treatment of IC5 cells did not activate NF-kB (figure 4.6.) in the same way 
that was observed within the HEK-hTLR4-NF-kB-mCherry cell line.  HT29 is 






HEK 293 cells, so it has not been possible to genetically modify them to make 
them equivalent to the HEK-hTLR4-NF-kB-mCherry.   
A study by Suzuki et al (2003) showed that priming of HT-29 cells with IFN-γ may 
augment LPS-mediated signalling by upregulating TLR4 transcripts and 
transporting internal TLR4 receptors to the cell surface.  Our preliminary studies 
corroborate this finding, showing that priming cells with 10ng/ml IFN-γ for 12 
hours leads to induction of NF-kB activation which is significantly potentiated with 
the addition of 100ng/ml LPS (p-value ≤ 0.05) when assessed using mCherry MFI 
(Figures 4.7.A and 4.7.B).  Interestingly, the number of mCherry expressing cells 
significantly decreased when cultured under identical conditions.  The results 
imply that a number of cells may undergo cell death when stimulated with both 
















Figure 4. 7  Priming of the HT29-NF-kB-mCherry reporter cell line with IFN-
γ is required for LPS responsiveness.  IC5 cells were selected and incubated 
with 10ng/ml rIFN-γ for 12 hours and then stimulated with 100ng/ml LPS. Cells 
were assessed at 24 hours post-LPS stimulation for mCherry expression. IC5 
cells primed with 10ng/ml IFN-γ prior to LPS stimulation led to a substantial 
increase in mCherry expression when compared to LPS or IFN-γ alone. A) 
Histogram depicting mCherry levels in IC5 cells.  B) Bar graph shows mCherry 
fold change (MFI) and mCherry positive cells (fold change) in cells primed with 
+/- 10ng/ml IFN-γ then stimulated with 100ng/ml LPS.  Cells were analysed for 
mCherry expression using a BD FACS Celesta.  The data represents the mean 
± SEM (n=3). (*) p-value ≤ 0.05 as calculated by one-way ANOVA with Dunnett’s 
correction for multiple tests. 
 
As discussed previously, HT29 cells are refractory to typical transfections and 
this led to numerous issues when handling these cells.  Aside from the 
aforementioned TLR4 vector, these technical constraints prevented the 
transfection of HT29 cells with the pIRES-CD74-CD44 vector.  With this in mind, 
we performed RT-PCR in order to detect transcriptional levels of MIF signalling 
proteins after IFN-γ priming as this has also been shown to increase 
transcriptional levels of MIF signalling receptors CD74 and CD44 in other 
systems.  We confirmed that like other cells, CD74 and CD44 expression is 
increased (Figure 4.8.A.) after priming with 10ng/ml IFN-γ.   After confirming the 
presence of CD74 and CD44 transcripts in HT29 cells, we co-incubated cells with 
10ng/ml LPS and 100ng/ml Hs-MIF-1 as a preliminary test. In IFN-γ primed cells, 






mCherry in those cells.  An interesting and unexpected result was that the number 
of mCherry expressing cells in non-primed samples were generally higher than 
those primed with 10ng/ml IFN-γ indicating that IFN-γ is selectively targeting a 
subgroup of HT29-NF-kB-mCherry cells.   In addition, these results validate that 













Figure 4. 8  Hs-MIF-1 suppresses TLR4-driven NF-kB signalling in HT29-NF-
kB-mCherry IC5 cells.  A) IC5 cells were stimulated with increasing 
concentrations of IFN-γ and RNA collected to assess RT-PCR assessment of 
transcriptional levels of GAPDH, CD74 and CD44.  RT-PCR products were run 
on a 2% agarose gel and visualised using a Bio-rad ChemiDoc.  B)  IC5 cells 
(non-primed or primed) were cultured with 100ng/ml LPS and or +/- 100ng/ml Hs-
MIF-1 for 18 hours and mCherry expression assessed using a BD FACS Celesta.  
Bar graph depicts (left) fold change mCherry MFI and (right) fold change mCherry 
positive cells. The data represents the mean ± SEM (n=3). (*) p-value ≤ 0.05 as 
calculated by one-way ANOVA with Tukey’s correction for multiple tests. 
 
4.6. MIF and TGF-β 
Finally, due to its reported varied roles in influencing activation of immune cells 
and inflammation an examination of the effects of MIF on regulatory immune 
signalling. Part of this work focussed on TGF-β, a key regulator of intestinal 
immune homeostasis that is implicated in a variety of GI disorders and 
pathologies including colorectal cancer (Bellam and Pasche, 2010).  
There are several studies that indirectly suggest MIF may interact with TGF-β 
however this has not been directly tested (Choi et al., 2012; Wang et al., 2015).   
To analyse the potential roles of MIF on TGF-β modulation of epithelial-derived 
immune responses we employed polyclonal HEK cells which have been 
previously transduced with the lentiviral vector pHRSIN-SBE-eGFP (cells 
provided by D.B Guiliano). This reporter construct has the fluorescent protein 
eGFP cloned down stream of set of SMAD binding elements (SBE). EGFP 






with TGF-β (figure 4.9).  Figure 4.9.A indicates that polyclonal HEK-SBE-GFP 
WT cells treated with 2.5ng/ml TGF-β show an increased bimodal GFP 
expression when compared to unstimulated cells. To increase the sensitivity and 
reliability of the eGFP reporter assay five single cell isogenic clones of HEK-SBE-
eGFP were isolated. After subsequent characterization, the clone IC3 was 
selected for use in all further studies (figure 4.9B/C). Initially the kinetics and 
specificity of the transcriptional reporter was assessed and then the effects of MIF 

























Figure 4. 9  Characterisation of HEK-SBE-eGFP Isogenic cell lines.  (A)  HEK 
SBE-eGFP WT cells were seeded at 3x103 cells per well in a 96-well microtitre 
plate and stimulated with 2.5ng/mL TGF-β for 18 hours. Expression of GFP was 
assessed using a BD FACS Celeste. (A) Incubation of HEK SBE-eGFP WT cells 
with 2.5ng/mL TGF-β for 18 hours leads to an increase in eGFP expression in a 
bi-modal manner. (B) Panel of histograms depicts GFP expression in response 
to TGF-β administration in isogenic clones.  (C) The bar graph shows the increase 
in mean fluorescence intensity of eGFP depicted as fold change. (D) The bar 
graph shows the increase in the number of cells showing eGFP-expressing cells 
as fold change in response to TGF-β administration.  Error bars represent +/- 
SEM. N=3.  
 
Previous studies have elucidated that the SBE is responsive to a common SMAD 
(Zawel., 1998), SMAD4, implying that both TGF-β and Bone Morphogenetic 
Protein 4 (BMP-4) should increase eGFP expression in HEK IC3 cells.  To further 
characterize the responses of the IC3 reporter cell to TGF receptor ligands a time 
course was performed analysing the increase in expression of eGFP after 
treatment with either TGF-β and BMP-4 over 24 hours. Interestingly, as shown in 
figure 4.10, incubation with 2.5ng/ml TGF-β induces a gradual increase in eGFP 
expression which begins to reach plateau at 12 hours.  Conversely, treatment 
with 2.5ng/ml BMP-4, had little effect on eGFP expression until 12 hours post-
stimulus and this remained constant.  The results obtained demonstrate that the 
responses of isogenic HEK-SBE-eGFP clones to TGFβ and BMP4 vary in signal 














Figure 4. 10  Analysis of the temporal dynamics of TGFβ and BMP4 
signalling and the expression of eGFP in the HEK-SBE-eGFP isogenic cell 
line, IC3.  IC3 cells were selected and incubated with 2.5ng/ml TGFβ or 2.5ng/ml 
BMP4 for 24 hours.  Cells were assessed periodically at 4, 8, 12 and 24 hours for 
GFP expression.  (A) GFP expression increases progressively over time, from 4 
hours to 24 hours, in response to 2.5ng/ml TGFβ.  (B)  GFP expression increases 
at 12 hours post-incubation with 2.5ng/ml BMP4.  
 
After defining the dynamics of TGF-b signalling in IC3 HEK-SBE-eGFP cells, 
preliminary experiments were performed to assess the role of MIF on the TGF-b 
signalling pathway.  Figure 4.11 shows that initial experiments did not show any 
MIF-dependent modulation of TGF-b signalling at 24 hours post-treatment, in the 
presence or absence of recombinant TGF-b, even at concentrations as high as 
20µg/mL recombinant human or T. spiralis-derived MIF protein.  Further 






absence of a MIF affect in this case is an outlier or whether MIF does not effect 












Figure 4. 11 MIF does not modulate TGF-b signalling in the HEK-SBE-eGFP 
isogenic cell line, IC3.  IC3 cells were co-incubated with either Hs-MIF-1 or Ts-
MIF-1 in the presence or absence of 2.5ng/ml TGF-β for 24 hours.  GFP 
expression increases after treatment of IC3 cells with TGF-b.  Neither Hs-MIF-1 









4.7. Discussion of the effects of MIF on intestinal epithelial immune 
signalling. 
The work encompassed within this chapter demonstrates that, in both HEK 293 
and HT29 cells, MIF may modulate responses to LPS via TLR-4 thus potentially 
playing a critical role in intestinal immune responses. In both epithelial cell line 
models, if the canonical MIF receptor complex (CD74, CD44) is present and or 
enhanced in its levels either via transfection or via upregulation after IFN-γ 
treatment this appears to affect responsiveness to MIF and mediate its effects 
on TLR-4 activity.  In addition to this, we successfully show in our preliminary 
data that MIF modulates TLR-4-driven NF-kB activation, in epithelial cell lines, 
HEK-hTLR4-NF-kB-mCherry and HT29-NF-kB-mCherry, which is demonstrated 
using a colorimetric reporter assay measuring alkaline phosphatase activity and 
utilising a fluorescent mCherry reporter assay both of which are detected upon 
NF-kB activation.  
As in studies by Roger et al (2001; 2003), our data initially indicated that Hs-MIF 
may augment TLR-4 signalling in HEK Blue™ hTLR4 cells when co-cultured 
with LPS. In comparison to this, we show that Ts-MIF-1 partially inhibits TLR4 
signalling within the same conditions and this may indicate that MIF’s 
evolutionarily conserved tautomerase site plays a role in the modulation of 
TLR4 signalling when considering that Ts-MIF-1 has a tautomerase activity 
which is six times greater than that of Hs-MIF-1.  However, the fact that there is 
a complete absence of the oxidoreductase conferring CXXC site in Ts-MIF-1 
proteins may also provide some clues as to the mechanisms required for TLR-4 
modulation.  Further studies will be required, which focus on utilising the MIF 






within this study, to determine whether the tautomerase activity or other parts of 
the protein are responsible for the observed results. 
One caveat to this study is that, MIF appears to opposingly modulate TLR-4 
signalling with respect to the SEAP versus mCherry reporter assays.  
Nevertheless, there are several potential reasons for this: MIF may modulate 
secretion of alkaline phosphatase in a mechanism that is independent of NF-kB 
a theory that has been previously tested and evidenced in a study by Kleemann 
et al (2000) which demonstrated MIF inhibits AP-1 activity via Jab1 bypassing 
NF-kB.  Use of a selective NF-kB inhibitor such as Sulfasalazine (Yeligar et al., 
2009) or Bay 11-7085 (Clark et al., 2015) would confirm whether the SEAP 
activity observed is being modulated independently of NF-kB. Furthermore, 
SEAP is particularly susceptible to changes in ER stress (Kitamura and 
Hiramatsu, 2011; Lenin et al., 2015) and as MIF targets Jab1 which is involved in 
regulation of protein degradation it is possible that the variations observed within 
this study are, in part, a result of induced ER stress.  Whilst this can be tested in 
several ways, an examination of MIF’s ability to modulate ER stress is not within 
the remit of this study.   
 As studies have indicated that MIF signals via CD74 and CD44 (Gore et al., 
2008; Mun et al., 2013; Schwartz et al., 2009; Shi et al., 2006) we transfected 
cells with a bicistronic vector expressing both sequences to observe whether 
overexpression of the MIF receptor affected MIF’s response to LPS.  Remarkably, 
the results showed that, in these conditions and those of IFN-γ primed HT29 cells, 
Hs-MIF-1 could inhibit TLR4-driven NF-kB activation in the presence of LPS.  
Disparities between MIF responses in HEK Blue™hTLR4 cells, as assessed by 






CD74-CD44 and IFN-γ-primed HT29 cells may be due to the increase in MIF 
receptors, however, there may be additional factors relating to the significant 
inherent differences within the genomes of each cell line.  
The lack of well-researched CD74 antibodies for the study of MIF signalling 
limited the analysis of cell surface expression of this key receptor in this study.  
Therefore, future optimisation of several commercially available CD74 antibodies 
against a positive control such as a CD74 expressing cell line like Raji or Daudi 
lymphoma cells, or a recombinant CD74 protein would be of significant benefit.  
Increasing the reliability of CD74 antibody detection will allow for rapid 
determination of cell surface CD74 in all cells. 
Several possibilities exist for future work in order to determine how MIF 
regulates TLR-4 signalling.  To determine whether MIF co-localises with TLR-4 
in vitro, MIF proteins should be fluorescently tagged using a commercially 
available Alexa Fluor antibody whilst simultaneously staining the TLR4 receptor. 
Studies that focus on whether MIF binds directly to the TLR-4 receptor thereby 
competing with LPS will enable further studies to investigate the differences in 
binding affinity between WT and mutant mammalian and Trichinella derived 
MIF’s.   As the effect observed in this study was partial inhibition or potentiation 
of the TLR-4 signal pathway this may suggest that MIF interacts with 
downstream components of the pathway such as the earlier mentioned AP-1 
transcription factor. Selective inhibition of AP-1 using a commercially available 
inhibitor, SR11032 (Ye et al., 2014), which importantly does not affect the levels 
of NF-kB, would provide evidence as to which part of the pathway MIF targets.   
In addition to our work examining MIF’s role on TLR-4 signalling in epithelial cell 






also undertaken.  TGF-b is a critical regulator of intestinal barrier function and, 
like MIF, is produced in significant amounts by the intestinal epithelial cells.  
Though the data presented here did not show that MIF regulated TGF-b 
signalling in HEK-SBE-eGFP cells, the results are representative of one 
experiment so future work should firstly replicate our earlier experiments.  
Moreover, it is entirely possible that MIF modulation of TGF-b is cell specific 
and cannot be observed in HEK cells or that, as our TLR-4 experiments 
showed, CD74 is not trafficked to the cell surface preventing MIF from 
transducing a signal effectively.  With this in mind, transient transfection of HEK-
SBE-eGFP IC3 cells with the pIRES CD74 or pIRES CD74/CD44 vector would 
provide further evidence for reliance on a cell surface receptor for MIF to 
efficiently mediate its effects.    
As we showed that HEK-SBE-eGFP IC3 cells also respond to members of the 
TGF-b family such as BMP-4, further studies could investigate MIF’s role in 
BMP signalling alongside TGF-b experiments.  This would determine whether 
MIF regulates the common SMAD, SMAD4 but by an alternative receptor or 
SMAD protein as TGF-b and BMP’s have very distinct mediators of signalling. 
Aside from this, the data in this chapter clearly evidences that MIF plays a 






Chapter 5:  Evaluation of MIF’s role in murine bone-marrow-
derived-macrophages. 
5.1. Introduction. 
5.1.1. The history of Macrophages. 
Macrophages are widely recognised as being the original responders to secreted 
MIF, elucidated in 1966, in vitro studies examining delayed-type hypersensitivity 
discovered that lymphocyte-derived MIF inhibited the random migration of 
macrophages (Deshmane et al., 2009).  Macrophages were first discovered by 
Elie Metchnikoff in 1883 though the existence of phagocytes had been revealed 
some 20 years earlier by the presence of coal dust in the alveolar macrophages 
from miners (Cavaillon, 2013; Merien, 2016).  Since that time, countless studies 
have taken place and a multitude of critical roles have been elucidated for 
macrophages including classical pro-inflammatory responses to upkeep of 
homeostasis by mechanisms comprising of clearance of cellular debris and tissue 
remodelling. Therefore, these cells are often termed ‘janitorial’ cells as they are 
complicit surveyors of their local area.  Though macrophages are part of the 
innate immune system, they are a key player in directing adaptive immune 
responses utilising both contact-dependent mechanisms and chemical signals 
such as cytokine and chemokines.  
The macrophage repertoire is extensive and many of the associated 
characteristics decidedly intricate; most circulating macrophages are derived 
from bone-marrow and begin their journey as monocytic cells, maturing as they 
exit the bone marrow after receiving chemical signals from the bone marrow 
stroma.  On the other hand, tissue resident macrophages express markers 






thought to develop prenatally, and this is largely linked to their anatomical niche 
(Haldar and Murphy, 2014).  A well-documented theory for why this may occur is 
that tissue resident macrophages are primed and act as sentinels ready to 
respond to any incoming threat in a timely manner.  Of interest to this study is 
that intestinal macrophages, despite having unique characteristics such as high 
IL-10 expression, are derived from bone marrow precursors and are consistently 
undergoing replenishment in order to facilitate efficient responses to infection.  
Several studies which have characterised intestinal macrophages have noted 
that, despite expressing elevated levels of IL-10, TLR stimulation via bacterial 
PAMPs leads to a classical inflammatory response (Bain et al., 2013; Bernardo 
et al., 2018) 
Macrophages are known to secrete a vast selection of cytokines such as TNF-α 
(Parameswaran and Patial, 2010; Young et al., 2001), IL-6 (Braune et al., 2017; 
Chen et al., 2018; Gubernatorova et al., 2018; Luckett-Chastain et al., 2016), IL-
8 (MCP-1 in mice) (Moore et al., 2015; Takada et al., 2010b; Takahashi et al., 
2009) and IL-10 (Elcombe et al., 2013; Sanin et al., 2015) but this is largely 
dependent on the chemical and mechanical signals they receive during their 
lifespan. 
A distinguishing feature of macrophages is their ability to engulf surrounding 
pathogens (phagocytose) and kill them with cytotoxic particles within the 
phagosome.  Though phagocytosis is a key feature of all macrophages, prior 
work suggests that alternately activated M2 polarised macrophages have an 
increased ability to phagocytose.  Aside from phagocytosing pathogens, 
macrophages can ingest and clear cellular debris from dying cells preventing 






internalisation can induce immune-suppressive cytokines such as IL-10 and 
TGF-β.  
Though it has long been known that parasitic helminths can modulate local 
immune response via numerus mechanisms, studies investigating innate immune 
cells responses to T. spiralis infection or T. spiralis crude excretory/secretory (ES) 
products have demonstrated that, firstly, macrophages dominate the T.spiralis 
site of infection (Beiting et al., 2004) and secondly, they undergo alternative 
activation becoming regulatory M2 macrophages.  ES perturbs NF-kB signalling 
in BMDMs and RAW 264.7 cells, inhibiting LPS-driven expression of pro-
inflammatory cytokines IL-6 and TNF-α while increasing IL-10 production in vitro 
(Bai et al., 2012; Du et al., 2014; Han et al., 2018).  Additionally, a more recent 
study by Kang et al (2019) showed that, not only do peritoneal macrophages from 
T. spiralis infected mice produce high levels of Arginase-1 and CD206, but that 
adoptive transfer of bone marrow derived macrophages, cultured in the presence 
of ES, into DSS-induced colitis mice significantly reduce clinical scores.  This 
study also confirmed that transferred macrophages had migrated to the site of 
inflammation verifying that it is specifically macrophages which are directly 
responsible for reducing DSS-scores. 
A critical point of interest is that, although T. spiralis produces MIF at all stages 
of its life cycle, after embedding into the intestinal epithelium, molting and 
maturing into an adult worm, MIF expression is greatly increased and the amount 
of tautomerase activity increases 7-fold from the larvae stage (D.B. Guiliano, 
unpublished).  This might suggest that T. spiralis utilises MIF to modulate 






   In this study, we propose that Ts-MIF proteins modulate macrophage activation 
using mechanisms that contrast with mammalian MIF and that this may be 
conferred by MIF’s conserved tautomerase site.  
5.2. MIF in macrophage studies. 
Studies investigating macrophage subsets such as the pro-inflammatory M1 and 
alternatively activated M2 ‘healing’ types have revealed that endogenous MIF 
expression is essential for M1 polarisation and this has been demonstrated in 
murine MIF-/- models of obesity and tumourigenesis.   In obesity studies, MIF was 
shown to be an essential upstream regulator of the M1 cytokine profile as 
inhibiting expression of MIF led to complete absence of M1 macrophages whilst 
M2 macrophages were significantly increased.  Intriguingly, within the context of 
tumourigenesis, MIF was found to promote M2 polarisation indicating that the 
modulatory actions of MIF are, in part, contextually governed by the local 
environment.  Sánchez-Zamora et al (2016) demonstrated, in a type 1 Diabetes 
mouse model, that macrophages in MIF-/- mice  have lower levels of antigen-
presenting and co-stimulatory molecules such as MHC-II, CD80, CD86 and TLR-
4 than that of WT mice and these deficits can be recovered by the addition of 
exogenous recombinant MIF.  Additionally, studies utilising mouse models of 
obesity indicated that MIF-deficient mice have improved glucose metabolism and 
significantly decreased levels of adipose tissue while also inhibiting pro-
inflammatory cytokine, TNF-α, which was also associated with a decrease in 
adipose tissue macrophage infiltration (Finucane et al., 2014).  In contrast, within 
the tumour microenvironment MIF plays a protective role by preventing the 
expansion of tumour growth.  Two pivotal studies demonstrate this:  Castro et al 
(2017) revealed that Bevacizumab resistance in glioblastoma patients is a 






tumour periphery.  Microarrays performed within the study indicated that this is 
most likely attributable to a decrease in MIF expression in patients receiving 
Bevacizumab.  Additionally, MIF-/- mice with colitis-associated-cancer have 
significantly decreased levels of TAMs and increased tumour burden as a result 
(Rodriguez-Sosa et al., 2017).  Conversely, Yaddanapudi et al (2013) show that 
TAMs from MIF-/- melanoma tumour bearing mice secrete vast levels of 
inflammatory markers such as TNF-α, IL-12 and iNOS when compared to their 
WT counterparts.  Moreover, cytokines associated with the resolution of 
inflammation were significantly decreased in MIF-deficient TAMs suggesting that, 
in this context, MIF is required for the polarisation and expansion of an M2 TAM 
phenotype.  Taken together, these studies indicate that MIF’s mechanisms of 
action are highly context dependant and may modulate both inflammatory and 
regulatory responses.  
In addition to the aforementioned research, additional studies have revealed, 
utilising MIF-/- mice, that MIF is essential for the proper induction of TNF-α (Bozza 
et al., 1999; Thierry Roger et al., 2001), IL-6 (Roger et al., 2016), MCP-1 (Barnes 
et al., 2013; Gregory et al., 2006a; Xie et al., 2016) and IL-10 (Rodriguez-Sosa 
et al., 2017) and that loss of cytokine production disrupts macrophage function 
by altering polarisation or preventing the recruitment of monocytes to the 
inflammatory location.  
While numerous studies have elucidated a role for MIF in both regulatory and 
proinflammatory immune responses, to date, none have characterised the effect 
of exogenous MIF and tautomerase-null MIF mutants on macrophage cytokine 






5.3.  Chapter aims and objectives. 
To examine the role of MIF on macrophage activation, including whether MIF and 
MIF P2G mutants modulate inflammatory responses by regulating IL-6, MCP-1, 
IL-10 and TNF-α, the following aims were proposed: 
1. Utilising qPCR assess transcriptional changes in three key macrophage 
derived cytokines IL-6, MCP-1 and IL-10 after exposure to LPS +/- MIF 
homologues and mutants. 
2. Assess secretion of the proinflammatory cytokines IL-6 and TNF-α, in 
media from MIF treated macrophage cultures, utilising ELISA.   
3. Ascertain whether MIF and tautomerase-null MIF can modulate 


















5.4.  MIF modulates the macrophage cytokine transcriptome in response to 
LPS. 
To determine whether administration of exogenous MIF or MIF P2G tautomerase 
mutants induced a specific cytokine profile in macrophages, murine bone marrow 
derived macrophages from C57BL/6 female mice aged six to eight weeks old 
were generated.  Figure 5.1. depicts the gating strategy used to assess F4/80 
expression in M-CSF matured macrophages after a seven-day incubation period 
and demonstrates the successful generation of macrophages with >90% 













Figure 5. 1  Successful generation of bone marrow derived macrophages from C57BL/6 female mice.  Bone marrow from the femurs 
of 6-8-week female C57BL/6 mice was seeded at 1 x 106/mL, at a total volume of 10mL, in a sterile petri dish.  Cells were grown in the 
presence of 30% L292-cell conditioned media for a total period of 7 days with 10mL fresh media added at day 3 and 5 after which cells 
were assessed for the expression of pan-macrophage marker, F4/80.  From left to right: figure shows the successful development of 
macrophages (as shown by light microscopy); during FACs assessment, doublets were excluded to prevent any false signal being included 
in analysis; dead cells are omitted to ensure detected F4/80 expression is in live cells;  histogram depicting F4/80 expression (grey filled) 








To test whether exogenous MIF or MIF P2G mutants modulate macrophage 
activation, murine BMDMs were incubated with 10ng/ml LPS +/- 100ng/ml MIF 
for 20 hours before performing transcriptomic analysis to examine the relative 
levels of IL-6, MCP-1 and IL-10 using GAPDH as the reference housekeeping 
control gene.   Representative results for IL-6 expression are depicted in figure 
5.2 which shows that Mm-MIF-1 significantly (p ≤0.05) enhances IL-6 mRNA 
levels when incubated with LPS in comparison to LPS alone.  Additionally, Mm-
MIF-1 P2G failed to increase IL-6 expression when co-incubated with LPS 
suggesting that the tautomerase site is required for the rise in IL-6 transcription.  
However, in contrast to this, Ts-MIF-1 and Ts-MIF-1 P2G marginally increased 
IL-6 expression in response to LPS which was a surprising result considering that 
the tautomerase activity of Ts-MIF-1 is three times higher than that of Mm-MIF-







Figure 5. 2  MIF homologues modulate the IL-6 transcriptional responses to 
LPS in BMDMs.  The graphs above show the qPCR analysis of BMDMs in 
response to 10ng/ml LPS +/- 100ng/ml MIF.  Data represents the mean ±SEM 
(n=4) of the fold change.   All values were assessed utilising the Pfaffl equation 
prior to statistical testing.  (*) p-value ≤ 0.05, as determined by a one-way ANOVA 
with Dunnett’s corrections for multiple comparisons.  
 
MCP-1, the murine equivalent to human IL-8, is a chemokine which is highly 
expressed by activated macrophages and chemoattracts additional monocytes 
and macrophages to the site of inflammation (Deshmane et al., 2009). MIF has 
previously been shown to upregulate MCP-1 and the absence of MIF leads to 
abrogated MCP-1 responses including decreased leukocyte and monocyte 
recruitment.  To this end, we predicted that MIF’s tautomerase site may play a 
role in macrophage-derived MCP-1-driven chemotaxis.  Therefore, we assessed 
the mRNA expression levels of MCP-1 in response to LPS in the presence or 
absence of MIF homologues.  
Figure 5.3 shows that, in the presence of LPS, Mm-MIF-1 partially inhibits the 
expression of MCP-1 (no significance) and this response is not affected by the 
absence of MIF’s tautomerase site.  On the other hand, Ts-MIF-1 and Ts-MIF-1 
P2G appear to act in concert with LPS to increase MCP-1 transcripts indicating 
that mammalian MIF elicits different responses to helminth-derived MIF that are 








Figure 5. 3 MIF homologues modulate the MCP-1 transcriptional responses 
to LPS in BMDMs.  The graphs above show the qPCR analysis of BMDMs in 
response to 10ng/ml LPS +/- 100ng/ml MIF. The data represents the mean ±SEM 
(n=4) of the fold change.   All values were assessed utilising the Pfaffl equation 
prior to statistical testing.  (*) p-value ≤ 0.05, as determined by a one-way ANOVA 







When we examined the effects of LPS and MIF homologues on IL-10 expression 
in macrophages. Aside from a small decrease in samples cultured with LPS and 
Mm-MIF-1 P2G, there were no significant differences between groups (Figure 
5.4).  This likely means that MIF does not modulate LPS-driven IL-10 responses 










Figure 5. 4  MIF homologues do not modulate the IL-10 transcriptional 
responses to LPS in BMDMs.  The graphs above show the qPCR analysis of 
BMDMs in response to 10ng/ml LPS +/- 100ng/ml MIF.  The data represents the 
mean ±SEM (n=3) of the fold change.   All values were assessed utilising the 
Pfaffl equation prior to statistical testing.  (*) p-value ≤ 0.05, as determined by a 
one-way ANOVA with Dunnett’s corrections for multiple comparisons.  
 
To further expand our transcriptome studies levels of two proinflammatory 
cytokines IL-6 and TNF-α were assessed in the culture supernatants of MIF and 
LPS stimulated BMDMs by ELISA.  Figure 5.5. shows that, whilst the amount of 
IL-6 and TNF-α increased considerably in the culture supernatants of LPS 
stimulated macrophages, there were no notable differences in samples derived 
from cells co-incubated with LPS and MIF or in samples incubated with MIF 















Figure 5. 5  MIF homologues do not modulate the secretion of IL-6 and TNF-α from BMDMs after LPS stimulation.  The graphs 
above show the secreted cytokine (pg/ml) levels of IL-6 and TNF-α within BMDMs in response to 10ng/ml LPS +/- 100ng/ml MIF.  The data 







5.5. Discussion of MIF’s role in modulation of cytokine and phagocytic 
responses to LPS in BMDM’s 
Whilst MIF’s role in macrophage development and activation has been 
extensively explored, only limited studies have investigated the role that MIF’s 
tautomerase activity in MIF’s immunomodulatory actions. Nor have these studies 
examined the differences between mammalian and helminth-derived MIF 
homologues.    
In this chapter, the successful generation of F4/80 positive macrophages was 
achieved by differentiating bone marrow derived monocytes using conditioned 
media from L929 murine fibroblast cells.  L929 cells secrete large quantities of 
active M-CSF which is essential for the propagation and differentiation of 
macrophages.  Using these BMDMs the relative transcriptional levels of IL-6, 
MCP-1 and IL-10 were assessed after stimulation with LPS in the presence or 
absence of different MIF recombinants. These experiments yielded clear 
instances where differential activities between mammalian wild-type MIFs and 
mutants lacking tautomerase activity or murine and Trichinella MIF homologues 
could be observed.   
In experiments focussing on IL-6, Mm-MIF-1 significantly augmented the LPS-
mediated increase in IL-6 transcripts whilst in macrophages incubated with Mm-
MIF-1 alone there were no observable effects.  This data is consistent with results 
found by Kudrin et al (2006) showing that treatment of murine macrophages with 
MIF alone is not capable of inducing IL-6 expression. However, we show here 
that Mm-MIF-1 acts in concert with LPS to potentiate the transcriptional levels of 
LPS-mediated IL-6.  Contrastingly, Mm-MIF-1 P2G, did not augment IL-6 






activities of Mm-MIF-1 may be responsible for modulating the IL-6 transcriptional 
responses. The mechanism that this occurs through remains to be determined 
although one possible mechanism is that the tautomerase activity is required for 
receptor binding. Disruption of Pro2 and the subsequent tautomerase activity 
may prevent binding of murine MIF to the canonical MIF receptor CD74.  
Evidence for this is demonstrated in a study by Senter et al (2002) showing that 
MIF tautomerase inhibition by N-acetyl-p-benzoquinone imine induces a 
conformational change in the protein structure effecting MIF’s ability to override 
glucocorticoid suppression by dexamethasone.  
In terms of cytokine modulation by Ts derived MIF, the transcriptional levels of 
IL-6 were largely unaffected in the presence of LPS regardless of whether the 
tautomerase site was present demonstrating that; 1) the conserved tautomerase 
activity of Ts MIF is dispensable for the enhancement of LPS-mediated IL-6 
transcriptional responses in BMDMs and, 2) Ts-MIF-1 appears to act differently 
to Mm-MIF-1 in terms of the transcriptional regulation of IL-6 which may be an 
immune-subversion mechanism utilised by T. spiralis to prevent immune 
recognition. This finding indicates that factors beside the tautomerase activity are 
responsible for the modulation of LPS-directed IL-6 responses and this may 
include the oxidoreductase activity, nevertheless, future work utilising 
oxidoreductase mutant proteins will be required to elucidate if the CALC motif 
plays a role in directing macrophage development.  
IL-6 is a key player in driving intestinal immune responses such as ILC3, Th17 
and Th22 polarisation and dysregulation of IL-6 is associated with several 
intestinal immune disorders such as colitis.  Several studies have demonstrated 






T.spiralis infection in muscle from C57Bl/6 mice (Beiting et al., 2004). In addition, 
another study has shown ES from T. spiralis is capable of abrogating LPS-
mediated IL-6 production in J774A.1 macrophages (Bai et al., 2012), this data 
may provide clues as to the identity of the ES protein components responsible for 
immune-subversion in macrophages which is a novel finding. IL-6 expression in 
macrophages is generally accepted to be associated with a classical 
inflammatory M1 macrophage phenotype.  Our data demonstrates that whilst 
Mm-MIF-1 augments this response to LPS, Ts-MIF-1 has no effect on it’s 
expression. Though the oxidoreductase activity may provide some clues as to 
what is conferring IL-6 modulating activities, this is unlikely considering that Mm-
MIF-1 P2G retains the oxidoreductase motif yet does not modulate IL-6 
transcriptional responses.  Furthermore, as discussed in chapter 3, studies 
analysing the protein structure and enzymatic activities of MIF have shown that 
mutation of the proline site to an alternative amino acid like glycine does not alter 
the oxidoreductase activities of MIF when assessed within the insulin reduction 
enzyme assay.  
In addition to the above, we also found evidence that Mm-MIF-1 inhibited LPS-
mediated transcription of MCP-1 but this was not influenced by substituting the 
tautomerase-conferring proline residue for an inactive glycine residue in Mm-MIF-
1 P2G demonstrating that the tautomerase activities of MIF may only be partially 
responsible for cytokine regulation and additional factors like the oxioreductase 
activity may be a requirement for full enzyme activity in vitro and in vivo.  
Contrastingly, Ts-MIF-1 increased LPS–driven MCP-1 mRNA levels and like the 






MCP-1, otherwise known as CCL2, is a monocyte chemoattractant protein 
expressed by macrophages amongst other immune cells.  Although MCP-1 
recruits’ monocytes to the site of infection, several studies have shown that MCP-
1 expression drives the development of AAMs by increasing IL-6 which, in turn, 
re-amplifies MCP-1 expression in a loop mechanism (Roca et al., 2009).  
Conversely, Sierra-Filardi et al (2014) utilised a CCR2-/- murine model to 
demonstrate that abrogation of MCP-1 signalling increased IL-6 expression in 
LPS-treated macrophages. In addition to this, numerous studies have elucidated 
contrasting roles for MCP-1 in the polarisation of Th1 and Th2 responses (Helmby 
and Grencis, 2003; Huang et al., 2001; Lu et al., 1998; Omata et al., 2002).  These 
studies suggest that MCP-1, like many other cytokines and chemokines, acts 
accordingly with the environment in a temporal and contextual manner.   In this 
regard, we show that both Mm-MIF-1 and Ts-MIF-1 may act directly or indirectly, 
via MCP-1, to modulate IL-6 expression using distinct mechanisms although what 
these might be remain unclear. Future work in this study should focus on 
determining whether the oxidoreductase site plays a role in macrophage 
modulation due to the fact that Ts-MIF-1 lacks the oxidoreductase-conferring 
CXXC motif and thus in many respects might mimic the activities of murine MIF 
CXXC mutant.    
Despite being unable to demonstrate that mammalian MIF or Ts-derived MIF 
modulated IL-10 expression in response to LPS, it is important to note that studies 
eluding to MIF modulation of IL-10 responses frequently report correlative data 
patterns in clinical models of inflammatory disorders such as sepsis.  Additional 
work is required to determine whether there is a causative relationship between 
MIF signalling and IL-10 production.  MIF mediated modulation of cytokine 




















Figure 5. 6  Summary of MIF modulation of LPS-driven cytokine 
transcriptional responses in BMDMs.  Murine MIF potentiates the macrophage 
IL-6 transcriptional response to LPS and mutation of the tautomerase-conferring 
Proline site abolishes this effect.  Transcription of the chemotactic MCP-1 
cytokine, in the presence of LPS, is inhibited by murine MIF regardless of the 
tautomerase site.  LPS-mediated IL-6 transcription is unaltered by Trichinella 
spiralis derived MIF whilst MCP-1 levels are augmented.  The tautomerase site 
of MIF appears to play a critical role in murine MIF-modulation of IL-6 
transcription.  MIF does not play a role in the modulation of IL-10 in response to 
LPS in BMDMs. 
 
In this study there were no observable differences in the levels of IL-6 or TNF-α 
found in macrophage culture supernatants in response to LPS and MIF 
homologues or in samples incubated with MIF alone despite the results of our 
transcriptional assessment and other previously published studies.  Regardless 
of this there are notable differences between this study and in studies that allude 
to MIF modulation of IL-6 and TNF-α secretion:  Kudrin et al (2006) successfully 
demonstrated that recombinant human MIF enhanced LPS driven TNF-α 
secretion in human macrophages derived from peripheral monocytes.   However, 
the concentration of LPS used to stimulate macrophages was 1ng/mL which is 
10-fold lower than the LPS concentration utilised within this study; consequently, 
additional works investigating the effect of MIF on pro-inflammatory cytokine 
secretion in macrophages should introduce a titration of LPS and MIF to 
determine the precise point of interaction.  Within the same study it was also 






secretion of several additional pro-inflammatory cytokines typically associated 
with MIF, such as IL-6.  Contrastingly, a study by Prieto-Lafuente et al (2009) 
established that recombinant murine MIF significantly induces IL-6 secretion in 
BMDMs from C57BL/6 mice.  Upon further examination, the concentrations of 
MIF used were found to be excessively high, from 1µg/mL - 10µg/mL, suggesting 
that any result would have limited biological relevance.  Furthermore, 
recombinant MIF proteins used within the Prieto-Lafuente study were not purified 
with an additional ‘polishing’ stage to ensure the complete removal of endotoxin. 
Instead the study utilised the antibiotic Polymixin B (PmB) derived from Bacillus 
polymyxa, to try and inhibit any effects from endotoxin contamination.  In spite of 
this, the effectiveness of PmB as an inhibitor of LPS in cell based assays using 
antigen-presenting cells is somewhat disputed with one study demonstrating that 
PmB has limited efficacy as an inhibitor of LPS when assessing the secretion of 
cytokines IL-6 and TNF-α in dendritic cells (Tynan et al., 2012).  As the purification 
protocol of recombinant MIF proteins used within this study were based on 
methods used by Kudrin et al (2006) it is perhaps unsurprising that our data failed 
to show any response to MIF in ELISA assays.  This is likely to be a consequence 
of numerous contributing factors including the kinetics of protein turnover of these 
cytokines.  Introducing a time course study in future macrophage assays may 
allow for the detection of cytokines at earlier or later timepoints.     
Further explanations for the lack of translatability from transcriptome to proteome 
exist and include the inherent stochastic and dynamic nature of gene expression.  
Regardless of the fact that the work encompassed within this chapter did not 
show that MIF regulates the secretion of cytokines IL-6 and TNF-α at 20 hours 
after incubation, the possibility that MIF transcriptionally regulates cytokines, as 






This is investigated in detail in chapter 6 whereby RNA sequencing technology is 
utilised to assess MIF’s transcriptional profile in macrophages.  
Nonetheless, future work examining MIF’s role as a regulator of macrophage 
function will be required to characterise macrophage phenotypes by looking at 
cell-surface markers and transcription factors in order to understand the precise 
differences in macrophage responses to mammalian and Trichinella -derived MIF 
proteins.  Additionally, knock-out of endogenous MIF using siRNA techniques 
would be a rapid and efficient way of assessing whether observed traits are a 
result of exogenous recombinant MIF or the subsequent upregulation of 

















Chapter 6:  Transcriptomic analysis of MIF’s role using RNA 
Sequencing. 
6.1. Introduction. 
6.1.1.  Transcriptomic modulation by MIF homologues. 
Despite the fact that many aspects of MIF effects on different cell types or 
contribution to diseases has been extensively explored, information regarding 
transcriptional responses to exogenous MIF protein treatment is lacking.  The few 
studies which have attempted to unravel transcriptional responses to MIF have 
been focused on identifying specific markers of immune regulation which are 
modulated including cytokines IL-6 and IL-8 and chemokine, CCL-2 (Chuang et 
al., 2010a; Gregory et al., 2006b). These studies have primarily relied on using 
targeted techniques such as RT-PCR and qPCR and, whilst there is the 
suggestion that MIF may directly or indirectly modulate these specific targets, its 
precise mechanism of action on the cellular transcriptome remains elusive. 
Several studies have revealed an essential role for MIF in the regulation of  
immune responses by counter-regulating glucocorticoid suppression of 
inflammatory mediators such as TNF-α or modulating the expression and 
localization of innate immune receptors such as TLR-4 (Bernhagen et al., 1998; 
T. Calandra et al., 1995; Calandra and Bucala, 1997; Roger et al., 2003b; T. 
Roger et al., 2001), maintenance of barrier function (Maaser et al., 2002b; Man 
et al., 2008b; Vujicic et al., 2018b) and cell cycle progression (Fingerle-Rowson 
et al., 2003; Fingerle-Rowson and Petrenko, 2007; Welford et al., 2006).  The 
majority of these studies utilise murine MIF KO models to elucidate the effect of 






function in isolated colonic epithelial cells revealed that global KO of MIF 
increased levels of transcripts associated with the formation of cell-to-cell 
junctions such as zonula occludens-1 and claudin 2 whilst causing a decrease in 
the transcriptional levels of E-cadherin and occludin suggesting that MIF is 
essential for the maintenance of barrier integrity.  Interestingly, the same study 
also noted significantly increased levels of the Th1-associated cytokine, IL-18, a 
by-product of microbial receptor activation which may account for the 
dysregulation of the previously mentioned transcripts.  However, a recent study 
by (Pacheco-Fernández et al., 2019)  (2019) investigating the effect of MIF KO in 
dextran sodium sulfate (DSS)-treated mice revealed that, within this environment, 
IL-18 is decreased whilst iNOS, Arg-1 and IL-17 are all increased compared to 
their WT counterparts indicating that the absence of MIF leads to the 
development of inflammatory macrophages, and potentially the suppression of 
Th2 phenotypes, driven by intestinal epithelial cells.  MIF has also been shown 
to be a critical negative regulator of pro-inflammatory cytokine production in some 
cancer models where tumour associated macrophages from MIF-/- mice could not  
fully supress T-cell activation and enhanced transcription levels of TNF-α, COX-
2, IL-12 and iNOS in peritoneal exudate cells which typically include high levels 
of macrophages (Kavitha Yaddanapudi et al., 2013)   The observation that MIF 
may also promote an ‘anti-inflammatory’ macrophage phenotype is further 
examined in a study using primary bone marrow derived macrophages stimulated 
with recombinant MIF in which long-term (72 hours) culture of cells incubated with 
MIF increased the transcription of TGF-β, IL-10, PD-L1, and Arg-1 significantly in 
comparison to unstimulated macrophages.  Another study utilising microarray 
and qPCR to assess the effect of siRNA-mediated MIF knockdown in HEK293 






signalling (GADD45β, IKBα) and transcription factors linked to cell cycle 
progression (c-Myc, FOXO4) suggesting that HEK cells deprived of MIF were 
locked in the G0/G1 phase (Liu et al., 2012). While these studies have revealed 
numerous vital findings, particularly in respect to MIF’s role as a modulator of 
immune responses, how MIF treatment alters the global transcriptional response 
in macrophages has not been directly examined.    
While MIF’s tautomerase site is highly conserved across species, few attempts 
have been made to understand its role in MIF function or the target of its 
enzymatic activity.  Studies that have investigated the effect of tautomerase 
mutants in vitro have revealed conflicting results.  Swope et al (1998) 
demonstrated that substitution of the tautomerase conferring proline to glycine 
reduced superoxide production in human neutrophils by seventy-five per cent.  
Another study revealed that covalent modification of the proline site by the 
acetaminophen metabolite N-acetyl-p-benzoquinone imine (NAPQI) reduced cell 
surface binding in human microvascular endothelial cells (Senter et al., 2002b).  
Additionally, with respect to MIF’s distinctive ability to counter-regulate 
glucocorticoid suppression, the importance of the tautomerase conferring Pro2 
site is in dispute.  This biological activity appears to be dependent on the chosen 
substituted amino acid.  In monocytes, substitution of proline to serine maintains 
MIF’s counter regulation of glucocorticoid suppression despite abolishing the 
tautomerase enzyme activity (Bendrat et al., 1997).  Conversely, a catalytically 
inactive MIF mutant, whereby an alanine residue is inserted between Pro2 and 
Met3, does not override glucocorticoid suppression in LPS-stimulated human 
monocytes.  Despite this, the significance of MIF and MIF’s conserved 






function and with this is mind, this study utilised RNA sequencing technologies to 
fully explore the macrophage transcriptional landscape in response to MIF and 
MIF P2G recombinant proteins. 
In parallel with the studies of endogenous murine and human MIFs, homologues 
derived from pathogens have also been extensively studied revealing distinct and 
context-dependent transcriptomic responses.  MIF is commonly expressed and 
secreted by protozoan parasites and has been shown to drive pathogenesis and 
modulate host immunity.  For instance, MIF derived from Plasmodium berghei 
supressed PMA induced AP-1 transcription in HEK 293 cells pointing towards a 
potential role for Pb-MIF in cell cycle regulation (Augustijn et al., 2007) whilst 
Trypanosoma cruzi infected hearts from MIF-/-mice displayed significantly 
increased expression of IFN-γ but reduced IL-12p35, IL-12p40 and IL-23 
expression relative to WT MIF mice (Reyes et al., 2006).  Moreover, IL-22 
expression in ileal explants from Toxoplasma gondii infected MIF-/- is significantly 
increased compared to WT MIF though, surprisingly, TNF-α and IL-12 transcripts 
were decreased.  In addition to the aforementioned parasites Trichinella spiralis, 
a well characterised intestinal nematode, has been shown to produce several MIF 
homologues (Tan et al., 2001, Guiliano. D.B. unpublished).  The protein 
sequence of Ts-MIF-1 contains the conserved tautomerase-conferring Pro2 site 
but, remarkably, the activity of this is 6-fold greater than that of mammalian MIF 
suggesting that the tautomerase site may be of greater importance for infection 
purposes. This study utilises WT and tautomerase mutant Ts-MIF-1 proteins to 






6.1.2.  Utilising RNA sequencing technologies to assess the transcriptome. 
Assessing a cell or tissue’s transcriptome allows for quantification of varying 
types of transcript including mRNA and small RNA and the ability to 
comparatively deduce the relative expression of each transcript.   RNA-
sequencing profiles the transcriptome utilising deep sequencing technologies and 
the advantages of RNA sequencing over microarray assays is discussed below. 
RNA sequencing was elected as an alternative to microarray for transcriptomic 
analysis in this study for several carefully considered reasons.  RNA sequencing 
lacks the need for transcript-specific probes like many microarray-based assays, 
providing an unbiased view into the transcriptome, including novel transcripts, 
splice variants and nucleotide variants.  Moreover, RNA-sequencing has a larger 
dynamic range allowing greater sensitivity for transcripts expressed at very low 
or more accurate quantification of very high-level transcripts.  In addition to the 
above, several studies have undertaken comparative studies investigating 
whether one type of transcriptomic platform offers significant advantages over 
another with the general consensus being that RNA sequencing is far superior to 
microarray for transcriptomic analysis (Rai et al., 2018; Rao et al., 2018; Zhao et 
al., 2014) 
6.2.  Research aims and objectives.   
To examine the bone marrow derived macrophage transcriptome in response to 
MIF and MIF P2G mutants the following aims were proposed: 
1. To compare the transcriptional response to murine and Trichinella spiralis 






relative expression levels normalised to the untreated macrophages, using RNA 
sequencing technology.  
2. Perform gene ontology analysis to establish potential relationships 
between MIF targets and cellular process and pathways.  
 
6.3. Quality control of RNA sequencing. 
RNA sequencing was carried out at the Genomics facility (UCL) under the 
guidance of Dr Paola Niola and basic RNA seq analysis including the 
associated quality control which was performed by Tony Brooks (UCL).  The 
RNA seq workflow from the cellular assay to final analysis is summarised in 
figure 6.1.  Analysis included aligning reads to the reference genome for Mus 
musculus were generated using the STAR (Spliced Transcripts Alignment to 
a Reference) algorithm and low-quality, incorrectly called raw reads were 
trimmed prior to analysis.   A mean of 20.2 million reads per sample was 


















Figure 6. 1  Schematic representing RNA seq workflow.  Bone marrow from 
C57BL/6 female mice aged 6-8 weeks was isolation and cultured in the presence 
of M - CSF for 7 days.  Macrophages were treated with 100ng/ml recombinant 
MIF proteins for 20 hours before harvesting for RNA isolation.  rRNA was 
depleted to ensure reads were derived from mRNA and the sequencing library 








Sample Name mRNA Aligned Duplication PF Adapter 
Experiment 1      
Untreated 
Control 
75.10 87.70 4.50 99.40 2.30 
Mm-MIF-1 75.50 87.70 5.00 99.30 1.70 
Mm-MIF-1-P2G  77.00 88.80 10.60 99.40 1.20 
Ts-MIF-1  79.30 89.00 9.80 99.40 1.50 
Ts-MIF-1 P2G  75.50 87.80 14.50 99.40 0.90 
Experiment 2      
Untreated 
Control  
64.50 82.70 5.20 99.30 2.50 
Mm-MIF-1  79.30 88.20 3.80 98.90 3.80 
Mm-MIF-1 P2G  76.80 87.10 5.40 99.30 2.30 
Ts-MIF-I  76.50 87.70 5.60 99.30 2.40 
Ts-MIF-1 P2G  80.70 88.80 5.20 99.30 2.20 
Experiment 3      
Untreated 
Control 
80.80 87.80 6.20 98.80 3.90 
Mm-MIF-1 83.70 89.20 15.50 99.30 1.90 
Mm-MIF-1 P2G  80.80 88.60 7.30 99.40 1.70 
Ts-MIF-1  76.20 87.30 16.50 99.30 
 
Ts-MIF-1 P2G  82.60 88.60 15.60 99.30 1.80 
Table 6. 1 RNA seq quality control metrics.   Quality control results for RNA 
sequencing showing the percentage of mRNA, percent of uniquely mapped 
sequences aligned to the reference genome, duplication rate in filtered 
reads, percentage of reads passing filter (PF), percentage of adapter 






6.4.  Differential gene analysis. 
To determine the differentially expressed genes (DEGs), transcripts from Mm-
MIF-1, Mm-MIF-1-P2G, Ts-MIF-1 and Ts-MIF-1-P2G treated macrophages were 
analysed against a control of untreated bone-marrow-derived-macrophages.  
Analysis was performed using DEseq2 and EdgeR in R studio with a batch 
parameter defined in order to take the pre-determined batch variation into 
account.  This includes modelling of the dataset using surrogate variables to 
estimate the coefficients of the model (Leek, 2014, 2014) prior to statistical 
inference tests.  DEGs were primarily identified using the adjusted P value.  For 
this analysis, a Benjamini-Hochberg p-value adjustment was performed using the 
formula (i/m)Q	where i = P-value rank, m = the total number of tests and Q = 
false discovery rate, to ensure that P values below 0.05 were not a consequence 
of Type I error (Benjamini, 2010; Benjamini and Hochberg, 1995).  In this 
instance, the level of controlled false positive rate was set to 0.05.  To extract the 
most differentially expressed genes between MIF groups versus the control, 
genes were filtered to include only those genes with a log2 fold change and q 
value of < - 1.5 or > 1.5 and < 0.05, respectively. 
As depicted in figure 6.2 and figure 6.3, DEseq2 analysis revealed that, using the 
stringent criteria mentioned previously, there were 114 key genes differentially 
regulated between the sample groups. Specifically, there were 13 DEGs between 
Mm-MIF-1 and the relative untreated control, 8 of which were downregulated and 
5 was upregulated.  In macrophages incubated with the tautomerase-deficient 
Mm-MIF-1 P2G the number of DEGs increased to 27 with all DEGs being 
upregulated compared to the control; 5 of which were in common with genes 






Analysis of Ts-MIF-1 and Ts-MIF-1 P2G DEGs revealed that there were only 19 
differentially regulated transcripts in samples with Ts-MIF-1 when compared to 
the control,18 upregulated and 1 downregulated.  Additionally, in macrophages 
cultured with tautomerase-deficient Ts-MIF-1 P2G, 8 genes were found to be 
differentially regulated as compared to control cells, 5 downregulated, 3 
upregulated.  In Ts-MIF-1 treated samples, 2 upregulated transcripts and 1 
downregulated transcript overlapped with Ts-MIF-1 P2G samples.  Full gene lists 































Figure 6. 2  Number of differentially expressed genes identified in MIF-
treated macrophages.  Transcriptional variation in Mm-MIF-1, Mm-MIF-1 P2G, 
Ts-MIF-1 and Ts-MIF-1 P2G treated BMDMs.  (A) Pie charts depicting the 
number of regulated transcripts in Mm-MIF-1, Mm-MIF-1 P2G, Ts-MIF-1 and Ts-
MIF-1 P2G treated BMDMs.  (B) Venn diagram depicting the number of 
overlapping or exclusively up-regulated genes in MIF or MIF P2G treated 
BMDMs.  (C) Venn diagram depicting the number of overlapping or exclusively 













Figure 6. 3  Number of differentially expressed genes identified in MIF-treated macrophages.  Transcriptional variation in Mm-MIF-
1, Mm-MIF-1 P2G, Ts-MIF-1 and Ts-MIF-1 P2G treated BMDMs.  (A) Venn diagram depicting the number of overlapping or exclusively up-
regulated or downregulated genes in Mm-MIF-1 or Ts-MIF-1 treated BMDMs.  (B) Venn diagram depicting the number of overlapping or 






To determine whether specific gene groups were differentially regulated in 
response to MIF homologues, gene ontology analysis was performed using The 
Database for Annotation, Visualization and Integrated Discovery (DAVID).  
DAVID is an established classification tool which clusters genes into functional 
groups utilising a Fuzzy Heuristic Partition (FHP) algorithm allowing genes to 
cluster into several functional groups.  FHP automatically determines the 
optimum number of clusters (K) and excludes genes that have weak relationships 
to other gene groups (Dennis et al., 2003; Tjhi and Chen, 2008).   DAVID was 
utilised to identify key gene clusters using fold enrichment score to highlight the 
most differentially expressed groups.  Figure 6.4.A shows the DEG’s related to 
their functional groups with the most significantly enriched functional groups 
being BMP receptor binding (BMP3, BMP7), TGF-β receptor binding (BMP3, 
BMP7), regulation of SMAD phosphorylation (BMP3, BMP7), regulation of MAPK 
cascade (BMP3, BMP7), Structural molecule activity (Cldn8, Krt19, Krt5, Krt7, 
Krt15, Krt8, Krt4, Sprr1a, Sprr2a3), anatomical morphogenesis (Trp63, BMP7) 
and pattern specification processes (Trp63, BMP7, Rab27b).  In addition to gene 
ontology analysis, using the top 114 genes, the most differentially expressed are 







Figure 6. 4  Comparison of DEG’s in Mm-MIF-1, Mm-MIF-1 P2G, Ts-MIF-1 and Ts-MIF-1 P2G treated BMDMs.  (A) Enrichment analysis 
showing terms associated with modulation of the BMDM transcriptome by MIF homologues.  (B) Heatmap representing DEG’s, determined 
by DEseq2, in MIF-treated BMDMs.  Heatmap was generated using the complex heatmap package (ggplot2) in R.  Transcripts were 
considered significantly modulated with a log2 fold change > 1.5 and adjusted p value < 0.05.  Blocks are represented in a colour range 






6.4.1. Transcriptional divergence of TNF-α modulating genes in MIF and MIF 
P2G treated BMDMs. 
In this study, the expression profile of BMDMs cultured with Mm-MIF-1 
homologues and Mm-MIF-1 P2G mutants revealed that the tautomerase site of 
murine MIF is essential for the MIF’s overall modulatory actions on the 
macrophage transcriptome.  BMDMs cultured with Mm-MIF-1 P2G exhibited 
widespread upregulation of the transcriptome targets down-regulated by MIF.  
Despite this, there were a number of clear divergences in samples treated with 
Mm-MIF-1 and Mm-MIF-1 P2G with a notable difference being that several 
transcripts associated with the modulation of TNF-α signalling being dysregulated 
in the absence of the tautomerase activity including ADAM28, Trp63 and Rab27b. 
ADAM28 is a metalloproteinase and a member of the disintegrin family which is 
found at both the cell surface and as a soluble protein.  Involved in numerous 
biological functions including cell adhesion, proteolytic processes and cell 
signalling, ADAM28 has been implicated in several pathologies such as 
colorectal and lung cancer, Crohn’s disease and systemic lupus erythematosus 
(Seals and Courtneidge, 2003).   More recently, studies investigating the potential 
role of ADAM28 as a sheddase have revealed, utilising siRNA silencing of 
ADAM28 in human THP-1 cells, that levels of soluble, active TNF-α are 
significantly reduced in cells in which endogenous ADAM28 is inhibited indicating 
that expression of ADAM28 is an essential prerequisite for the cleavage and 
activation of TNF-α (Jowett et al., 2012; Worley et al., 2003).  Despite growing 
evidence that ADAM28 may modulate TNF-α, to date, there has been little 






Results from RNA-seq of MIF treated BMDMs in this study highlighted that 
ADAM28 transcripts were downregulated in Mm-MIF-1 treated macrophages 
whilst in cells treated with the tautomerase deficient Mm-MIF-1 P2G, ADAM28 
was significantly upregulated. In macrophages, the biological activity of TNF-α is 
generally regulated by processing at the protein level rather than transcription 
and these results suggest that the tautomerase site may be crucial for the indirect 
regulation of TNF-α processing.  
Regardless of there being clear differences between WT Mm-MIF-1 and the 
tautomerase deficient Mm-MIF-1 P2G in the modulation of ADAM28, when 
transcriptional differences in Ts-MIF-1 and Ts-MIF-1 P2G BMDMs were 
examined, there was no notable difference found in macrophages treated with 
either of the two homologues indicating that Ts-derived MIFs (with or without the 
tautomerase activity) do not modulate the levels of TNF-α via ADAM28.  
Interestingly, a distinct difference between mammalian MIF and Ts-derived MIF 
proteins is an oxidoreductase site which is conferred by a CXXC motif present in 
murine MIF which has previously been shown to regulate several innate immune 
pathways, as discussed in chapter 3.   
In addition to the aforementioned TNF-α sheddase ADAM28, a second gene 
involved in TNF-α activity Rab27b was also modulated in MIF treated 
macrophages.  Rab27b is a member of the RAS oncogene protein family and 
currently, knowledge regarding the role of Rab27b in macrophage function is 
limited.   Previous studies investigating the role of Rab27b in immune cell 
behaviour have shown that it is highly expressed by macrophages at sites of 
wound healing (Mori et al., 2011), that it is responsible for the secretion of 






Ostrowski et al., 2010), and is implicated in the induction of mast cell 
degranulation (Mizuno et al., 2007). 
Though Rab27b has been demonstrated to be essential for a number of secretory 
pathways, more recently, a role for Rab27b in the regulation of macrophage 
exosomal biogenesis and secretion has been revealed (Ostrowski et al., 2010).  
In addition,  Li et al (2018) demonstrated that blockade of Rab27b-mediated 
exosome release from MФ resulted in a significant downregulation of TNF-α after 
treatment with LPS suggesting that Rab27b is required for efficient TNF-α 
release.    Exosome release from primary macrophages plays a significant role in 
the cellular communication between macrophage and responding cells such as 
neutrophils and effector lymphocytes. Rab27b induces exosomal secretion in 
LPS stimulated macrophages causing an increase in proinflammatory cytokines 
(Alexander et al., 2017) whilst in the cancer microenvironment Rab27b - driven 
vesicle trafficking has been shown to contribute to tumour growth and metastasis 
(Tzeng and Wang, 2016). 
Data from our study indicates that BMDM’s treated with Mm-MIF-1 for 20 hours 
have significantly decreased transcriptional levels of Rab27b as compared to the 
untreated samples.  Contrastingly, Rab27b transcripts were significantly 
increased in the tautomerase deficient, Mm-MIF-1 P2G treated macrophages 
confirming earlier results that highlighted the significance of the tautomerase site 
in the modulatory capabilities of mammalian MIF.   
Notably, earlier studies have demonstrated that matrix metalloproteinases, such 
as ADAM28, are expressed in abundance in exosomes from tumour-associated 
macrophages suggesting that Rab27b and ADAM28 modulation may be linked in 






An additional key MIF-modulated gene involved in transcriptionally mediating 
TNF-α driven responses is Trp63.  Trp63, also known as p63 in humans, is a 
member of the p53 tumour suppressor family and shares approximately 63% 
amino acid sequence similarity with p53’s N-terminal transcription activation 
domain, a DNA binding domain and a C-terminal oligomerization domain.  
Though a large number of residues are homologous, the fact that 37% are 
dissimilar suggests that the functions of the p63 homologue diverge somewhat 
from that its counterpart, p53 (Levrero et al., 2000).  Moreover, it is well-
documented that p63 and a second p53 homolog p73 are principally involved in 
cellular development and are not involved in maintaining genomic stability like 
their counterpart p53 (Inoue and Fry, 2014).  Similarly, numerous studies have 
evidenced that while p53 is always mutated in cancer cells, p63 and p73, are 
typically unaltered (Dötsch et al., 2010).  Early studies using murine p63 knockout 
models proved largely unsuccessful in revealing the specific roles for p63 due to 
mice acquiring severe developmental abnormalities leading to early death (De 
Laurenzi and Melino, 2000). 
Further probing into the functions of p63 have revealed that there are several 
isoforms driven by two distinct promotors: TAp63 and ∆Np63, both of which have 
been implicated as inducers and targets of the NF-kB signalling pathway.  The 
promoter regions for TAp63 and ∆Np63 contain  NF-kB binding sites and mutation 
of these bases abolishes TNF-α driven NF-kB activation and the subsequent 
expression of p63 (Wu et al., 2010).  Of particular note, TAp63 appears to be 
modulated by the dimerization of the canonical MIF receptor, CD74.  Binsky et al 
(2010) noted a relationship between MIF and TAp63 in CLL cells, with CD74-






This was also demonstrated in primary ex vivo B-cells whereby MIF treatment led 
to the expression of several anti-apoptosis genes such as Bcl-2 and this was 
shown to be dependent on the CD74/NF-kB/TAp63 axis (Lantner et al., 2007).  
Conversely, several studies have shown that p63 expression increases cell 
surface expression of death receptors such as the TNF-α receptor, TNF-R, 
thereby inducing a subset of genes associated with apoptosis (Gressner et al., 
2005).  Apoptosis is typically associated with p63’s more widely researched 
counterpart, p53, nevertheless few studies have also shown that p53 can 
increase cellular survival under specific conditions such as cellular starvation by 
downregulating autophagic mediators (Scherz-Shouval et al., 2010). 
In this study, Trp63 was significantly downregulated in Mm-MIF-1 treated 
macrophages when compared to the untreated cells.  Conversely, treatment of 
BMDMs with Mm-MIF-1 P2G had no effect on the expression of Trp63 
demonstrating, firstly, that mammalian MIF in the setting of primary macrophages 
acts to decrease Trp63 which contradicts previous studies that noted MIF 
increased Trp63 through the CD74 receptor in leukemic cell lines and murine B 
cells  Secondly, we show here that the Mm-MIF-driven reduction in Trp63 
transcripts are dependent on MIFs tautomerase activity.  Future work should 
focus on identifying how the tautomerase site or its activity is linked for the 
modulation of Trp63 or whether it is a consequence of reduced receptor binding.  
This may be achieved by co-treating BMBMs with MIF homologues and 
commercially available tautomerase inhibitors to confirm whether the observed 
effect is a direct effect of MIF’s tautomerase enzymatic activity.   An additional 
objective would be to determine which isoform of Trp63 is being expressed within 






differentiate between Np63 or Tap63.  However, several studies suggest that 
Np63 is exclusive to epithelial cells whilst Tap63 is found in immune cells of 
haematological origin .  
Much like the mammalian MIFs, Ts-MIF-1 also represses Trp63 however in 
contrast to the murine MIF, this repression is maintained after treatment with the 
tautomerase deficient mutant Ts-MIF-1 P2G. This suggests that the tautomerase 
site is not completely required for MIF driven modulation of Trp63.  However, this 
may also be a consequence of differences in transducing signals between 
mammalian and Trichinella-derived MIFs.  A summary of the transcriptional 





















Figure 6. 5  Schematic of MIF’s TNF-α modulating capabilities.  Treatment of 
BMDMs with Mm-MIF-1 leads to an indirect downregulation of TNF-α processing 
and secretion by inhibition of TNF-α sheddase, ADAM28, preventing processing 
of TNF-α precursors to the active, mature state.  Mm-MIF-1 also inhibits TNF-α 
containing exosome release via Rab27b. Mammalian modulation of these two 
key genes is highly dependent on the Pro2 tautomerase-conferring site. 
 
6.4.2.  Ts-MIF-1 primes BMDM’s for polarization inducing transcripts 
involved in cell cycle regulation. 
Macrophages play an important role in the development of Trichinella spiralis 
infection and studies investigating the T. spiralis infected niche have 
demonstrated that macrophages, amongst other innate immune cells, dominate 
the local immune environment serving several key purposes including clearance 
of debris, caused by T. spiralis mechanically burrowing through epithelial cells, 
and the modulation of immune cells such as neutrophils and T-cells in the local 
area.  The majority of studies that investigate the macrophage profile in response 
to T. spiralis infection or administration of T. spiralis-derived excretory/secretory 
antigens suggest that macrophages undergo polarization to an M2 anti-
inflammatory phenotype (Bai et al., 2011; Chen et al., 2016). 
As described in Chapter 3, T. spiralis secretes vast amounts of a MIF homologue 
in response to the harsh acidic stomach environment, however, research 
exploring the potential role of Ts-MIF-1 in the modulation of the macrophage 
transcriptional landscape is lacking.  Furthermore, the significance of the 






The data from this study clearly demonstrates the novel prospect that Ts-MIF-1 
is driving a unique transcript profile consistent with structural remodelling and cell 
cycle regulation with the most upregulated genes being those involved in cell 
development (BMP3, BMP7, Hhip, IGFbp2), scaffold protein binding (Krt5, Krt15, 
Krt8), structural molecule activity (Cldn8, Krt19, Krt5, Krt7, Krt15, Krt8, Krt4, 
Sprr1a, Sprr2a3) and modulation of the TGF-β pathway (BMP3, BMP7).   
Morphogens, BMP and Hedgehog, are widely known for being critical regulators 
of embryonic morphogenesis and patterning, with BMP’s forming a subset of the 
TGF-β superfamily of proteins.  BMPs have been implicated in numerous 
diseases and studies have investigated their role in various cell types including 
B-cells, T-cells, epithelial cells and macrophages.  BMPs bind to the canonical 
receptor BMPRI and, upon phosphorylation of BMPRII form a heterotetrameric 
complex leading to phosphorylation of the receptors SMADs, SMAD 1, 5 and 8.  
The complex of SMAD 1, 5 and 8 associates with a common SMAD, SMAD4, 
whereby translocation across the nuclear membrane occurs leading to the 
regulation of gene expression.  Importantly, both TGF-β and BMP signalling 
converge via Smad4 and many of the pathways are interlinked.   All morphogens 
act through a series of reciprocal feedback loops and numerous studies have 
suggested a pattern of crosstalk dynamics between BMP and Hedgehog 
signalling.  Additionally, canonical Hedgehog signalling is inhibited by the 
induction of Hedgehog-interacting protein (Hhip) (Liao et al., 2017) which binds 
with high affinity directly to Hedgehog ligands to prevent binding to the hedgehog 
receptor, Patched1 (Chuang et al., 2003; Chuang and McMahon, 1999).   
Despite the fact that studies investigating the role of BMP and Hedgehog ligands 






essential for driving macrophage polarisation.  BMP-2 has been shown to inhibit 
several markers of the inflammatory M1 phenotype including IL-6 and iNOS (Wei 
et al., 2018) in RAW 264.7 cells and induce monocyte chemotaxis (Pardali et al., 
2018) while BMP-3 appears to antagonise BMP-2 signalling by upregulating 
components of the TGF-β pathway in a murine osteoblast cell line (Bahamonde 
and Lyons, 2001; Daluiski et al., 2001).  Moreover, BMP-7 has been described 
as a key mediator of macrophage plasticity and drives the differentiation of 
monocytes into M2 ‘healing’ macrophages expressing key M2 markers arginase-
1 and CD206 in THP-1 cells while simultaneously inhibiting iNOS expression 
(Rocher and Singla, 2013; Shoulders, 2016; Singla et al., 2016).  In contrast, 
BMP-7 antagonises TGF-β signalling despite TGF-β being a potent inducer of the 
M2 macrophage phenotype (Feng et al., 2018; Gong et al., 2012) highlighting the 
importance of the environmental context.  However, a serious caveat to these 
studies is that, contextually, all of the systems examine a cancer environment 
which is likely to bias the direction of macrophage polarisation towards an M2 
phenotype.  
Notably, a more recent observation of a role in p53 modulation by BMP and 
Hedgehog proteins has been revealed.  BMP7 is a target gene of the tumour 
suppressor protein p53 with a p53-responsive element located at nucleotide 
2,852 to 2,871 of intron 1 Yan and Chen (2007) . Additionally, Hedgehog 
signalling can override p53 driven tumour suppression by directly activating 
MDM2 thereby increasing proliferation (Abe et al., 2008).  Likewise, inhibition of 
receptor binding by Hhip increased phosphorylation of p53 in a podocyte cell line 






With this in mind, it is interesting to note that MIF has previously been shown to 
antagonise p53 and has been established as a ligand of the MAPK/ERK/ Jab1 
signalling pathway (Mitchell et al., 2002).  Mammalian MIF physically interacts 
with the p53 protein to prevent nuclear translocation and inhibit the anti-
proliferative effects of p53 in vitro and in vivo. In the same study, mutation of 
cysteine 81 to serine abolished the inhibitory actions of MIF on p53 (Jung et al., 
2008a) indicating that, within the context of HEK 293T cells, MIF cysteine 81 is 
critical for p53 modulation.  In addition to this, p53 dependent inhibition of ras-
mediated transformation in embryonic fibroblasts was significantly increased in a 
C57BL/6 MIF-KO model (Fingerle-Rowson et al., 2003).  Despite this, Brock et al 
(2014) demonstrated that efficient p53 inhibition in A549 alveolar epithelial cells 
was dependent on the collective action of MIF-1 and the MIF homologue DDT-
1/MIF-2. 
With this is mind, we demonstrate that Ts-MIF-1 distinctively modulates genes 
involved in cell cycle regulation.  In this study, BMP-3 and BMP-7 remained at 
basal levels in Mm-MIF-1 treated macrophages whilst, substitution of the 
tautomerase conferring proline residue to inert glycine led to a significant increase 
in the expression of the transcripts indicating that the enzymatic activity is vital 
for the regulation of MIF-dependant macrophage function.  Crucially, both Ts-
MIF-1 and Ts-MIF-1 P2G treated macrophages upregulated BMP-3 transcripts 
when compared to the untreated cells whilst BMP-7 was exclusively upregulated 
in Ts-MIF-1 cultured macrophages and did not change in response to Ts-MIF-1 
P2G.  In addition, the hedgehog inhibitory protein, Hhip, was upregulated in all 






Interestingly, during nurse cell formation in Trichinella spiralis infection BMP’s and 
components of the TGF-β signal pathway that are also common to BMP such as 
the shared mediator, Smad4, are significantly upregulated contributing to cell 
cycle arrest and regenerative processes within the infected muscle tissue (Wu et 
al., 2006, 2005).  This data may provide evidence to suggest that Ts-MIF-1 
modulates the macrophage cell cycle to prevent differentiation into an 
inflammatory phenotype in the presence of an additional stimulus such as LPS.  
However, further work should be undertaken to determine macrophage 
phenotypes in response to Trichinella derived MIF’s.  Additionally, the data 
presented here may provide novel insight into MIF’s p53 regulatory mechanisms 
and provide further evidence for the idea that mammalian MIF-mediated inhibition 
of p53 may be dependent on cysteine 81, as previously described, as the protein 
sequence of Ts-MIF-1 is devoid of any cysteine residues.  Nevertheless, as Ts-
MIF-1 P2G treated cells failed to exhibit upregulation of many of the genes 
associated with Ts-MIF-1, it is difficult to rule out the possibility that the conserved 
tautomerase site may play a direct or indirect partial role in driving this behaviour.  
This novel finding provides crucial insight into mammalian MIF’s role as a p53 
antagonist and future work should investigate the p53 status in macrophages 
after treatment with Ts-derived MIF utilising western blot and immunoprecipitation 
techniques.  
Further validation for the concept that MIF proteins regulate p53 associated 
pathways was observed in the Ts-MIF-1 but not Mm-MIF-1 driven increase in 
Insulin growth factor binding protein 2 (Igfbp2).  Igfbp2 encodes for a protein 
involved in the negative regulation of insulin growth factor 1 (IGF-1) and insulin 






to be significantly upregulated within the Trichinella spiralis nurse cell niche (Wu 
et al., 2008) contributing to cell cycle arrest and re-entry. Additionally, IGFBP-2 
has been shown to inhibit IGF driven tumorigenesis using several distinct 
mechanisms: competing for the IGF receptor (Bach, 2018) and binding to IGF-1 
or IGF-2 leading to sequestration of the proteins (Pickard and McCance, 2015).  
Furthermore, IGFBP-2 has been implicated in several processes associated with 
tumour suppression; Grimberg et al (2006) revealed that shRNA knockout of 
IGFBP-2 in PC3 cells, a prostatic cancer cell line, resulted in a significant increase 
in IGF-1 signalling which is known to be inhibited by p53, highlighting the fact that 
IGFBP-2 is a transcriptional target of p53. 
With the exception of p53 modulatory activities, IGFBP-2 has been shown to have 
contradictory roles in macrophage polarisation.  Recent work by Du et al (2019) 
demonstrated that IGF-2 primes developing macrophages driving an anti-
inflammatory phenotype by reprogramming the metabolic profile towards 
performing oxidative phosphorylation and increasing the expression of inhibitory 
ligand, PD-L1.  Additionally, IGF-1 is expressed and secreted by IL-4 mediated 
M2 macrophages derived from bone marrow monocytic cells (Martinez et al., 
2006) and inhibition of IGF-1 abrogates Akt activation and the upregulation of M2 
markers (Barrett et al., 2015; Spadaro et al., 2017).  As IGFBP-2 binds to and 
inhibits the actions of both IGF-1 and IGF-2 this would suggest that an increase 
in IGFBP2 may inhibit the polarization of several macrophage phenotypes to 
prevent the clearance of infections.  
Aside from its putative role in the inhibition of IGF proteins, several studies have 
established a direct role for IGFBP-2 in the modulation of tumour progression by 






glioblastoma tumour cells (Wang et al., 2006).  In the context of macrophage 
development, Liu et al (2019) reported that shRNA knockdown of IGFBP2 in 
gliomas significantly reduced the overall number of CD163+ M2 macrophages.  
Importantly, several studies have elucidated a negative regulatory role for IGFBP-
2 in phagocytosis with one study demonstrating that it increases phosphorylation 
of FCYRIIB on macrophages thereby downregulating the phagocytic capabilities 
to prevent uptake of local debris (Clynes et al., 2000).  
6.4.3.  Ts-MIF-1 drives architectural changes in murine BMDM cells. 
Interestingly, a further set of genes in involved in strengthening components of 
cellular cytoskeleton (Krt4, Krt5, Krt7, Krt8, Krt15, Krt19, Cldn8, Sprr1a, Sprr2a3) 
were found to be upregulated in macrophages treated with Ts-MIF-1 and, to a 
lesser extent Ts-MIF-1 P2G.  Minimal modulation of these genes were noted in 
Mm-MIF-1 treated samples, however, abolishing the tautomerase activity led to 
a significant increase in all of the aforementioned transcripts suggesting that the 
enzymatic activity is crucial for canonical MIF signalling to occur.  
Krt genes code for Keratin proteins that act to strengthen the intermediate 
filaments associated with the cellular cytoskeleton and their function in 
macrophage development and polarisation is poorly understood. Nevertheless, 
modulation of Krt genes has been noted in several studies that utilise RNA 
sequencing to analyse the macrophage transcriptome including: expression of 
Krt4 and Krt19 in alveolar macrophages (Mould et al., 2019) and Krt5 expression 
in monocyte derived macrophages infected with influenza H5N1 (Zhang et al., 
2018).   An interesting finding is that granuloma macrophages express high levels 
of Krt genes when compared to alternative macrophages subtypes.   Additionally, 






2012).  Granuloma macrophages are a distinct sub-population of macrophages 
originally designated ‘epithelioid cells’ due to their ability to acquire epithelial-like 
characteristics.  Immunophenotypically, they exist partway along the M1/M2 
continuum and are considered intermediate macrophages due to concomitant 
expression of markers such as iNOS, Arg1 and the Krt genes (Adams., 1974; 
Mattila et al., 2013).  Additionally, epithelioid macrophages lack the phagocytic 
capabilities associated with M1 and M2 polarised cells (Turk and Narayanan, 
1982; Williams and Williams, 1983) which would confirm our earlier finding that 
increased expression of IGFbp2 also negatively regulates phagocytosis.  
In addition to Krt genes, Claudin-8 was highly upregulated in Ts-MIF-1 treated 
macrophages.  The paucity of studies investigating the role of Cldn genes in 
macrophages suggests that the expression may be dispensable for macrophage 
function, however, Bossche et al (2012) noted a significant increase in the 
induction of Cldn8, as well as several other Cldn genes, in IL-4-driven M2 bone 
marrow derived macrophages from BALB/c mice.  The increase in tight junction 
proteins in macrophages may be relevant in a number of scenarios such as: the 
fusion of macrophage and tumour cells; macrophage integration during wound 
healing processes; and, more crucially in the formation of granuloma structures. 
Interestingly, granulomatous inflammatory reactions have previously been linked 
to infection with T. spiralis larvae in rats (Etewa et al., 2018) and a study by (Li 
and Ko, 2001) also observed granulomatous inflammation at sites nearby worm 
invasion, however, it is important to note that these studies were both 
investigating muscle stage infections.  Furthermore, T.spiralis undergoes a long 
period of convalescence following the acute phase of infection within the 






cells inducing dedifferentiation to form a cyst termed a ‘nurse cell’.   Several 
studies have revealed that T.spiralis secretes a number of proteins that act to 
regulate the cell cycle and includes the modulation of genes such as IGF’s, IGF 
binding proteins and TGF-β/BMP molecules (Wu et al., 2005)  A summary of the 























Figure 6. 6 Trichinella derived MIF’s halt macrophage polarisation.   
Treatment of BMDMs with Ts-MIF-1 leads to cell cycle arrest via the 
downregulation of Trp63 and the concurrent increase in IGFBP2.  Ts-MIF-1 
increases expression of BMP-3, BMP-7 and Hhip to prevent macrophage 
polarisation.  Transcripts involved in increasing the tensile strength of the cellular 
architecture such as Krt’s and Cldn8 are upregulated to strengthen the 
cytoskeleton and inhibit motility. Transcripts in black are upregulated.  Transcripts 
in pink are downregulated.  Transcripts within a black box are not dependent on 
the tautomerase activities of Ts-MIF-1. 
6.5.  Discussion of the transcriptomic analysis of MIF’s role using RNA 
sequencing. 
MIF proteins have been widely studied and are implicated in numerous 
pathologies from responses to exogenous antigens such as the bacterial 
endotoxin, LPS, through to the development of both solid tissue tumours and 
haematopoietic cancers.  Aside from endogenous mammalian MIFs, a plethora 
of organisms secrete MIF homologues that are known to modulate host immunity 
in order to increase their survival and drive pathogenesis.  A commonality 
between all MIF homologues is a highly conserved proline residue that confers 
its tautomerase activity. The significance of the enzymatic activities of MIF is still 
unclear despite various studies attempting to demonstrate clear links to its known 
biological functions.   
One of the most critical cell types in the innate response to antigens is the 
macrophage which can polarise into numerous subsets owing to high plasticity 
that is dependent on the local environment.  Despite the discovery several 
decades ago that MIF, secreted from T-cells, can inhibit the migration of 
macrophages, to date there is insufficient evidence to suggest that MIF and MIF’s 






of the macrophage transcriptome.  Taking this into account, whole transcriptome 
RNA sequencing was utilised to analyse the global macrophage transcriptome in 
response to M. musculus and T.spiralis derived MIFs and tautomerase deficient 
mutants of these proteins. 
Differential gene expression analysis revealed that, in bone marrow derived 
macrophages after 20 hours of treatment, murine and Trichinella derived MIFs 
modulate two distinct gene groups. Murine-derived MIF modulated transcripts 
associated with the processing and secretion of TNF-α whilst Trichinella-derived 
MIF predominantly modulated genes involved in cell cycle regulation and 
strengthening of cellular architecture.   
Overall, a limited selection of genes were regulated by MIF homologues aside 
from the tautomerase mutant Mm-MIF-1 P2G which appeared to drive significant 
dysregulation of the MIF controlled transcriptome indicating that the tautomerase 
site may be critical for the modulatory actions of MIF.  Despite the small number 
of modulated transcripts, in Mm-MIF-1 treated macrophages, ADAM28, Trp63 
and Rab27b were significantly downregulated.  While these transcripts are not 
considered to be conventional regulators of the TNF-α pathway there is ample 
data to suggest that they are involved in the indirect regulation of TNF-α 
processing for several reasons: (1) knockout of ADAM28 in mice led to a 
significant decrease in secreted TNF-α (Jowett et al., 2012); (2) Trp63 modulated 
NF-kB signalling (Si et al., 2016) and  (3) TNF-a secretion  in Rab27b-/- mice is 
severely dysregulated (Alexander et al., 2017).  Taking this into account, we 
propose that MIF may prime macrophages for a particular response ready upon 
receiving and additional stimulus such as LPS.   This is further evidenced by our 






for 20 hours had significantly increased transcriptional levels of IL-6 when 
assessed by qRT-PCR.  Given that a level of reciprocal regulation exists between 
IL-6 and TNF-α (Lee et al., 2017; Sanceau et al., 1991; Yimin and Kohanawa, 
2006), Mm-MIF-1 may negatively regulate TNF-α at the post-transcriptional level 
subsequently potentiating an IL-6 response to PAMPs such as LPS.  
Furthermore, ADAM28 and Rab27b transcriptional levels increased after 
treatment with Mm-MIF-1 P2G whilst Trp63 is unchanged, which again was 
supported by results in chapter 5 showing that relative levels of IL-6 transcripts 
were not potentiated in macrophages co-incubated with LPS and MIF attesting to 
the idea that the tautomerase site is essential for the regulation of the IL-6/TNF-
α axis in murine bone marrow derived macrophages.  Despite the apparent role 
of the tautomerase site in the regulation of these transcripts in Mm-MIF-1, neither 
Ts-MIF-1 or Ts-MIF-1 P2G mutant treatment significantly modulated ADAM28 or 
Rab27b.  However, the fact that mammalian MIF and Trichinella-derived MIF 
regulate distinct gene groups is a completely novel finding.  As before (in chapter 
5), in macrophages treated with the two Trichinella-derived MIF proteins and LPS, 
there was a negligible increase in transcriptional levels of IL-6 suggesting that the 
tautomerase enzymatic activities may play a more critical role in mediating the 
transcriptional responses of mammalian MIF homologues.  
The data presented in this chapter also demonstrated that all MIF proteins with 
the exception of Mm-MIF-1 P2G significantly downregulated Trp63.  Relatively 
little is known regarding the role of Trp63 in macrophage development, however, 
multiple studies have shown that naturally occurring tumour p53 gain-of-function 
mutants bind the p63 DNA binding domain with high affinity leading to a 






Strano et al., 2002).  Furthermore, under normal circumstances p53 proteins do 
not have the ability to hetero-oligomerize with p63 and this is suspected to be a 
consequence of mutation-driven conformational changes in the DNA binding 
domain of p53 as demonstrated by Gaiddon et al (2001).  Interestingly, 
mammalian MIF has been shown to physically bind with residues 113 – 290 of 
p53 in a co-immunoprecipitation assay. Mutation of mammalian MIF’s cysteine 
81 residue limits its ability to for a complex with p53 (Jung et al., 2008a) thereby 
abrogating its ability to inhibit apoptosis.  Conversely, MIF has also been shown 
to stabilise responses to DNA damage as in murine p53-/- MIF-/- models there is 
increased proliferation of lymphoma cells when compared to p53-/- mice, 
indicating that MIF may also play a protective role in cell cycle check point 
process (Nemajerova et al., 2007).  Our data, taken in concert with the evidence 
provided above suggests that MIF may indirectly downregulate p63 as a 
consequence of p53 binding.  Additionally, we propose that the mechanism of 
p63 regulation may be a result of MIF inducing a conformational change within 
the DNA binding domain of p53 leading to sequestration of p63 and 
transcriptional inhibition, however, future work looking at utilising co-
immunoprecipitation techniques to study protein interactions would be required 
to confirm this.  Moreover, the data from these RNA sequencing results suggest 
the possibility that the oxidoreductase site may be required for mammalian MIF 
p53 regulation, which is not conserved in Trichinella-derived MIF’s.    
Further confirmation of p53 modulation was found in the large number of 
Trichinella-derived-MIF modulated transcripts that play a key role in cell cycle 
regulation and cellular architecture including BMP3, BMP7, Hhip, IGFbp2, Cldn8 






of p53.  With the exclusion of Hhip, none of the other aforementioned transcripts 
were affected by Mm-MIF-1 suggesting that the modulation of widespread 
macrophage cell cycle pathways is exclusive to Trichinella-derived MIF.  Several 
previous studies have assessed the role of parasite derived MIF proteins on p53 
activation as earlier research using mammalian MIF’s evidenced that p53 could 
be inhibited in the presence of MIF proteins.  Despite a study by Jung et al (2008) 
noting that the physical interaction of p53 and  MIF is abolished by the substitution 
of cysteine 81 to serine, there is likely to be a more complex mechanism of p53 
modulation. This most likely involves the MIF receptor CD74 and the interaction 
between MIF and Jab1 and we show here that Ts-MIF-1 and Ts-MIF-1 P2G, both 
of which lack any cysteine residues, also downregulate Trp63. 
The differences between Mm-MIF-1 and Ts-MIF-1 mediated transcriptional 
regulation may be a result of differences in the way the two homologues bind 
receptors and transduce signals.   Mammalian MIF’s have previously been shown 
to bind with high affinity to the canonical MIF receptor CD74 (Leng et al., 2003; 
Shi et al., 2006b), in addition to, undergoing endocytosis and colocalising with 
the intracellular protein, Jab1, leading to Jab1/AP1 inhibition (R. Kleemann et al., 
2000a).  Studies investigating MIF/Jab1 binding using a short peptide that 
competed with full length MIF, have revealed that region spanning aa 50 – 65, 
which encompasses the CXXC motif, is critical for efficient colocalization with 
Jab1 (R. Kleemann et al., 2000a; Nguyen et al., 2003).  Despite the results of 
several conflicting studies which attempt to establish if the cysteine residues are 
essential for binding, it is clear that most parasite derived MIF’s that are also able 
to bind Jab1 contain some cysteine residues.  Plasmodium MIF represses AP-1 






residue at amino acid 59 (Augustijn et al., 2007).  Additionally, MIF derived from 
Anisakis simplex binds human Jab1 with high affinity, however, irrespective of the 
fact that As-MIF has a cysteine at amino acid 58, substitutions K91A and G111A 
disrupted the MIF/Jab1 interaction significantly (Park et al., 2017).    With this in 
mind, we propose that if Ts-MIF-1 and Ts-MIF-1 P2G are unable to bind Jab1 this 
would lead to the observed differences in gene expression.   
Future work should focus on identifying differences in p53 and Jab/1 binding 
between mammalian and T. spiralis derived MIFs and tautomerase deficient MIF 
proteins, encompassing the murine oxidoreductase mutants generated in this 
study.  Identifying MIF’s specific binding residues may enhance the previous 
knowledge surrounding MIF’s role in tumorigenesis and provide additional insight 
into therapeutic targets.  This, combined with shRNA knockout of endogenous 
MIF or deletion of enzymatic sites within endogenously expressed MIF using 
CRISPR-Cas9 editing techniques, could be utilised to characterise phenotypes 






Chapter 7:  Assessment of MIF’s role in the intestinal immune 
response in an ex vivo colonic explant model. 
7.1.  MIF and the intestinal immune response. 
MIF is a critical modulator of innate and adaptive immune responses and is 
ubiquitously expressed within the small intestinal and colonic epithelium of 
humans and mice (Maaser et al., 2002c; Ohkawara et al., 2005; Yao et al., 2005). 
It is has been shown to positively regulate innate immune responses to bacterial 
antigens such as the endotoxin, LPS; peritoneal macrophages isolated from MIF-
/- mice are hyporesponsive to LPS stimulation as a result of reduced TLR-4 cell 
surface expression (Roger, 2001; Roger et al., 2003a).  Within the intestine MIF 
regulates antigen-sampling through specialised M-cells located within the 
epithelium (Man et al., 2008c).  Additionally, the canonical  MIF receptor, CD74, 
is highly expressed in colonic epithelial cells and promotes cell survival by 
inhibiting apoptosis and increasing cell viability when assessed by Annexin and 
Propidium Iodide (Maharshak et al., 2010b).  
Besides this, several studies have elucidated a role for MIF in the pathogenesis 
of IBD and intestinal tumorigenesis.  In these environments MIF is responsible 
for driving production of pro-inflammatory cytokines such TNF-α and IFN-γ 
(Ohkawara et al., 2002, 2005, 2008). Antibody based blockade of MIF activity 
reduces the production of these cytokines.  Additionally, G > C polymorphisms in 
the MIF promoter region at location -173 are strongly associated with IBD as 
revealed by several meta-analytic studies (Hao et al., 2013; Illescas et al., 2018).  
In relation to MIF’s potential tumorigenic properties,  patients with colorectal 
cancers have increased serum MIF levels which correlates with disease severity 






Recently, MIF has been implicated in the modulation of cytokines essential for 
maintaining barrier function such as IL-6, IL-22, TNF-α and IL-17, however, even 
though these cytokines are involved in preserving the intricate balance of 
intestinal homeostasis, disorders and cancer progression, as of yet, studies 
which examine the interplay between MIF, IL-6, IL-22 and IL-17 are lacking.  
 In this study, we investigated the role of MIF on LPS-mediated intestinal 
inflammation by analysing both the transcriptional responses and release of the 
cytokine’s TNF-α, IL-6, IL-22 and IL-17.  The significance of these key cytokines 
to this study is discussed individually in detail below. 
7.1.1.  IL-6 
IL-6 is an essential cytokine in intestinal immunology with particular importance 
in epithelial integrity. In humans, IL- 6 is increased in the serum of IBD patients 
(Aderka et al., 1989; Gross et al., 1992) and blockade of the IL-6 receptor has 
been shown to reduce the clinical symptoms of Crohn’s disease (Danese et al., 
2019; Ito et al., 2004). Studies utilising DSS - induced colitis models in mice have 
demonstrated that IL-6 is increased in both serum and tissue, and has a 
proliferative effect on colonic epithelial cells (Lee et al., 2012) which is not 
unexpected as it has been previously reported to increase the growth and survival 
of colitis - associated colonic tumours by upregulating survival factors such as 
Bcl-2 (Grivennikov et al., 2009). Interestingly, while mice deficient in IL-6 are 
protected from tumorigenesis they show increased susceptibility to DSS-induced 
colitis. This indicates that, like many cytokines, the context within which it is 
present determines the outcome.   
IL-6 is a prerequisite for protection against Citrobacter rodentium (Dann et al., 






2003), which are all enteric pathogens.  IL-6 has been shown to be critical for the 
development of pathogenic and regulatory Th17+ cells by inducing expression of 
IL-21 (Bettelli et al., 2006; Voo et al., 2009; Zhou et al., 2007), and the 
development of Th22 cells within the GT (Basu et al., 2012). In addition, studies 
investigating crosstalk of IL-6 with other cytokines discovered that IL-6 acts 
synergistically with IL-17 to promote viral longevity, by diminishing apoptosis, in 
Theiler’s Murine Encephalomyelitis (Hou et al., 2014).     
MIF has long been recognised as a crucial cytokine for the initiation and 
promotion of pro-inflammatory responses. It has been shown to activate the 
MAPK pathway and via this pathway act in both autocrine and paracrine fashions 
to upregulate additional immunomodulatory cytokines such as IL-6 (Chuang et 
al., 2010b; Kudrin et al., 2006; Lang et al., 2018; Piddock et al., 2015).  
7.1.2.  IL-17 
IL-17 is a recently discovered cytokine and has emerged as a key player in 
intestinal immune responses.  Structurally, IL-17 lacks homology to other known 
cytokines, however, a study by Hymowitz et al (2001) found that the IL-17 protein 
structure contains a cysteine knot also found in morphogens, TGF-β and BMP, 
providing a clue as to the regulatory mechanisms of IL-17.   Several cell types 
within the mucosal environment express IL-17 including pathogenic Th17+ cells, 
FOXP3+ Th17+ regulatory T cells, Innate lymphoid cells and γδ T cells.  IL-23 
independent IL-17 production by γδ T cells has been shown to be  critical for early 
resolution of inflammation (Lee et al., 2015) while IL-17+ regulatory T cells are 
increased in the mucosa during colitis and within the colonic tumour niche in mice 
(Kryczek et al., 2011).  Moreover, in an Abcb1a-/- multidrug resistant murine 






IL-17R exacerbated the symptoms of colitis by increasing epithelial permeability 
causing a corresponding increase in mortality indicating that IL-17 is essential for 
upkeep of epithelial integrity (Maxwell et al., 2015).  On a transcriptional level, IL-
17 has been shown to inhibit expression of chemokines associated with 
recruitment of Th1 cells while simultaneously upregulating expression of 
chemokines which are responsible for recruiting neutrophils such as CXCL1 and 
CXCL8 (Lee et al., 2008) by stabilising the mRNA of these transcripts via the 
cytosolic adaptor protein Act1 (Song and Qian, 2013). 
A notable finding is, MIF may regulate the Th17 response; this is demonstrated 
in a study by Stojanovic et al (2012) who show that lymph node cells from MIF-/- 
mice lack the ability to produce IL-17 when compared to their WT counterparts.  
Additionally, MIF is directly responsible for the recruitment of tumour associated 
Th17 cells in nasopharyngeal cancers. However, MIF-driven IL-17 cells are 
associated with an increase in positive clinical outcomes (Li et al., 2012).  Within 
this context of this research study, a significant finding is that the number of Th17 
cells increase significantly in mice infected with the parasitic nematode T.spiralis 
and this is associated with intestinal hypermotility and an increase in worm 
expulsion (Fu et al., 2009a, 2009b; Steel et al., 2019).  Conversely, studies 
utilising mice with DSS-induced colitis noted that infiltrates of Th17 and IL-17 are 
reduced in the presence of excretory/secretory products from T.spiralis (Yang et 
al., 2014).  However, the exact composition of excretory/secretory products from 
T.spiralis that mediate this activity have not yet been characterised.  
7.1.3.  IL-22   
For some time, IL-22, an IL-10 family cytokine, has been recognised as a key 






expressed in the small intestine to prevent pathogen colonisation, within the colon 
it is expressed only during inflammatory conditions such as IBD (Andoh et al., 
2005; Cella et al., 2009; Sanos et al., 2009).  Like many cytokines, IL-22 may 
play opposing roles depending on the context in which it is expressed.  For 
example, it has long been known that IL-22 plays a central role in the 
pathogenesis of psoriasis (Ma et al., 2008) and collagen-induced arthritis 
(Geboes et al., 2009), however, recent advances have shown that IL-22 may play 
a protective role in the GT.  In one such study, the genetic transfer of IL-22 into 
mice was shown to diminish symptoms of DSS-induced colitis (Sugimoto et al., 
2008) and studies examining potential gene mutations in IBD have identified IL-
22 as a strongly associated candidate (Silverberg et al., 2009). Though IL-22 is 
produced by numerous immune cells one of the major producers are Th17 and 
Th22 cells within the mucosa.  Expression of IL-22 is predominantly driven by IL-
6 and repressed by TGF-β (Zheng et al., 2006). It is essential for epithelial cell 
regeneration after damage and within the intestine the IL-22 receptor (IL-22R1) 
is exclusively expressed by epithelial cells (Wolk et al., 2004).     
Though a number of investigations have revealed a role for MIF in IL-17 
associated immune responses, one single study has revealed a link between MIF 
and IL-22 by utilising a MIF knockout model which failed to upregulate IL-22 in 
response to infection with Toxoplasma gondii (Cavalcanti et al., 2011b) 
demonstrating that MIF may be a requirement for IL-22 signalling in response to 
infection. 
7.1.4.  TNF-α 
TNF-α is a classical pro-inflammatory cytokine first isolated in 1984 from 






signalling pathway (Hayden and Ghosh, 2014) implicated in countless immune 
disorders and cancers. 
Within the intestine, TNF-α via NF-kB increases tight junction permeability by 
activation of the myosin light chain kinase gene (MLCK3) (Al-Sadi et al., 2016), it 
is involved in modulating the levels of mucins transcriptionally, by abrogating 
MUC2 expression (McElroy et al., 2011), and post-translationally, increasing 
sulphation of secreted mucins which acts to prevent the breakdown of the mucus 
layer by bacterial enzymes (Arnold et al., 1993; Raouf et al., 1992).  In a TNF-α 
knock-in mouse model, whereby TNF-α is overexpressed, mice spontaneously 
develop Crohn’s disease (Leppkes et al., 2014).  
Like MIF, the active, stable confirmation of TNF-α is a trimeric protein with a 
central channel.  A relationship between MIF and TNF-α has long been 
established with studies showing that exogenously administered TNF-α rapidly 
induces MIF expression (Cao et al., 2006; Hirokawa et al., 1997) and, likewise, 
MIF stimulates TNF-α secretion (ref).  Amaral et al (2007) utilised MIF-/- mice to 
reveal that MIF is responsible for the TNF-α production in response to damage to 
heart muscle in ischemia and reperfusion injury.  However, the same study 
showed that there was no difference in intestinal reperfusion-associated 
neutrophil infiltration between WT and MIF-/- mice indicating that MIF may act 
selectively in certain types of injury.  In addition to this, Coeliac patients have 
significantly increased levels of MIF and TNF-α when compared to their healthy 
matched controls (O’Keeffe et al., 2001).  Although a number of immune cells 
produce TNF-α, such as pathogenic Th17 cells (Kempski et al., 2017; Wang et 
al., 2013), a key point to consider for the purposes of this study is that IEC’s are 






TNF-α along with IL-6, are required for the development of Th22 cells (Trifari et 
al., 2009). 
In an infection model with T. gondii, TNF-α levels are greatly reduced in  MIF-/- 
knock out mice (Ruiz-Rosado et al., 2016).  Conversely, MIF isolated from B. 
malayi induced the production of alternatively activated macrophages in the 
presence of IL-4 and TNF-α indicating that, MIF and TNF-α may in some 
circumstances have a role in the resolution phase of inflammation (Prieto-
Lafuente et al., 2009b). 
7.1.6. Ex vivo models 
To date, studies examining intestinal immune responses have relied heavily on 
the use of transformed cell lines (Kaur and Dufour, 2012), however, although they 
are considered to be economical and ethical these are not without drawbacks, 
particularly in the case of colon adenocarcinoma cell lines such as Caco-2 and 
HT-29, as these cells are prone to spontaneous differentiation and mutations 
which cause them to behave in ways that are different from normal colonic 
epithelial cells (Pearce et al., 2018).  On the other hand, in vivo studies are often 
expensive, time-consuming and unsuitable for screening purposes.  A solution to 
the aforementioned issues are to utilise ex-vivo intestinal tissue as studies have 
indicated that tissue biopsies retain the inherent heterogenicity associated with 
mucosal surfaces and that cellular permeability is successfully preserved (Nunes 
et al., 2015; Pearce et al., 2018).  In this study, the use of an intestinal explant 
model was employed as this has previously shown considerable success in the 
lab and has been successfully utilised to study drug absorption (Bareiss et al., 






at mucosal sites (Fábrega et al., 2016, 2017) and cytokine responses in disease 
models such as IBD (Garrido-Mesa et al., 2019; Powell et al., 2012, 2015).      
7.2. Chapter aims and objectives.  
To assess how MIF can modulate intestinal immune responses to an archetypical 
PAMP LPS, including whether MIF affects the Th17 cytokine milieu by regulating 
IL-6, IL-17, IL-22 and TNF-α, the following aims were suggested: 
1. Assess whole tissue transcriptional changes in colonic explants via qPCR, 
to determine how IL-6, IL-17 and IL-22 are affected after exposure to LPS and/or 
MIF homologues. 
2. Assess changes in IL-6, IL-22 and TNF-α, secreted into the media by 
explant cultures after exposure LPS and/or MIF homologues, utilising ELISA. 
3. Compare and contrast the activities of murine and parasite derived MIF 
homologues in these assays along with mutant (P2G) MIF recombinants lacking 
the tautomerase activity.   
 
7.3. MIF modulates the expression of IL-6, IL-17 and IL-22 transcripts in ex 
vivo intestinal explants. 
MIF has been shown previously to be a critical modulator of immune responses 
and is expressed widely within the GT.  To date, numerous studies have 
demonstrated that murine MIF knock out models have dysregulated levels of IL-
6, IL-17 and Il-22 (Gomes et al., 2018; Stojanović et al., 2009), despite this, no 
study has investigated the role of exogenous MIF proteins on these cytokines 
within the context of responses to bacterial endotoxin, LPS.   This investigation 
assessed MIF’s capacity to regulate the transcriptional responses of key 






22.  As discussed in chapter 4, the concentrations of LPS and MIF used in 
experiments utilising cell lines, primary cells and tissue are most biologically 
relevant between 10ng/mL – 100ng/mL.  Accordingly, in intestinal explants, 
100ng/mL of LPS and recombinant MIF homologues were used and from here 
on any reference to LPS and MIF will denote these concentrations. 
 To assess the differential expression patterns of IL-6, IL-17 and IL-22 in 
response to MIF, explants were cultured, for 20 hours, in the presence of LPS +/-
recombinant MIFs.  Subsequently, biopsies were removed, and RNA extraction 
optimised using a Trizol/Chloroform protocol (appendix figure A.5) in preparation 
for qPCR.  Initial experiments focused on ensuring the qPCR efficiency for each 
primer set was between 1.9 – 2.1. 
Figure 7.1 shows that IL-6 transcripts increase in intestinal tissue cultured in the 
presence of LPS and Mm-MIF-1 or Mm-MIF-1 P2G but not LPS alone indicating 
that MIF may be acting cooperatively with LPS or a component of the LPS 
signalling pathway to modulate IL-6 transcription.  Ts-MIF-1 also increases the 
expression levels of IL-6 in the presence of LPS while, interestingly, Ts-MIF-1 
P2G co-incubated with LPS lacks the ability to augment IL-6 transcription.  It is 
worth considering that although these are key trends to consider, there is no 
statistical significance.  Unexpectedly, the levels of IL-6 transcript in colonic 
explants failed to increase in response to LPS alone, however, studies which 
depict an increase in IL-6 transcription in response to LPS frequently use LPS 
concentrations in the range of 1µg/ml.  Furthermore, due to the baso-lateral 
location and orientation of TLR-4 receptors within the intestine, LPS can only 
activate the TLR-4 pathway when barrier integrity is compromised, in this case, it 






hand, MIF may comprise barrier function thereby allowing LPS to enter the 
mucosal layer and activate TLR-4.  
 
Figure 7. 1 MIF homologues modulate the transcriptional responses of IL- 
6 in an ex vivo explant model.  The graphs above show the qPCR analysis of 
intestinal explant tissue in response to 100ng/ml LPS +/- 100ng/ml MIF.  The data 
represents the mean ±SEM (n=4) of the fold change.   Changes in gene 
expression were assessed utilising the Pfaffl equation prior to statistical testing 








In contrast, IL-17 expression was upregulated in LPS treated samples and this 
was then significantly reduced (p≤0.05) in tissues cultured with LPS and Mm-
MIF-1 (figure 7.2A) or Ts-MIF-1 (figure 7.2B) and, whereas Mm-MIF-1 P2G also 
significantly decreased IL-6 transcripts (p≤0.05), Ts-MIF-1 P2G, though reduced 
had no significance.  Despite initially postulating that LPS and MIF may be 
increasing IL-6 levels and inhibiting the transcription of IL-17, there is the distinct 
possibility that the increase in IL-6 transcript in the tissue is responsible for 
impeding the transcription of IL-17 (or vice versa).  Furthermore, the regulation of 









Figure 7. 2 MIF homologues supress LPS induced IL-17 transcription in an 
ex vivo explant model.  The graphs above show the qPCR analysis of intestinal 
explant tissue in response to 100ng/ml LPS +/- 100ng/ml MIF.  The data 
represents the mean ±SEM (n=4) of the fold change.   Changes in gene 
expression were assessed utilising the Pfaffl equation prior to statistical testing.  
(*) p-value ≤ 0.05, as determined by a one-way ANOVA with Dunnett’s 
corrections for multiple comparisons.  
 
Bearing this is mind, it was hypothesised that MIF and LPS may be acting in 
concert to modify the behaviour of Th17 or potentially Th22 associated cytokines, 
therefore, it was decided that assessing the differential expression of IL-22 was 
vital. Figure 7.3 illustrates that explants cultured with LPS and Mm-MIF-1 or Ts-
MIF-1 had significantly decreased transcript levels (p≤0.05) when compared to 
LPS alone.  Remarkably, in tissues incubated solely with Mm-MIF-1 there was a 
significant increase in expression of IL-22 (p≤0.01) when compared to the control.  
IL-22 induces pro-inflammatory IL-18 in IECs which in turn drives Th1 responses 










Figure 7. 3  MIFs homologues supress LPS induced IL-22 transcription in 
an ex vivo colonic explant model.  The graphs above show the qPCR analysis 
of intestinal explant tissue in response to 100ng/ml LPS +/- 100ng/ml MIF.  The 
data represents the mean ±SEM (n=4) of the fold change.   All values were 
assessed utilising the Pfaffl equation prior to statistical testing.  (*) p-value ≤ 0.05, 
(**) p-value ≤ 0.01 as determined by a one-way ANOVA with Dunnett’s 







7.4.  MIF treatment skews Th17 cytokines in response to LPS-mediated 
signalling. 
To confirm if the previously observed transcriptional responses were also 
affecting levels of secretion of these cytokines, a series of ELISA assays were 
employed.   Early experiments focussed on assessing the secreted levels of IL-6 
and IL-22 within the explant culture media.   Unfortunately, the results obtained 
from the ELISA assays conflicted with our previous qPCR results.  Figure 7.4. 
shows the levels of secreted IL-6 and IL-22 in response to LPS +/- MIF.  In terms 
of IL-6, though there was a minimal decrease in samples incubated with LPS and 
Mm-MIF-1 or Ts-MIF-1, none were statistically significant.  Notably, Ts-MIF-1 
P2G alone significantly reduced (p≤0.05) the levels of IL-6 secreted protein in 
explant supernatants when compared to the control. 
IL-22 protein quantities slightly decreased in samples with LPS alone which is 
contradictory to earlier results with an increase in transcriptional levels (figure 7.3 
vs 7.4).  In samples co-incubated with LPS and Mm-MIF-1 there was a small 
increase in IL-22, however, Mm-MIF-1 P2G significantly increased IL-22 in 
response to LPS (p≤0.05).  Conversely, though LPS and Ts-MIF-1 cultures had 
slightly increased levels of IL-22, LPS and Ts-MIF-1 P2G decreased when 
compared to LPS alone, and, explants cultured in the presence of Ts-MIF-1 P2G 
alone did not have the ability to reduce IL-22 suggesting that the tautomerase 
activities of Mm-MIF-1 and Ts-MIF-1 may be modulating IL-22 responses via LPS 











Figure 7. 4 MIFs modulate secretion of the cytokines IL-6 and IL-22.  The 
graphs above show the secreted cytokine (pg/ml) levels of IL-6 and IL-22 within 
intestinal explant supernatants in response to 100ng/ml LPS +/- 100ng/ml MIF.  
The data represents the mean ±SEM (n=3) of the fold change. (*) p-value ≤ 0.05, 
as determined by a one-way ANOVA with Dunnett’s corrections for multiple 
comparisons 
 
As TNF-α is a key cytokine responsible for driving the polarisation of T0 cells to 
Th22 cells and is chiefly produced by epithelial cells in the GT, it was vital to 
assess the secreted levels in response to LPS and/or MIF as earlier 
transcriptional results suggested that LPS and MIF may act synergistically to 
promote the development of a particular immune cell subset .  Surprisingly, Mm-
MIF-1 and Ts-MIF-1 appear to have contrasting effects when co-incubated with 
LPS; LPS and Mm-MIF-1 had reduced TNF-α levels when compared to LPS 
alone whereas secreted levels of TNF-α increased in the presence of LPS and 
Ts-MIF-1 suggesting that these two homologues contain a structural feature 
which explains the variances.  In addition, despite the fact that LPS and Mm-MIF-
1 P2G reduced TNF-α quantities to the same level as LPS and Mm-MIF-1, 
suggesting that the enzymatic activities of Mm-MIF-1 are not responsible for TNF-
α modulation, the absolute amounts of TNF-α in response to LPS and Ts-MIF-1 
P2G, which were decreased when compared to LPS alone,  were in direct 
contradiction to  results for LPS and Ts-MIF-1 which had greatly increased levels 








Figure 7. 5 MIFs modulate the secretion of TNF-α.  The graphs above show 
the secreted cytokine (pg/ml) levels of TNF-α within intestinal explant 
supernatants in response to 100ng/ml LPS +/- 100ng/ml MIF.  The data 
represents the mean ±SEM (n=3) of the fold change. (*) p-value ≤ 0.05, as 








7.5. Discussion of MIF’s role in the intestinal immune response in an ex vivo 
colonic explant model.  
The results of this study illustrate that MIF regulates cytokine production within 
colonic explants indicating a potential role in modulating GT immune responses.  
This is demonstrated at both the transcriptional level and the release of secreted 
protein utilising qPCR and ELISA.   
Examination of the transcriptional responses to murine MIFs show that both Mm-
MIF-1 and Mm-MIF-1 P2G augment IL-6 transcription in response to LPS 
stimulation when compared to the LPS alone, whilst the mRNA levels of IL-17 
significantly decrease within the same sample set eluding to the possibility that 
while MIF may differentially regulate LPS-mediated IL-6 and IL-17, the increase 
in IL-6 may also be responsible for inhibiting IL-17 transcription.  Interestingly, 
samples co-incubated with LPS and Mm-MIF-1 displayed decreased 
transcriptional levels of IL-22 in comparison to LPS alone which, surprisingly, 
induced IL-22 transcription substantially.  Conversely, Mm-MIF-1 P2G lacked the 
capacity to modulate IL-22 transcription which may implicate the tautomerase 
enzyme activity in MIF’s IL-22 modulatory mechanisms.  
In respect of the secreted cytokine response to Mm-MIF-1 and Mm-MIF-1 P2G, 
this study revealed that murine MIF regulated the release of two key intestinal 
cytokines, IL-6 and IL-22 frequently associated with epithelial modulation of 
immune responses.  We showed that Mm-MIF-1 slightly decreased IL-6 secretion 
in samples co-incubated with LPS in comparison to LPS alone which had no 
effect on IL-6 protein levels.   Interestingly, the Mm-MIF-1 decrease in IL-6 was 
also apparent in samples that had not been stimulated with LPS and, in the 






tautomerase-conferring site.  On the other hand, whilst Mm-MIF-1 did not 
modulate IL-22 secreted levels in the presence of LPS, the tautomerase mutant, 
Mm-MIF-1 P2G significantly increased IL-22 secretion in the presence of LPS 
providing crucial insight into MIF’s IL-22 regulatory role.  In addition to IL-6 and 
IL-22, the classical pro-inflammatory cytokine secreted by IEC’s, Th17 and Th22 
cells (Xu et al., 2014), TNF-α, was assessed.  As expected, LPS significantly 
increased TNF-α secretion in colonic explants, however, both Mm-MIF-1 and 
Mm-MIF-1 P2G slightly inhibited this effect within co-cultured samples.  Cytokine 





























Figure 7. 6 Summary of transcriptional and secreted cytokine responses to 
LPS + murine MIF homologues.  Diagram representing murine MIF modulation 
of LPS mediated cytokine expression and cytokine secretion.  Mm-MIF-1 
potentiates the IL-6 transcriptional responses to LPS whilst inhibiting both IL-17 
and IL-22 gene expression.  IL-22 modulation is dependent on MIF’s tautomerase 
activity.  Mm-MIF-1 inhibits IL-6 and TNF-α secretion after LPS treatments of 
explants.  The absence of MIF’s tautomerase conferring Pro2 site leads to 






In terms of T.spiralis-derived MIF’s, Ts-MIF-1 in the presence of LPS, like its 
mammalian equivalent Mm-MIF-1, drove the transcription of IL-6 whilst inhibiting 
both IL-17 and IL-22 transcription.  In contrast, Ts-MIF1-P2G had no effect on the 
transcriptional levels of IL-6 or IL-17 and only minimal inhibitory effects on IL-22 
which may well be an experimental artefact.  Other than the transcriptional data, 
experiments focussed on quantifying absolute protein concentrations of cytokines 
revealed that Ts-MIF homologues inhibit IL-6 secretion in response to LPS whilst 
samples cultured with Ts-MIF-1 P2G alone saw a significant decrease in IL-6 
responses.  Conversely, IL-22 secretion was increased by Ts-MIF-1 both in the 
presence and the absence of LPS and this effect was not maintained with 
substitution of the tautomerase site.  In fact, conversely, IL-22 levels were 
decreased in samples incubated with LPS and Ts-MIF-1 P2G.   A key difference 
between Mm-MIF-1 and Ts-MIF-1 was the observation that Ts-MIF-1 enhanced 
LPS mediated TNF-α secretion while Mm-MIF-1 inhibited this result somewhat.  
Neither Ts-MIF-1 or Ts-MIF-1 P2G played a role in the secretion of TNF-α when 
cultured without an additional stimulus. Cytokine responses to T. spiralis-derived 

























Figure 7. 7 Summary of transcriptional and secreted cytokine responses to 
LPS + T. spiralis MIF homologues.  Diagram representing T. spiralis-derived 
MIF modulation of LPS mediated cytokine expression and cytokine secretion.  Ts-
MIF-1 potentiation of the IL-6 transcriptional responses to LPS is dependent on 
MIF’s tautomerase activity.  Ts-MIF-1 inhibits the LPS driven secretion of IL-6 
whilst increasing secreted IL-22 and TNF-α both of which are highly dependent 






Countless previous studies have attempted to characterise the immune response 
to MIF and, in particular, which domains confer MIF’s mechanisms of actions. 
The assessment of cytokine responses to WT and tautomerase-null MIFs in this 
study is a novel investigation and demonstrates that the tautomerase activity of 
MIF may be responsible, in part, for the both transcriptomic and post-translation 
modulation of IL-6, IL-17, IL-22 and TNF-α.  Here we show entirely original data 
evidencing that MIF’s previously uncharacterised tautomerase activities are 
critical for murine MIF to transcriptionally regulate cytokines IL-17 and IL-22 
whilst, on the contrary, the tautomerase site of Ts-MIF-1 appeared redundant in 
this context.  Despite this, IL-6 transcriptional regulation by Ts-MIF-1 was 
dependent on the presence of the tautomerase-conferring Pro2.  In respect of 
secreted cytokine levels, interestingly, the tautomerase site of Mm-MIF-1 
appeared to play a substantial role in the regulation of IL-22, a critical mediator 
of intestinal epithelial immunity.  Conversely, Ts-MIF-1-mediated modulation of 
IL-6, IL-22 and TNF-α all relied on the presence of Pro2 and the related enzyme 
activity.  Several disparities between the two WT homologues and the Pro2 
mutants exist including the lack of an oxidoreductase site within the protein 
sequence of Trichinella-derived MIF’s and the fact that the tautomerase activity 
of Ts-MIF-1 is 6-fold greater than its mammalian counterpart in previously 
published works (Tan et al., 2001) and 2.5-fold lower than the murine MIF purified 
and kinetically characterised in this study. 
Though the results indicate that the tautomerase activity is required for cytokine 
modulation, what remains unknown is precisely where the tautomerase is 
interacting as it may be interacting with a component of the TLR-4 signalling 
pathway in an undiscovered mechanism.  Further work will be required to 






pathway.  One possible explanation for this is that Mm-MIF-1 and Ts-MIF-1 target 
different parts of the NF-kB pathway. Several recent studies have suggested that 
non-classical TLR signalling, in which the YxxM PI3K binding motif is activated, 
leads to bypassing of the NF-kB complex and activation of CREB resulting in a 
response characterised by high IL-22 levels (Lutay et al., 2014).  Archetypal TLR 
signalling which results in NF-kB activation promotes the transcription of 
inflammatory cytokines such as IL-6 and TNF-α.  With this in mind, we propose 
that Mm-MIF-1 and Ts-MIF-1 transduce signals via different receptors, for 
example, while several studies have shown that mammalian MIF’s can bind both 
the transmembrane receptor, CD74 and intracellular receptor, Jab1, to date the 
binding capabilities of Ts-MIF-1 is unknown.  
In terms of speculating which cells may be responding to MIF, the experiments 
within this study do not allow for direct extrapolations as the explant tissue 
encompasses an incredibly heterogenous and variable population of cells.  
Nevertheless, the data provided here alludes to the prospect that T. spiralis may 
utilise Ts-MIF-1, along with LPS, to drive the development of an Th22 or ILC3 
population, both characterised by IL-6- IL-22+ TNF-α+ (Glatzer et al., 2013; Killig 
et al., 2014; Parks et al., 2016) in order to decrease intestinal expulsion by 
suppressing Th2-related ILC2 responses (Garrido-Mesa et al., 2019; Neill et al., 
2010).  In contrast, Mm-MIF-1 in this study, limits the secretion of all analysed 
cytokines in response to LPS-mediated TLR-4 signalling.  Once again, this 
reiterates an earlier proposal that Ts-MIF-1 and Mm-MIF-1 have distinct 
mechanisms of action.   Future studies, including the isolation of specific colonic 
cells such as epithelial cells or ILC’s, will be required in order to characterise the 
expression of associated transcription factors such as T-bet, ROR-γt, GATA-3 






assessment of additional factors like the well-characterised morphogen, TGF-β, 
may help to determine whether this molecule polarises cells to subsets that are 
pathogenic or regulatory.  Finally, endogenous MIF is essential for the production 
of key Th17, Th22 and ILC3 associated cytokines as shown by studies which 
report that mice lacking a functional MIF gene (Lang et al., 2018; Stojanović et 
al., 2009) or where MIF silencing by siRNA treatment (Li et al., 2012) have 
severely impaired production of IL-17, IL-22 and TNF-α.  Therefore, future studies 
should explore the actions of exogenous MIFs, including the tautomerase-
deficient mutants, on cells lacking the confounding influence of endogenous MIF. 
There are numerous limitations to the results found in this study including 
discrepancies between transcriptional data and absolute cytokine protein 
concentration, however, this is not uncommon and there are several possible 
reasons for this as discussed in a study by Greenbaum et al (2003).  Firstly, the 
cellular environment is responsible for maintaining the levels of translation by 
post-translationally modifying transcripts; many mRNAs will be held within the 
ribosome and prevented from translation.  Secondly, factors affecting protein 
stability such as the protein half-life, rate of turnover and degradation influence 
the final protein concentration to varying degrees.  In addition to this are issues 
surrounding what the methodologies represent; generally, assessing mRNA 
levels is correlative while quantifying absolute protein concentrations is 
causative.  Furthermore, both qPCR and ELISA measure steady state levels and 
therefore do not reflect translation efficiency and protein stability.  In addition to 
the limitations in terms of protein dynamics described above, a further potential 
reason for variation in protein levels of cytokines is the lack of cell surface, aside 
from the basal section and the epithelia, retaining the capacity to secrete 






Importantly, there are several other caveats to this study.  Namely, that studies 
examining the cell viability dynamics of ex vivo colonic explant tissue are less well 
established and further work using explants will need to implement a time course 
to assess whether there are differences in responses to MIF and LPS.  However, 
ideally future studies should initially focus on replicating this study utilising 
isolated primary intestinal epithelial cells and intestinal innate immune cells.  
Following this, MIF homologues and the associated P2G mutants should be 
assessed within an in vivo murine model of intestinal inflammation such as DSS-
induced colitis in WT and tautomerase-null MIF mice.  
In summary, the work described within this study has provided novel insight into 
MIF’s potential role in directing intestinal immune responses in the context of 
classical TLR-4 activation, also revealing critical differences between WT MIFs 






Chapter 8:  General Discussion 
8.1 Discussion  
The rationale for this PhD study was to investigate the role of MIF proteins in 
driving intestinal immune responses, focussing specifically on intestinal epithelial 
cells and the phagocytic antigen presenting cells, macrophages.   Generation of 
enzymatically active recombinant MIF proteins, in addition to, mutant MIF 
proteins that lack the critical but functionally elusive tautomerase domain formed 
a vital part of this body of work as initial analysis of commercially available 
recombinant MIF’s revealed the complete absence of the conserved tautomerase 
activity associated with all known MIF homologues.  An additional aim of this work 
was to further characterise the activities of Trichinella spiralis derived MIF 
homologues, Ts-MIF-1 and Ts-MIF-2, one of which (Ts-MIF-2) has not been 
previously described (isolated by D.B Guilliano, unpublished).  
An examination of MIF’s ability to modulate key immune regulatory complexes, 
such as NF-kB, within epithelial cell lines was undertaken to determine whether 
MIF might influence NF-kB signalling in this important cell type. The role of MIF’s 
tautomerase activities play in this process and whether it was significant in 
epithelial immune regulation in the context of TLR4 activation was also examined.  
Additionally, in order to determine the molecular profile of the intestinal 
environment and macrophage populations in the presence of MIF and mutant 
MIF homologues, several key experiments analysing either specific cytokine 
transcripts or whole transcriptome profiling, were performed.    
In Chapter 3 the successful expression and isolation of soluble protein for all MIF 
homologues allowed for the enzymatic analysis of the recombinant MIF proteins 






E.coli expression systems for the production of recombinant MIF’s had 
encountered limitations due to difficulties in removing residual endotoxin 
contamination (Bernhagen et al., 1994; Thierry Calandra et al., 1995b).  Here, we 
establish a protocol that allows for isolation of a variety of recombinant MIF 
homologues and mutants from E.coli which, after IMAC and anion exchange 
chromatography based polishing, reduces endotoxin contamination to virtually 
undetectable levels.  Additionally, protocols were developed for expression and 
purification active and soluble recombinants of several MIF homologues and 
mutants that are renowned for mis-folding, including the oxidoreductase mutant 
Hs-MIF-1 C57S/C60S, human and murine DDT-1/MIF-2 proteins, and the novel 
parasite derived MIF, Ts-MIF-2. This eliminated requirements for timely, 
unstandardizable and error-prone misfolding techniques to be used for 
production of these proteins (Kleemann et al., 1999b; Merk et al., 2011b).  
Furthermore, we confirmed previous studies (Jung et al., 2008b; Kleemann et al., 
1999b; Robert Kleemann et al., 2000b; Tan et al., 2001), demonstrating that 
active and properly folded MIF proteins contain two catalytic domains conferring 
tautomerase activity with additional oxidoreductase activity in mammalian MIF 
homologues.  Despite this, we noted that the tautomerase activity of the Ts-MIF-
1 produced using our protocols was two-fold lower than previously published (Tan 
et al., 2001) although this may be ascribed to alternative reaction buffers and 
varying substrate concentrations.  Notably, the work contained within these 
studies is the first of its kind to characterise the enzyme activities of a novel T. 
spiralis derived MIF homologue (MIF-2), that we demonstrate, resembles the 







Loss of epithelial integrity within the mucosal barrier is commonly associated with 
intestinal disorders including IBD and infections such as diverticulitis.  A distinct 
feature of loss of barrier integrity is the infiltration of luminal antigens or PAMPs 
such as LPS resulting in epithelial PRR activation.  MIF is expressed and 
secreted from cells of the GT during tumorigenesis and intestinal infections and 
several previous studies have suggested that MIF may play a role in the 
regulation of LPS mediated TLR4 signalling modulating innate immune 
responses.  The data presented in Chapter 4 demonstrates that, in HEK 293 and 
HT29 cells, while some MIF homologues appear to be capable of inhibiting or 
potentiating TLR4 signalling, this is largely dependent on both the cell line and 
the experimental system used.  In the HEK-Blue™ hTLR-4 reporter assay we 
saw limited evidence of human and murine MIFs inhibiting TLR4 signalling.  
However, this was not consistent between the assay systems tested and when 
MIF’s were tested in response to LPS in our generated HEK hTLR4-NF-kB-
mCherry reporter line, though preliminary, we demonstrated that MIF caused a 
decrease in NF-kB activation.  Interestingly, MIF recombinants could when 
administered on the own cause some level of NF-kB activation in HEK-hTLR4-
NF-kB-mCherry reporter in indicating MIF may inhibit secretion alkaline 
phosphatase HEK-Blue™ hTLR-4 reporter cells independent of LPS-mediated 
TLR4 stimulation.   
In the colonic epithelial cell line, HT29, initial results indicated that they were 
unresponsive to LPS even at large concentrations.  In line with one study 
suggesting that priming of HT29 cells with IFN-γ induced LPS responsiveness by 
upregulating transcripts for TLR4, MD2 and CD14 (Suzuki et al., 2003b), we 
confirmed that HT-29 cells gain LPS responsiveness after 12 hours of IFN-γ 






LPS-mediated NF-kB activation.  This may be linked to observations that IFN-γ 
induces the canonical MIF receptor, CD74, which might enhance any effect it has 
on NF-kB activation.  
Within the intestinal environment, the mucosal barrier is modulated by several 
key cytokines that exert protective effects on the epithelial cells that line the GT.  
Although the cytokine network within the GT is incredibly complex and 
intertwined, those such as IL-6, IL-17, IL-22 and TNF-a play a significant part in 
maintaining barrier homeostasis, both in healthy and diseased tissue states, by 
increasing the expression of antimicrobial peptides, mucins and, modulating 
epithelial tight junctions to prevent further infiltration of luminal antigens. To date, 
very little is known regarding the role MIF plays in regulating barrier maintenance 
despite the fact that it is highly expressed in epithelial cells at mucosal sites.  With 
this in mind, transcriptional and secreted analysis of key immune-modulating 
cytokines levels in ex vivo colonic explants revealed several novel findings.  Both 
Mm-MIF-1 and Ts-MIF-1 potentiate TLR4 driven IL-6 gene expression whilst 
simultaneously inhibiting IL-17 and IL-22 transcriptional responses in ex vivo 
explants.  Interestingly, in this context Mm-MIF-1 alone significantly increased IL-
22 expression which suggests two potential immunomodulatory mechanisms: 1) 
MIF, in the context of TLR4 stimulation inhibits TLR4 mediated signalling by 
binding to LPS or directly to TLR4; or 2) treatment of explants with LPS and MIF 
leads to cellular exhaustion caused by a threshold being surpassed, such as 
sustained activation of cell surface receptors, leading to a downregulation of IL-
22.  When this was translated to secreted cytokine levels, whilst IL-6 levels were 
slightly inhibited in the presence of Mm-MIF-1 and Ts-MIF-1 homologues, we 
observed distinct differences in the IL-22 response; namely, that Mm-MIF-1 does 






it.  Though IL-22 is expressed and secreted by a number of cells in the colon, 
expression of the IL-22 receptor is unique to epithelial cells within the GT.   
Aside from providing evidence that the two MIF homologues may drive opposing 
immune responses in the GT, we also clearly show for the first time that MIF’s 
tautomerase activities are critical for the transcriptional and secreted cytokine 
response particularly in the case of secreted IL-22 and TNF-a whereby loss of 
the tautomerase site led to a significant increase in Mm-MIF-1 IL-22 levels in the 
presence of LPS and we observed a downward trend in the levels of TNF-a in 
Ts-MIF-1 tautomerase mutants.   Importantly, the data presented here also 
demonstrates that the tautomerase activities are dispensable for the modulation 
of some cytokines.  For example, MIF induced changes in IL-17 and IL-6 
transcription in colonic explants after LPS stimulation did not change when 
tautomerase deficient MIF mutants were used although the context of explants 
whereby the cellular milieu is so heterogenous, there is the possibility that the 
effect of tautomerase mutants is compensated by the actions of additional 
cytokines.  Consequently, we provide key evidence that MIF’s tautomerase 
activities are essential for modulating barrier integrity in response to luminal 
antigens or PAMPs that gain access to basolateral spaces after epithelial 
damage.   
Innate immune responses in the GT are a complex orchestrated process 
dominated by epithelial cells, professional APC’s and ILC’s.  The importance of 
MIF in macrophage function has been widely researched but, aside from its role 
as an inhibitor of monocyte migration and counter regulator of glucocorticoid 
hormones, the role of MIF in innate immune regulation is still poorly understood. 






dependent.  In this PhD thesis, we confirm, along with previous studies, that MIF 
does not modulate IL-6 and MCP-1 transcription in macrophages directly but 
synergizes with PAMPs such as LPS. This suggests MIF may be play an 
important role in driving immune responses during infection or inflammation 
where barrier function has been lost. Although IL-6 transcription was unaffected 
by the absence of MIF’s tautomerase site in ex vivo explants, in the context of 
primary murine BMDMs this was not the case.  In these experiments in 
macrophages, LPS and Mm-MIF-1 treatment led to a significant increase in IL-6 
which was completely abrogated when the tautomerase P2G mutant was used. 
Surprisingly, though the Ts-MIF-1 recombinant drove a modest increase in IL-6 
transcription when it was coadministered with LPS, coadministration with the 
tautomerase mutant of the Ts-MIF-1 yielded similar increases in IL-6 
transcription.  With this in mind, we propose that the mammalian oxidoreductase 
site, which is absent from Trichinella-derived MIFs, may contribute in concert with 
its tautomerase activities to modulate gene expression in macrophages.    
Further analysis of the transcriptomes of murine bone marrow derived 
macrophages in response to MIF treatment led to the novel finding that 
mammalian and Trichinella-derived MIF’s modulate distinct gene groups. This 
may provide insights into how they prime cells for responses to antigens or 
PAMPs such as LPS.  In this work, mammalian derived Mm-MIF down regulated 
several targets involved in the regulation of TNF-α including a TNF-α sheddase, 
Adam28, murine p53 paralogue, Trp63, and regulator of exosome biogenesis, 
Rab27b.  We show further evidence of the biological relevance of MIF’s 
tautomerase activities as cells treated with tautomerase deficient MIF showed 
alterations in a distinct set of transcripts. Interestingly, Ts-MIF-1 upregulated a 






cellular architecture including BMP3, BMP7, Hhip, IGFbp2, Krt5 and Claudin8.  
Unlike transcriptome changes induced by murine MIF the expression of many of 
these genes remain similarly altered in cells treated with tautomerase deficient 
Ts-MIF-1.   Furthermore, the data we show in this thesis provides additional 
evidence for MIF’s role in the regulation of p53 and, in particular, that Ts-MIF’s 
appear to modulate p53 activities by a mechanism distinct to that used by 
mammalian MIF’s.  
Taking together all of the data presented in this thesis we demonstrate evidently 
the novel prospect that Mm-MIF-1 and Ts-MIF-1 drive the development of distinct 
immune responses when barrier function is comprised by TLR4 activation.  With 
this in mind, we propose two preliminary divergent models for MIF mediated 
epithelial-driven immune responses in the GT including WT and tautomerase 












Figure 8. 1    Proposed model for Mm-MIF-1 mediated development of 
protective immune responses at the intestinal barrier surface after 
translocation of LPS.  Mm-MIF-1 inhibits epithelial NF-kB driven TNF-a 
secretion driving the polarisation of local macrophages to an alternatively M2 
phenotype.    M2 macrophages inhibit typical LPS-mediated responses in the 
colon secreting Th2 promoting/attracting cytokine IL-6 and inhibiting pro-
inflammatory cytokine MCP-1/TNF-a.  Cytokines reliant on the  conserved 











Figure 8. 2  Proposed model for Ts-MIF-1 mediated development of Th1, 
Th22 and ILC3 responses at the intestinal barrier surface after translocation 
of LPS.  Ts-MIF-1 potentiates epithelial NF-kB driven TNF-a secretion 
exacerbating the polarisation of local macrophages to an inflammatory M1 
phenotype.    M1 macrophages inhibit protective Th2 responses in the colon 
secreting Th1/Th22 promoting/attracting cytokine IL-6 and TNF-a.  Cytokines 







8.2. Future directions. 
To further address and unravel the role of MIF and MIF’s evolutionarily conserved 
tautomerase activity in intestinal epithelial mediated immunity several future 
experiments are outlined below.  
Whilst this PhD thesis shows key novel preliminary data to suggest MIF 
homologues modulate TLR4 mediated NF-kB activation, refinement of the NF-kB 
reporter system used earlier in our work should answer several unanswered 
questions such as why we see a difference in the hTLR4 mCherry NF-kB assay 
compared to the SEAP reporter assay when incubated with MIF alone.  One 
possibility could be that MIF regulates secreted alkaline phosphatase post-
translationally thereby skewing earlier results. To date there is no single study 
that has investigated MIF’s role in protein regulation and synthesis.  
Determination of this could be achieved by, initially, analysing SEAP transcripts 
by qPCR after MIF treatment in order to confirm that MIF regulation of SEAP is 
post-translational.  Additionally, co-localisation studies to determine the location 
of the SEAP protein within the cell could be achieved by utilising a commercially 
available SEAP antibody and antibodies for several subcellular locations involved 
in protein synthesis such as the ER (Calreticulin), the lysosome (Lamp1) and the 
Golgi apparatus (Golgi coiled coil protein).  If SEAP is found to be inhibited post-
translationally by MIF proteins additional experiments tracking general protein 
synthesis using newer, safer alternatives to pulse chase such as Click-iT™ 
(Invitrogen) technologies would establish whether MIF targets components of the 






A remaining unanswered question is, how does signalling from the multiple MIF 
receptor combinations confer its observed biological activities.  While numerous 
studies have proposed that mammalian MIF has several receptors such as CD74, 
CD44, CXCR4 and Jab1, none have investigated how and whether Trichinella- 
derived MIF’s bind to the same receptors.  This is important for several reasons: 
identifying differences in receptor specificity and binding will offer valuable insight 
into which MIF domains are important for binding and signal transduction, and 
potential differences in the way the two homologues transduce signals will 
provide essential evidence for the mechanism involved in their very distinct 
immune responses.  With this in mind, future studies should look to undertake 
protein-protein interaction studies to enhance the knowledge regarding MIF’s 
tautomerase site and receptor binding.  Furthermore, as discussed earlier in this 
thesis, it is highly likely that Ts-MIF-1 and Ts-MIF-P2G are unable to bind Jab1 
due to the absence of any cysteine residues within the protein sequence.  It would 
be important to confirm this using co-immunoprecipitation studies.  An addition to 
this area of research should also address WT and mutant MIF interactions with 
p53 after our RNA-seq work revealed that Mm-MIF’s and Ts-MIF’s may modulate 
p53 using distinct mechanisms. 
To build on the novel work in this PhD project evidencing that MIF homologues 
play a critical but discrete role in mediating intestinal immune responses 
particularly when barrier function is compromised, further experiments validating 
the observed responses should include the use of primary epithelial cells and 
tissue specific macrophages such as the highly specialised colonic 
macrophages.  Additionally, this should extend to detailed immunophenotyping 
macrophage and T cell subsets in intestinal tissue to bridge the gap in knowledge 






immunity.  This should include but not be limited to analysis of key transcription 
factors involved in regulating Th responses such as T-bet (Th1), Gata-3 (Th2), 
FoxP3 (Treg) and critically, ROR-gT (Th17/Th22).  While we show promising data 
here that MIF alone, and in the context of the TLR4 ligand LPS, regulates local 
cytokines to modulate barrier function in ex vivo explants, obtaining further 
clarification as to the identity of MIF responsive cells and the specific mechanism 
of action utilised by MIF.   
The research encompassed in this study utilised recombinant MIF proteins for 
cellular assays, however, MIF-1 and MIF-1/DDT is also produced endogenously.  
To further extrapolate the contribution of endogenously produced MIFs, silencing 
techniques such as shRNA or knock out using CRISPR/CAS9 (which also allows 
for cleavage of specific enzymatic sites) would be useful in colonic cell lines in 
order to identify whether exogenous and endogenous MIFs work in concert or as 
a positive feedback look to regulate intestinal immunity.  Treatment of MIF-
silenced IEC cells, with WT and mutant mammalian and Trichinella-derived 
recombinant MIFs, versus treatment of WT IEC lines would potentially reveal 
whether the two MIF homologues require the presence of endogenously 
produced MIFs to exert their varied biological effects. 
Of upmost importance is the validation of the roles of MIF-1 and MIF-2’s 
tautomerase activities in vivo.  The previously published MIF-1 P2G knock in 
murine model (Fingerle-Rowson et al., 2009) would be incredibly useful when 
assessed in the context of loss of barrier function such as the well-documented 
DSS-induced colitis model.  This would combine and build on our work in this 
study that demonstrated the importance of the tautomerase site in maintaining 






Key experiments should include histological analysis and disease activity scoring 
after colitis induction to identify whether loss of the tautomerase site plays an 
initial role in the induction and severity of disease.  Additionally, isolation and 
characterisation of immune cell subsets including macrophage and T cell 
populations would support our earlier ex vivo studies showing that the 
tautomerase site is essential for IL-22 and TNF-a production.  Furthermore, to 
confirm that macrophages require the endogenous tautomerase site to mediate 
MIF’s innate responses in the GT, adoptive transfer of WT macrophages into DSS 
induced WT and MIF-P2G knock in mice will provide crucial insight into the 
biological significance of MIF’s tautomerase site.   
8.3. Concluding remarks. 
Overall, the work encompassed in this thesis provides valuable insight, through 
in vitro and ex vivo models, into MIF’s regulatory capabilities in the intestinal 
environment during barrier injury.  We have shown clear evidence that the 
tautomerase site is, at least in part, responsible for the regulation of cytokines, 
IL-22 and TNF-a, associated with the maintenance of barrier integrity.  
Additionally, we have characterised the transcriptomic profile of primary murine 
BMDMs after treatment with MIF which has revealed several interesting findings 
such as the Mm-MIF-1 specific regulation of TNF -α regulating genes and the Ts-
MIF-1 driven upregulation of genes associated with cell cycle progression.   
Having just begun to characterise the effect of MIF and MIF tautomerase mutants 
on the intestinal epithelial driven immune response, the further work described 
previously will be required to accurately understand the role that MIF and 
crucially, MIF’s enzymatic activities contribute in intestinal disorders such as 
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Primer name  Primer sequence 
Hs_MIF1_Fw  CATATGCCGATGTTCATCG  
Hs_MIF1_Rv  CTCGAGTTAGGCGAAGGTGG  
Hs_MIF1P2G_Fw CATATGGGCATGTTCATCGTAAACACC 
Hs_MIF1C57S/C60S_Fw AGC GCG CTC AGC AGC CTG CAC AGC ATC GGC AAG 
Hs_MIF1C57S/C60S_Rv ATG CTG TGC AGG CTG CTG AGC GCG CTC GGC 
Hs_DDT_Fw  CATATGCCGTTCCTGGAGCTGG  
Hs_DDT_Rv  CTCGAGGGGCTAGCTCCTTGGTGAG  
Mm_MIF1_Fw  CATATGCCTATGTTCATCGTGAACACC  
Mm_MIF1_Rv  CTCGAGAGCGAAGGTGGAACCGTTCCAGCC  
Mm_MIF1P2G_Fw CATATGGGCATGTTCATCGTGAACACC 
Mm_DTT1_Fw  CATATGCCATTCGTTGAGTTGGAAACA  
Mm_DTT_Rv  CTCGAGCAGAAATGTCATGACAGTTCCTTT  
Ts_MIF1_Fw  CATATGCCTATCTTTACTCTTAATAC  
Ts_MIF1_Rv  CTCGAGGAATGTAGTACCGTTCCAACCAAC  
Ts_MIF1_P2G CATATGGGCATCTTTACTCTTAATACA 
Ts_MIF2_Fw  CATATGCCAATTTTCACAATAA  
Ts_MIF2_Rv  CTCGAGCGCTCGCAGACAGCCACT  

























































































































































































































































































































































































Table A. 3  qPCR primers used in this study. 
Primer name Primer sequence 
Hs_TBP_Fw   ACCCAGCAGCATCACTGTTTC  
Hs_TBP_Rv  CAAGCCCTGAGCGTAAGGTG  
Mm_GAPDH_Fw CTCCCACTCTTCCACCTTCG 
Mm_GAPDH_Rv  GCCTCTCTTGCTCAGTGTCC 
Mm_IL-6_Fw  CCCCAATTTCCAATGCTCTCC  
Mm_IL-6_Rv  AGGTTTGCCGAGTAGATCTCAA 















Sample ID  Gene ID Accession Number Gene Name  Log2FC Adjusted p value  
Mm-MIF-1 
     
 
Snx31 NM_025712 sorting nexin 31 22.805 0.0084773099 
 
Foxa1 NM_008259 forkhead box A1 15.93 0.0026540933 
 
Hhip NM_020259 Hedgehog-interacting protein 13.146 0.0019448917 
 
Krt7 NM_033073 keratin 7 12.893 0.0031562406 
 
Krt15 NM_008469 keratin 15 2.242 0.0002851333 
 
Wfdc2 NM_026323 WAP four-disulfide core domain 2 -14.026 0.0001562889 
 
Upk2 NM_009476 uroplakin 2 -14.277 0.0002851333 
 
Fam25c NM_183278 family with sequence similarity 25, member C -15.053 0.0001831548 
 
Adam28 NM_010082 a disintegrin and metallopeptidase domain 28 -16.523 0.0002241468 
 
Rab27b NM_030554 RAB27B, member RAS oncogene family -16.628 0.0040745852 
 
Upk1b NM_178924 uroplakin 1B -17.593 0.0002217725 
 
Sprr1a NM_009264 small proline-rich protein 1A -23.883 0.0000397287 
 
Trp63 NM_001127259 transformation related protein 63 -28.424 0.0000397287 
      
Mm-MIF-1 P2G 
     







Snx31 NM_025712 sorting nexin 31 29.907 0.0000023700 
 
Foxa1 NM_008259 forkhead box A1 25.244 0.0002818600 
 
Krt7 NM_033073 keratin 7 24.462 0.0000155000 
 
Bmp3 NM_173404 bone morphogenetic protein 3 20.858 0.0087996100 
 
Nfe2l3 NM_010903 nuclear factor, erythroid derived 2, like 3 20.779 0.0087996100 
 
Krt19 NM_001313963 keratin 19 20.674 0.0090747000 
 
Fhl1 NM_001077362 four and a half LIM domains 1 20.393 0.0102459000 
 
Hhip NM_020259 Hedgehog-interacting protein 20.118 0.0102459000 
 
Tmprss2 NM_015775 transmembrane protease, serine 2 20.088 0.0102459000 
 
Krt15 NM_008469 keratin 15 20.056 0.0102459000 
 
Krt5 NM_027011 keratin 5 19.952 0.0102459000 
 
Igfbp2 NM_008342 insulin-like growth factor binding protein 2 19.914 0.0102459000 
 
Psca NM_028216 prostate stem cell antigen 19.838 0.0102459000 
 
Krt8 NM_031170 keratin 8 19.749 0.0105545800 
 
Krt4 NM_008475 keratin 4 19.074 0.0157563500 
 
Fam84a NM_029007 family with sequence similarity 84, member A 18.974 0.0158858600 
 
Bmp7 NM_007557 bone morphogenetic protein 7 18.969 0.0158858600 
 
Klhdc7a NM_173427 kelch domain containing 7A 18.944 0.0158858600 
 
Sprr2a3 NM_001309382 small proline-rich protein 2A3 18.929 0.0158858600 
 







Upk1b NM_178924 uroplakin 1B 14.525 0.0016875100 
 
Upk2 NM_009476 uroplakin 2 10.227 0.0017721000 
 
Wfdc2 NM_026323 WAP four-disulfide core domain 2 9.692 0.0018324200 
 
Rab27b NM_030554 RAB27B, member RAS oncogene family 8.657 0.0018796900 
 
Fam25c NM_183278 family with sequence similarity 25, member C 8.252 0.0018833900 
 
Adam28 NM_010082 a disintegrin and metallopeptidase domain 28 6.566 0.0025662800 
 
Sprr1a NM_009264 small proline-rich protein 1A 4.13 0.0026212200 
      
Ts-MIF-1     
     
 
Snx31 NM_025712 sorting nexin 31 21.513 0.0000068970 
 
Hhip NM_020259 Hedgehog-interacting protein 20.356 0.0000199348 
 
Krt15 NM_008469 keratin 15 19.253 0.0000535239 
 
Tmprss2 NM_015775 transmembrane protease, serine 2 18.814 0.0000800932 
 
Krt5 NM_027011 keratin 5 18.782 0.0000824047 
 
Klhdc7a NM_173427 kelch domain containing 7A 18.368 0.0001195510 
 
Krt7 NM_033073 keratin 7 17.916 0.0000163666 
 
Psca NM_028216 prostate stem cell antigen 17.741 0.0001954905 
 
Nfe2l3 NM_010903 nuclear factor, erythroid derived 2, like 3 17.728 0.0002257294 
 
Igfbp2 NM_008342 insulin-like growth factor binding protein 2 15.924 0.0008349219 
 







Bmp7 NM_007557 bone morphogenetic protein 7 15.327 0.0013297415 
 
Krt8 NM_031170 keratin 8 14.837 0.0018887475 
 
Fam84a NM_029007 family with sequence similarity 84, member A 14.797 0.0019448134 
 
Bmp3 NM_173404 bone morphogenetic protein 3 14.785 0.0021270654 
 
Krt4 NM_008475 keratin 4 13.982 0.0036324032 
 
Cldn8 NM_018778 claudin 8 13.941 0.0037382788 
 
Sprr2a3 NM_001309382 small proline-rich protein 2A3 13.905 0.0036606252 
 
Trp63 NM_001127259 transformation related protein 63 -28.39 0.0000000024 
      
Ts-MIF-1 P2G 
     
 
Hhip NM_020259 Hedgehog-interacting protein 18.953 0.0000763000 
 
Bmp3 NM_173404 bone morphogenetic protein 3 14.928 0.0019237500 
 
Foxa1 NM_008259 forkhead box A1 12.725 0.0087344700 
 
Sprr1a NM_009264 small proline-rich protein 1A -6.967 0.0140244100 
 
Wfdc2 NM_026323 WAP four-disulfide core domain 2 -13.602 0.0048860700 
 
Upk2 NM_009476 uroplakin 2 -14.265 0.0031559400 
 
Fam25c NM_183278 family with sequence similarity 25, member C -14.566 0.0025819400 
 









Figure A. 1  Explant RNA concentration.  Colonic explants were cultured for 
20 hours in the presence or absence of 100ng/ml LPS +/- 100ng/ml MIF.  Explant 
tissue was weighed and lysed in an appropriate volume of Trizol using beads to 
homogenise.  Chloroform was added to Trizol and, after incubation, the aqueous 
phase was precipitated with isopropanol and put through a direct-zol column.  
RNA concentration and integrity were analysed using a Nanodrop 2000.  Figure 
represents RNA concentration obtained from experiments represented in this 
study.   The data represents the mean ±SEM (n=4). 
 
 
 
 
 
 
 
 
